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A thorough understanding of the natural history of Hepatitis C is needed to 
instruct patients and clinicians on the clinical course and prognosis of this 
infection.  Only then can both parties make an informed decision on 
management. It also informs cost/benefit analyses, on which important 
decisions on the funding of therapy is made.  
 
Since its discovery in 1989, much has already been written on the 
epidemiology and natural history of Hepatitis C. The patient population studied 
has an important bearing, however, on the results of epidemiological studies of 
disease progression in Hepatitis C. The majority of studies have focused on 
patients attending tertiary referral centres and exclude patients with co/
morbidity such as hazardous alcohol consumption. The principle aim of the 
collection of studies that form this thesis is to enhance our understanding of the 
natural history of Hepatitis C by examining a geographically determined 
population that typifies those patients currently attending our hepatitis clinics.  
 


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The epidemiology and natural history of Hepatitis C has been studied in a large 
geographically determined population (Trent HCV study).  
 
It has previously been suggested that patients with Hepatitis C and a 
persistently normal Alanine aminotransferase (PNALT) represent a group of 
patients with mild disease and at low risk of disease progression. Patients with 
PNALT were, therefore, compared to those with an elevated ALT. The 
majority of patients initially fulfilling the definition of a PNALT had an 
abnormal ALT within 3 years of follow/up. They also demonstrated similar 
rates of fibrosis progression as a sub/group of HCV infected patients with an 
elevated ALT who were re/biopsied prior to any institution of therapy. They, 
therefore, warrant the same consideration with regard to treatment. 
 
The morbidity and mortality associated with Hepatitis C with severe fibrosis 
was assessed in a group of patients with a liver biopsy demonstrating Ishak 
fibrosis stage ≥ 4. A worse prognosis than previously reported was observed 
for this patient population. Once decompensation develops, HCV infection is 
associated with a high mortality rate. Indicators of poor synthetic liver function 
and hypergammaglobulinaemia were important prognostic factors for 
mortality, while combination antiviral therapy was associated with improved 
survival. 
 
The majority of HCV infected patients (75%) diagnosed with hepatocellular 
carcinoma (HCC) were known to have cirrhosis at least 6 months prior to 
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diagnosis of HCC and were, therefore, amenable to surveillance. There was a 
variable application of surveillance, however, and no significant improvement 
in survival was demonstrated. Age, duration of infection and immunoglobulin 
G levels were associated with an increased risk of HCC in cirrhotic patients in 
the univariate analysis. Achieving an SVR was associated with a reduced risk. 
No variable in cirrhotic patients was shown to be independently associated 
with HCC in the multivariate analysis. 
 
A comparison of disease progression and treatment outcome in White and 
Asian (Indian subcontinent) patients was made. Asian patients generally 
presented at an older age and with more severe disease on biopsy. The patient’s 
ethnic group was not associated with the likelihood of either an SVR or 
completion of therapy. Instead cirrhosis and a raised GGT were associated with 
a failure to achieve SVR in the multivariate analysis. 
 
The platelet count is a surrogate marker for the severity of liver fibrosis and 
correlates with the Ishak fibrosis stage. An analysis of factors associated with 
an SVR was performed. In the multivariate model, age at start of treatment was 
the only independent predictor of SVR in Genotype 1, while estimated duration 
of infection and Ishak stage were predictors in genotype 2/3 patients. The 
platelet count was not an independent predictor of SVR or completion of 
therapy.   
 
 Hepatitis C, Sustained virological response (SVR), Hepatocellular 
carcinoma (HCC), Ishak stage 
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Hepatitis C (HCV) is a positive sense single strand, enveloped RNA virus, 
which constitutes a separate genus (hepacivirus) within the 	 family. 
The HCV genome was defined in 1989 [1]. It contains a highly conserved 5‘ 
untranslated region, preceding the translation initiation codon. This is the target 
of diagnostic testing for HCV as because it is highly conserved it is suitable for 
PCR primers. There is also a 3‘ untranslated region of variable length. The N/
terminal quarter of the genome encodes the structural proteins; a non/
glycosated nucleic acid binding nucleocapsid protein (core, C) and membrane 
associated glycoproteins (envelope, E1 and E2/ NS1). The rest of the genome 
encodes the non/structural proteins NS2/NS5[2/3]. 
 
The investigation of the HCV life cycle and pathogenesis has been hampered 
by the lack of efficient cell culture systems and small animal models. Recent 
advances, including the development of HCV replicons and infectious viral 
particles in tissue culture systems [4/5] and the establishment of an in vitro 
model of HCV virions [6/7] expands the tools available for HCV study. The 
virus mainly replicates in the hepatocytes, but can also replicate in peripheral 
blood mononuclear cells. The virus enters cells, through a complex interaction 
between virions and cell surface molecules, including CD81, SR/BI, claudin/1, 
occludin, LDL receptor and DC/SIGN [8]. Once in the cell cytoplasm the virus 
is uncoated and the genome transcribed to form a complementary negative 
sense RNA molecule, which in turn is translated into the progeny positive 
 2 
strand RNA molecules. The enzyme capable of performing both steps of RNA 
synthesis is the virally encoded RNA dependent RNA polymerase NS5B[9]. 
The virus is not directly cytopathic to hepatocytes and persistent infection 
appears to rely on rapid production of virus and continuous cell/to/cell spread, 
along with a lack of vigorous T/cell immune response to HCV antigens.  
 
HCV has a wide variety of genotypes (1/6), defined by the sequence of genetic 
material within the virus. It mutates rapidly due to rapid viral replication (1010 
to 1012 virions per day) and a high error rate on the part of the NS5B coded 
RNA dependent RNA polymerase. HCV is, therefore, highly heterogeneous, 
existing as a collection of virus quasispecies [10]. Mutations are most 
pronounced in the hypervariable regions of the envelope proteins. The virus, 
therefore, typically escapes immune surveillance by the host and as a 
consequence most patients develop chronic infection [2/3]. Moreover such 
heterogeneity hinders the development of vaccines [11].   
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In 1999 the World Health Organisation (WHO) estimated that the worldwide 
seroprevalence (positive HCV antibody) of Hepatitis C infection was 
approximately 3%, with the virus infecting 170 million people [12]. There is 
wide geographic variation with estimates ranging from < 1% in Northern 
Europe to greater than 5% in Northern Africa. In Europe higher seroprevalence 
rates > 1% are reported from Italy and France [13/14], with higher levels still 
in Eastern Europe (median 2%) [15]. In the United States nearly 2% of the 
population are infected [16].  The United Kingdom is among countries with the 
lowest seroprevalence, with the Health Protection Agency reporting a 
seroprevalence of antibodies to HCV (anti/HCV) of 0.44% in individuals aged 
15/59 years living in England and Wales [17]. It is estimated that there are 
approximately 200,000 HCV infected individuals living in the United 
Kingdom.  
 
As well as geographic variation, there are temporal differences in the pattern of 
HCV infection. Countries, such as the United States, Australia, Spain, Turkey, 
Italy and Japan have a similar overall seroprevalence of HCV infection (1/
1.9%), but differ in their age specific seroprevalence. In the United States and 
Australia persons 30/49 years old account for two/thirds of those infected, with 
lower than average rates among those less than 20 years and greater than 50 
years old. In contrast it is those persons greater than 50 years old who in Spain, 
Turkey, Italy and Japan account for most infections. These patterns indicate 
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that most HCV transmission occurred in the last 20/40 years in the US and 
Australia and twenty years earlier to this in Spain, Turkey, Italy and Japan [18]. 
The highest seroprevalence has been reported from Egypt (13/24%), equating 
to more than 10 million anti/HCV positive patients and with high rates of 
infection observed in all age groups [19/20].  
 
Determining the incidence of HCV infection is difficult due to most acute 
infections being asymptomatic and laboratory assays being unable to 
distinguish acute from chronic infection. In the United States HCV incidence 
has been modelled using age/specific incidence from reported cases of acute 
disease (identified by detectable HCV RNA while HCV antibody negative) 
[21] and age/specific seroprevalence from a cross/sectional national survey 
(National Health and Nutrition Examination Survey – NHANES) [22]. The 
model demonstrates that the estimated annual incidence of HCV infection was 
low (18 per 100,000) prior to 1965, rose steadily through to 1980 and then 
remained high (130 per 100,000) through to 1989 [23]. Because chronic liver 
disease may develop many years after infection, the past incidence is a major 
determinant of the future burden of HCV associated complications [24]. Since 
1989 the incidence of reported cases of HCV in the United States has declined 
by 80% [25]. According to the Centers for Disease Control and Prevention 
(CDC) HCV infection in the United States has fallen from approximately 
230,000 per year in the 1980s to 19,000 per year in 2006 [26]. In a complex 
Markhov model, Davis et al estimated that the seroprevalence of HCV 
infection peaked in the United States in 2001 at 3.6 million and will fall to half 
that number by 2030 [27].  
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High incidence rates persist in African countries and in Egypt in particular, 
where the incidence rate ranges from 80 to 680 per 100,000 depending on the 
background seroprevalence [28]. More than 60% of acute infections are in 
persons below the age of 15 years and high incidence rates (1410 per 100,000) 
have been detected in Egyptian children younger than 10 years of age living in 
households with an anti/HCV positive parent [28/29].  
 
In the UK a back calculation method based on knowledge of age/specific HCV 
progression and using information on deaths from HCV/related hepatocellular 
carcinoma from the Office of National Statistics (ONS), together with age 
specific prevalence of end stage liver disease from Hospital Episode Statistics 
(HES) records allows estimates of incidence in the distant past. By this 
approach it is suggested that again there was an increase in incidence until the 
late 1980s, peaking at around 14,900 (95 % CI: 8,000 – 28,100) new infections 
per year in 1988 [17]. Estimates of current HCV incidence in the UK are based 
on studies of intravenous drug users (IDUs). Mathematical modelling using 
seroprevalence data in those attending a range of specialist services for drug 
users in England and Wales estimated the incidence in susceptible IDUs 
between 1999 and 2003 [30]. The incidence of infection was 16% in the first 
year of injecting declining to 6% thereafter. Other studies have estimated the 
incidence by identifying individuals with recent infection, as evidenced by the 
presence of HCV RNA in IDUs who are anti/HCV negative. A London/based 
study[31] using stored serum from anti/HCV negative current IDUs (1999/
2001) and a surveillance study[32] (2002/3) involving IDUs having HCV tests 
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in five English regions estimated the incidence at 14.3 and 12.9 per 100 person 
years respectively. 
 
As well as reporting the seroprevalence of HCV infection in the United States, 
the NHANES study has provided a picture of the HCV infected population. In 
the context of an overall seroprevalence of 1.8%, seroprevalence was higher in 
men (2.5% vs 1.2%, P<0.05) and in non/hispanic blacks (3.2% vs 1.5%, 
P<0.05) as compared to non/hispanic whites. 65% of all those with HCV 
infection were aged 30/49 years. There was also a higher seroprevalence in 
those living below the poverty level (3.2% vs 1.6% P<0.05) and in those who 
had completed 12 or fewer years of education (2.8% vs 1.3%, P<0.05). Neither 
sex nor ethnic group were associated with HCV infection independently of 
socio/demographic and behavioural risk factors. On the other hand living 
below the poverty level (OR 2.37, 95% CI 1.5/3.75) and 12 or fewer years of 
education (OR 1.92, 95% CI 1.01/3.67) were independently associated with 
HCV infection [22]. In a study of the epidemiology of HCV in a UK regional 
population of approximately 5 million, the male to female ratio was 2:1 and 
95% were Caucasion [33]. Since 1990 the Public Health and NHS Laboratories 
in England/ Wales have reported confirmed cases of HCV infection. Between 
1996/2007 69% of reported infections were in men and 51% were in 
individuals aged 25/39. These figures were similar for IDUs and those where 
no risk factor was identified [34]. In 2008 61 blood donors tested positive for 
HCV (31 per 100,000 donations). The ethnic origin was known in 56/61. 
43(77%) were white and 8 (14%) were South Asian (Pakistan, India, 
Bangladesh). The proportion of donations from new white donors that tested 
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positive for HCV was 26.5 per 100,000 donations (0.03%) compared to 185.3 
per 100,000 donations (0.19%) in South Asian Individuals[34].  
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Hepatitis C is most likely to be transmitted through large volume or repeated 
direct percutaneous exposure to blood, for example through blood transfusion 
from infected donors, unsafe therapeutic injections or injecting drug use. Three 
characteristics – an abnormal alanine aminotransferase (ALT), history of IDU 
and a history of transfusion prior to 1992 identified 85% of HCV RNA positive 
individuals aged 20/59 years within the NHANES study [16]. Table 1.1 details 
the main risk factors for HCV transmission. Historically blood product 
transfusion has been a major mode of transmission. The introduction of HCV 
screening in the United States in 1990 reduced post transfusion HCV from 
3.84% to 0.57% per patient (0.03% per unit of blood)[35].  In England 
estimates for the frequency of HCV infected donations dropped from 
1:520,000 (1993/98) to 1 in 30 million (1999/2001) when all donations were 
tested for HCV RNA[36]. Nucleic acid testing (NAT) has the advantage over 
anti/HCV testing in that the potential “window period” between infection and a 
positive test is shortened. Individuals who received multiple transfusions, 
including those with thalassemia or haemophilia, have been at particularly high 
risk of developing hepatitis C. The seroprevalence of anti/HCV in 
haemophiliacs who regularly received concentrates of clotting factors before 
adequate procedures were used to inactivate viruses was 76/99% [37/38]. The 
risk of transfusion associated HCV remains an important risk factor in other 
areas of the world that lack the resources to implement adequate donor 
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screening and continue to use commercial donors to supplement their blood 
supplies [39/41].  
 
Intravenous drug use is an efficient means of HCV transmission and the 
predominant mode of transmission in the United States and Europe. In a study 
of 716 IDUs from Baltimore, USA, the seroprevalence among those who had 
injected for one year or less in 1998/9 was 64.7% [42]. Cumulative 
seroprevalence rates in IDUs  living in New York City during the first 2/3 
years of injecting have declined from 80% during the late 1980s to 30% in the 
late 1990s[43], most likely due to heightened awareness and needle exchanges 
motivated in principle by concern for HIV risk. In 2007, 42% of current and 
former IDUs from England who participated in the Unlinked Anonymous 
Prevalence Monitoring Programme (UAPMP) survey had positive salivary 
HCV antibodies. There were regional variations in seroprevalence from 21% in 
North East England to 58% in London and 60% in the North West. One in four 
injectors reported sharing needles and syringes[44].  Another UK (London) 
study found that 44% of IDUs below the age of 30 were anti/HCV positive 
compared to 4% for HIV[45]. The seroprevalence of anti/HCV among people 
who acquired HIV through IDU is approximately 90%[46]. Of those laboratory 
confirmed HCV infections in England between 1996 and 2008, in which risk 
factor for acquisition was reported, 92.5% were as a consequence of IDU[17].  
 
There is a high seroprevalence of HCV in prison inmates. In Rhode Island, 
United States, 23.1% of inmates in an adult correctional facility were HCV 
positive, compared to 1.8% for HIV [47]. The higher seroprevalence is also a 
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consequence of IDU, with a study of four Scottish prisons in 1994/6 
demonstrating positive salivary HCV antibodies in 49% of injecting inmates 
compared to 3% of non/injectors[48]. In a follow/up study of the incidence of 
HCV infection in prison inmates conducted between 1999/2000, the incidence 
per 100 person/years of incarceration risk for inmates who reported never 
having injected drugs, ever having injected drugs, having injected drugs during 
follow/up, and having shared needles/syringes during follow/up were 1, 12, 19, 
and 27, respectively[49]. 
 
In many developing countries unsafe therapeutic injections performed by both 
professionals and non/professionals remains an important route of HCV 
transmission. It is estimated that 2 million HCV infections are acquired 
annually as a consequence of contaminated health care injections and that this 
may account for 40% of all HCV infection worldwide[50]. The re/use of glass 
syringes during a mass treatment campaign of parenteral Schistosomiasis 
therapy may have played a major role in the spread of HCV throughout Egypt 
[51]. In the District Buner study in Pakistan (1998/2002), which demonstrated 
a seroprevalence of HCV infection of 4.6%,  all 751 anti/HCV positive 
individuals had a history of injection[52].  With the adoption of universal 
precautions, nosocomial infection had declined in developed countries as a 
mode of HCV transmission, though in the 1990s seroprevalence rates of 10/
50% were reported among haemodialysis patients [53/55]. Health care workers 
are also judged to be among those at risk of HCV infection, though the 
reported seroprevalence is no greater than found in blood donors [56]. A 
 10 
contaminated needlestick injury is associated with an anti/HCV seroconversion 
in 1.2% of cases [57].  
 
One of the most controversial areas of Hepatitis C epidemiology is the extent 
to which HCV is transmitted by sexual activity. Phylogenetic analysis enables 
the genetic relatedness of viral isolates in sexual partners to be determined, but 
even then studies on the sexual transmission of HCV are limited by the 
potential of the confounding variable of IDU or shared items such as razors 
between sexual partners. In the NHANES study, the number of sexual partners 
(OR 2.54 for 2/49 partners) and age at first sexual intercourse (OR 2.94) had a 
significant correlation with anti/HCV [22]. The evidence for sexual 
transmission is also supported by a study of non IDU women with an injecting 
partner, in which 15% of the women were positive for HCV[58].  On the other/
hand a 10 year prospective study evaluated transmission in 895 monogamous 
spouses (providing a follow/up period of 8060 person/years) and showed no 
evidence of heterosexual sexual transmission [59]. There is also a lack of 
evidence for significant sexual transmission among men who have sex with 
men [60], except in those with HIV co/infection [61]. Overall sexual 
transmission of HCV is believed to be rare, though may be less so in higher 
risk populations. In a review of the subject the incidence of HCV 
seroconversion in long/term monogamous couples was reported as 0/0.6%/ 
year and for individuals with multiple partners or a history of sexual 
transmitted diseases 0.4/1.8%/ year. Studies in monogamous, heterosexual 
partners of HCV/infected, HIV/negative persons, demonstrate a frequency of 
antibody/positive and genotype/concordant couples of 2.8% to 11% in 
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Southeast Asia, 0% to 6.3% in Northern Europe, and 2.7% in the United 
States[62]. The risk of sexual transmission appears to be higher when the index 
case is co/infected with HIV, with anti/HCV seroprevalence 2.2 times higher 
compared to partners of those with HCV only [63]. The increased risk of 
transmission in HIV co/infection probably relates to the enhanced HCV 
viraemia associated with co/infection.  
 
Perinatal transmission of HCV has been the subject of a systematic review 
which included studies published between 1992/2000. The perinatal 
transmission rate was 1.7% in infants of anti/HCV positive mothers 
irrespective of HCV RNA, 4.3% when the mother was HCV RNA positive and 
19.4% if the mother was co/infected with HIV [64].   
 
There are a wide variety of other activities that may pose a risk for HCV 
transmission. These include tattooing, body piercing, acupuncture, intranasal 
drug use and religious or cultural practices. There is insufficient data, however, 
with which to determine their contribution to overall HCV transmission, 
though it is likely to be small. 
 
-.2.65$+5*31,15&
In addition to the geographic variation in seroprevalence of HCV, there are 
also region/specific patterns in terms of the virus’ genome, which have arisen 
during the evolutionary history of HCV in different human populations. 
Variants are classified into six major viral genotypes, each with a number of 
closely related subtypes. Some HCV genotypes (1, 2 and 3) are distributed 
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worldwide, while others are confined to more restricted geographical areas. 
Type  1a  is  most frequently  found  in  Northern  Europe  [65/66]   and  North  
America [69], while 1b is the most common genotype in Japan[70], Southern 
and Eastern Europe [65/66]. Type 2 is less frequent than type 1, though type 2c 
is common in Italy [71]. Type 3 is endemic in South/East Asia [66] and the 
Indian Sub/continent [72]. It is also particularly prevalent in IDUs in the 
United States and Europe [73/74]. A study of 567 individuals, including IDUs, 
Haemophilia patients, blood donors, antenatal patients and those attending 
genitourinary (GUM) and liver clinics showed that genotype 1 (1a 32%, 1b 
15%) and 3a (37%) were the most prevalent genotype in England and Wales. 
The genotype distribution was similar in the different groups, except for 
Haemophilia patients in whom there was a lower frequency of genotype 3a 
(21%)[75].   
 
Of the rarer HCV genotypes, type 4 is principally found in the Middle East, 
Egypt and Central Africa[76], type 5 is almost exclusively found in South 
Africa[77] while type 6 is present in Hong Kong and Vietnam[78]. The 
geographic distribution of HCV genotypes may provide clues to the evolution 
of HCV. The presence in some regions of numerous subtypes may suggest 
HCV has been endemic there for a long time, whereas limited diversity of 
genotype could be related to recent introduction of the virus to a region[79].  
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Acute HCV infection by definition must precede the development of chronic 
infection, but understanding of the natural history of the acute stage of HCV 
infection is limited. Acute HCV is usually defined as the new occurrence of 
viraemia, at which stage serum from the patient is usually HCV RNA positive 
and anti/HCV negative[80]. It is infrequently diagnosed as the majority of 
acute infections are asymptomatic [81/82], but is reported to account for 
approximately 10% of acute hepatitis in China [83], 8% in Japan [84] and 31% 
in Egypt [28]. The 25/30% of patients with acute HCV who develop 
symptoms, do so 3/12 weeks after exposure to the virus and as jaundice is 
often absent, fatigue may be the only manifestation [85/86]. Based on a study 
of healthcare workers who acquired HCV through accidental needlestick 
exposure, HCV RNA is detectable in the majority of patients within 1/2 weeks 
and a rise in serum transaminases is observed after 2/8 weeks, with ALT 
capable of reaching levels greater than 10 times the upper limit of normal [85]. 
Acute HCV is nearly always self/limiting though when symptoms are present 
they can persist for several weeks. Fulminant liver failure as a consequence of 
HCV is rare [87]. Anti/HCV seroconversion typically occurs near the onset of 
symptoms, approximately 3/12 weeks after exposure. Anti/HCV is unreliable, 
however, in the diagnosis of acute HCV as 30% of patients will test negative at 
the onset of symptoms [88]. Almost all patients will eventually develop anti/
HCV, though titres may be low in the context of immunosuppression.  
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The majority of patients infected with HCV will go on to develop chronic 
infection, a fact attributed to the genetic diversity of the virus and its tendency 
to rapid mutation, thus allowing it to escape immune recognition. A proportion 
of patients, estimated as being between 20/40% [89], will however, 
spontaneously clear the virus, becoming HCV RNA negative. It is unusual for 
this to occur more than 6 months after the onset of acute infection and, 
therefore, persistence of HCV RNA for 6 months is indicative of chronic HCV 
infection. There are no reliable predictors of spontaneous resolution, though 
several factors have been reported to influence chronicity. Table 1.2 gives the 
details of those factors associated with spontaneous clearance of HCV. 
 
The NHANES study demonstrated a chronicity rate of 30% in subjects aged 
less than 20 years and 76% for those more than 20 years [22]. Similarly the 
Dionysos study in Italy showed chronicity rates of 56% in residents aged 12/25 
years and 87% in those over the age of 25 years [90]. Further evidence that age 
at infection influences the likelihood of spontaneous clearance comes from a 
long/term follow/up study of children with post/transfusion hepatitis, where 
only 55% remained HCV RNA positive in adulthood [91].  
 
Although the NHANES [22] and Dionysos [90] studies showed similar rates of 
chronicity in men and women, there is evidence from elsewhere that the rate of 
chronicity is lower for women than men. Two large follow/up studies of 
women who received contaminated immune globulin, both showed a chronicity 
rate of 55% after approximately 20 years [92/93]. A study within an IDU 
population also  showed women to have a significantly higher incidence of 
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viral clearance than men (age/adjusted hazard ratio, 2.91 [95% CI, 1.68/5.03]) 
[94]. Bakr 	
. similarly found clearance rates to be significantly greater in 
women (44.6%) compared with males (33.7%, adjusted OR 1.77) in an 
Egyptian community [95].  Overall spontaneous clearance of HCV occurs in 
approximately 40% of women and 19% of men [89]. 
 
African Americans have a higher rate of chronic HCV infection than 
Caucasians or Hispanic Whites (African American 86% vs Caucasian 68%, 
P=0.02) [22]. The host immune genetics are important in determining the 
likelihood of spontaneously clearing HCV. HLA class II alleles DRB1*11 and 
DQB1*0301 have both been shown to be associated with spontaneous 
resolution of infection [96]. Recent genome/wide association studies have shed 
more light on the underlying host factors that may be involved in the ability to 
spontaneously clear virus and present a possible explanation for racial 
differences. A single nucleotide polymorphism (rs12979860) at a site close to 
the IL28B gene has been shown to influence clearance rates of HCV RNA. In a 
study of 1008 patients the presence of the C/C allele was associated with 
spontaneous clearance rates of 50/55% as compared to 16/20% for the T/T 
allele [97]. The C/C allele is more common in individuals of European ancestry 
compared to African ancestry. In a further study of 284 patients, the  C/C allele 
was present in 73% of the 69 patients who spontaneously cleared HCV RNA, 
compared to 46% in those with persistent infection [98].
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Jaundice during acute hepatitis was more common in patients with the C/C 
allele as compared to non/C/C patients (C/T and T/T), though interestingly 
despite the C/C allele being associated with spontaneous clearance, jaundice 
was not [102]. 
 
The host immune response plays a crucial role in determining the likelihood of 
spontaneous resolution of HCV. Viral clearance is associated with a robust and 
multispecific CD4+ and CD8+ T cell response in the blood and liver [85, 103]. 
In situations such as HIV co/infection with a CD4 < 200, where the host’s 
ability to mount an appropriate immune response is compromised, rates of 
HCV chronicity are higher(adjusted OR for clearance in HIV negative patient, 
2.19 [95% CI, 1.26/3.47]) [101]. Jaundice may result from a more robust 
immune response and there is evidence within IDU patients [104] and in the 
German contaminated Rhesus immune gobulin cohort [93] of lower rates of 
chronicity when there is a history of jaundice with acute HCV.  
 
-.6.24/1$
3*0101*/)1%13&1/
Infected individuals who do not achieve viral clearance are at risk of 
progressive liver disease, characterised by hepatocellular inflammation and 
fibrosis. Increasing hepatic fibrosis in chronic HCV may ultimately lead to 
cirrhosis and in time decompensated liver disease and/ or hepatocellular 
carcinoma. The interval between HCV infection and the subsequent 
development of significant liver disease is long, often measured in decades 
rather than years. In a Japanese cohort the mean interval between blood 
transfusion and diagnosis of HCC was approximately 29 years [105]. Similar 
observations were made in the United States with a mean interval between 
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blood transfusion and cirrhosis of 20.6 years and HCC 28.3 years [106]. A 
systematic review of 111 studies analyzing the natural history of HCV 
estimated that the prevalence of cirrhosis 20 years after infection was 16 % 
(95% CI 14/90%) [107]. This will vary, however, depending on the cohort 
studied. Sweeting et al. evaluated 971 patients with HCV from 3 separate 
cohorts and showed that the 20 year probability of cirrhosis varied from 6% in 
a cohort of transfusion recipients to 23% in a cohort from a tertiary referral 
centre [108]. Fibrosis progression is, therefore, highly variable and is 
influenced in particular by several host factors, such that some patients are 
without significant liver disease after many decades, while others rapidly 
develop cirrhosis.  
  
Given that the natural history of infection may be over decades rather than 
years, progression of fibrosis on liver biopsy has been extensively used as a 
surrogate marker for the hard end points of cirrhosis (compensated and 
decompensated) and hepatocellular carcinoma. Such studies are of two types; 
cross/sectional and longitudinal.  Both rely on scoring fibrosis on biopsy 
samples, usually either the METAVIR[109] or Ishak[110] Histological 
Activity Index (HAI) staging systems. Cross/sectional studies use a single liver 
biopsy and a known date of infection, usually the date of blood transfusion or 
the first year of intravenous drug use. These studies include large numbers of 
patients but rely on the accuracy of the estimate of duration of infection and 
assume that liver fibrosis progresses at a linear rate. The largest study, which 
included 1157 untreated patients demonstrated a  median rate of fibrosis 
progression of 0.133 METAVIR fibrosis stages/ yr (0.125/0.143), which 
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equates to a median duration from infection to cirrhosis of 30 years (28/
32)[111].  
 
Longitudinal studies require 2 liver biopsies and assess the rate of fibrosis 
progression between them. With this method there is no assumption that 
fibrosis progression is linear or a requirement to estimate the duration of 
disease. The need for two biopsies means the number of patients in these 
studies is smaller and biased toward patients with mild disease, as it is these 
untreated patients who often have repeated biopsies to detect worsening. In a 
study of 123 patients from Maryland, United States with all stages of fibrosis 
on the initial biopsy and a mean interval between biopsies of 44 months, 
fibrosis progressed at a mean of 0.12 Ishak fibrosis stages/ year, with 39% of 
patients demonstrating worsening fibrosis between biopsies [112]. In a UK 
population of predominantly patients with mild liver disease on initial biopsy; 
183/214 (85.5%) with Ishak stage 0 or 1 and a  median interval between 
biopsies of  30 months, a third of patients progressed by at least 1 Ishak stage 
and 11% by at least 2 stages.  This equated to an overall rate of fibrosis 
progression of 0.17 Ishak fibrosis stages/ yr [113].

Histological scoring systems for fibrosis do by necessity consist of rather arbitrary 
points on a continuum between normal and cirrhosis. Evaluation of the collagen 
proportionate area demonstrates that the relationship between the Ishak stage and the 
amount of fibrous tissue is non/linear. The greatest gains in fibrous tissue are seen 
between stage 3 and 5, with the higher stages in particular depending more on 
architectural change than fibrous tissue [114]. Since progression through each 
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stage does not follow a straight line, there has been justified criticism of studies 
such as those described above, that apply statistical analysis to the numerical 
value of the stages in order to calculate an annual fibrosis progression rate 
[114]. Though fibrosis progression between Ishak stages is non/linear, the 
stages have been shown using data collected from the HALT/C trial to have 
prognostic value. Using a composite clinical outcome that included an increase 
in Child/Pugh score to ≥ 7, ascites, encephalopathy, bleeding varices, 
hepatocellular carcinoma or death, the 6 year cumulative incidence of first 
outcome showed a remarkably linear increase through each stage – 2 (5.6%), 3 
(16.1%), 4 (19.3%), 5 (37.8%) and 6 (49.3%) [115].  
 
Several factors (Table 1.3) can accelerate fibrosis progression in a given 
individual. Age is the key factor enhancing fibrosis risk, with a stepwise 
reduction in the median duration to cirrhosis with advancing age at infection; 
from 44 years (40/48) in those infected aged 20 years or less, to 30 years (25/
36) for those aged 31/ 40 years and 12 years in those older than 50 years at the 
time of infection [111]. Age 	 	 also appears to be important during 
infection with HCV, with the rate of fibrosis progression suggested to increase 
in those over the age of 50 years whatever the duration of infection [116].  
These findings also strongly suggest that fibrosis progression is not linear, the 
risk increasing with increasing age. The means by which age influences 
fibrosis progression is uncertain but evidence taken from fibrosis progression 
in the post liver transplant setting suggests that it is liver factors which are the 
most important.  Patients who received a liver from a donor aged less than 40 
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years progressed to cirrhosis after an average of 10 years, compared to 6.7 
years if the donor was aged 41/ 49 years  and 2.2 years if 50 years or older 
[117]. An ageing liver might be more vulnerable to progression of fibrosis via 
an increased vulnerability to oxidative stress or a reduction in hepatic blood 
flow or mitochondria capacity. 
 
Fibrosis progression is also greater where another cause of liver injury is 
present.  Alcohol intake >50g/d has been consistently associated with an 
increased rate of fibrosis progression in HCV [111, 116, 118/120], the rate of 
fibrosis increasing by 34% in those drinking > 50g/d compared to non/
drinkers[111]. In another study of 176 HCV infected patients; those who drank 
> 40g/d for women and > 60g/d for men had a 58% chance of having cirrhosis 
by the second decade of infection compared to 10% who drank non significant 
levels [119]. Lower levels of alcohol intake may still carry an increased risk. In 
a paired biopsy study of patients who drank < 40g/d, more progressive fibrosis 
was observed in those with higher levels of alcohol consumption (5.7 vs 2.6g/ 
day P=0.03) and a higher drinking frequency (34.5 vs 8.2 days/ year P=0.006) 
[121].  It is suggested that alcohol accelerates fibrosis progression in HCV 
through its effect on both the virus (increased viral load and increased mutation 
(quasispecies)) [122] and on the liver through increased apoptosis, steatosis, 
increased iron stores and through oxidative stress secondary to the increased 
production of oxygen free radicals [123]. 
 
Co/infection with other viruses also plays an important role in fibrosis 
progression. A meta/analysis of published data in HIV co/infection shows that 
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fibrosis progression is increased at least 2/fold [124]. Liver fibrosis progresses 
faster in HIV co/infected patients as compared to those with HCV infection 
alone, with expected time to cirrhosis of 26 years compared to 34 years [125]. 
A CD4 cell count of ≤ 200 cells/ µl was an independent factor associated with 
higher liver fibrosis rates suggesting it may be immunosuppression, as is also 
seen post liver transplantation [126] and in patients with primary 
hypogammaglobulinaemia [127] that influences fibrosis progression. Similarly, 
patients with co/infection with either Hepatitis B (n=19) or B and D (n=17) 
have been shown to exhibit more severe fibrosis at presentation than with HCV 
infection alone [128]. Conversely, HCV has been shown to accelerate 
progression of HIV to Acquired immunodeficiency syndrome (AIDS) [129]. 
 
HepaticSteatosis is a frequent histological finding in chronic HCV infection 
and HCV core protein causes progressive steatosis in a transgenic mouse 
model [130].  Cross/sectional studies of HCV infected patients have shown 
higher grades of steatosis to be associated with an increased body mass index 
(BMI) and that these patients have higher serum levels of ALT, increased 
periportal necrosis and increased levels of fibrosis [131/132]. In patients with a 
known date of infection the estimated annual rate of fibrosis progression was 
higher in those with steatosis grade 3/4 (> 30% of hepatocytes affected) 
compared to lower grades [132]. Progression of fibrosis between paired 
biopsies is also more likely if patients had steatosis evident on the first 
biopsy[133]. This effect was seen mainly in genotype 3 patients, and it is well 
recognised that steatosis is more common in this group than with other 
genotypes [133/134]. Further evidence highlighting the importance steatosis 
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plays in fibrosis progression comes from a small study where  a 3 month 
weight reduction programme led to reduction in steatosis on the second biopsy 
in 9/10 patients with 5/9 showing decreased fibrosis [135]. The mechanism is 
not understood but it is hypothesised that steatosis increases lipid peroxidation 
which in turn increases stellate cell activation [131]. It is also likely that 
genotype 3 exerts a direct cytopathic effect involving steatosis with reports of 
steatosis disappearing after successful antiviral therapy [136].  
 
Steatosis in HCV infection is also intimately associated with insulin resistance, 
particularly in genotype 1 infection  [137]. Increasing insulin resistance 
(homeostasis model assessment of insulin resistance / HOMA/IR > 2) 
correlates positively with the stage of fibrosis in HCV [138]. This association 
is independent of obesity and diabetes [139]. 
 
Given that steatosis is much more common in genotype 3 HCV infection it 
may be expected that this genotype would carry a greater risk of fibrosis but 
there is little concrete evidence to support this. Data from a UK registry 
suggests that genotype 1 infection is associated with a histological stage above 
the median compared to non/genotype 1 types (OR 2.03, 95% CI 1.07/3.83, P 
= 0.03) [100]. Indeed, there have been several other reports that genotype 1b is 
associated with more severe disease, but this may simply be a cohort age 
related effect as this genotype formed the first wave of infected humans in 
Europe [141/142]. Benvegnù 	
[143] examined histopathological severity in 
429 HCV positive patients and found no association with genotype. In addition 
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/ ≤ 20 years                      
                                             21/30 years 
                                             31/40 years 
                                             41/50 years 
                                               > 50 years
 
                                         44 (40/48) 
38 (32/40) 
30 (25/36) 
20 (17/23) 
12 (11/15) 
 
 
< 0.001 
 
 
Poynard et al [111] 
 
= Female
                                                 Male 
 
                                         36 (32/40) 
26 (24/28) 
 
< 0.05 
 
Poynard et al [111] 
 
04/1$10 African American 
                                   Non African American 
 
% cirrhotic by 2nd decade of infection  / 9%      4th*   / 22% 
                                                              / 28%             / 51% 
 
* <0.05 
 
Wiley et al.[140] 
 
5$45*15 Nil
                                                 1/49g 
                                                 ≥ 50g 
 
                     ≤ 40g (women) or ≤ 60g (men) 
                      > 40g (women) or > 60g (men) 
 
                                         32 (28/36) 
28 (25/34) 
24 (23/30) 
 
% cirrhotic by 2nd decade of infection  / 10% 
                                 / 58% 
 
 
< 0.05 
 
 
Poynard et al [111] 
 
 
Wiley et al.[119] 
 

 HIV infection 
                                           Non/ HIV infected
 
26 (22/34) 
38 (32/47) 
 
<0.001 
 
Benhamou et al [125] 
 

3*01$0*01 a)Nil 
                                         b)  Grade 1/2 
                                         c)  Grade 3/4 
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17 
 
a v c = <0.001 
b v c = 0.03 
 
Adinolfi et al [132] 
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                                                 3 
 
31 (20/44) 
44 ( 36/50) 
24 (18/32) 
 
 
ns 
 
 
Poynard et al [111] 
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no correlation has been reported between the level of viraemia and liver 
fibrosis outside of the transplant setting [144/145]. 
 
 
Hepatic ironoverload is known to cause hepatic fibrosis and iron is an essential 
element in viral replication. Serum iron stores, though not necessarily hepatic 
iron concentration are frequently increased in chronic HCV [146/147]. The 
presence of iron staining on liver biopsy was associated with a higher stage of 
fibrosis in a study of 38 HCV positive patients[148], though there was no 
correlation between the amount of iron and fibrosis score. It has also been 
suggested that iron may be released from damaged hepatocytes [149], and the 
question of whether the relationship between hepatic iron and fibrosis 
progression in chronic HCV is one of cause or effect is unanswered. In a study 
of 164 HCV positive patients neither the C282Y or H63D mutation was 
associated with an increase in the hepatic iron concentration or in the grade or 
stage of the HCV related liver injury [150].  
 
Male sex has been consistently shown to increase fibrosis progression. Poynard 
	
  [111], showed male sex to be an independent risk factor for fibrosis 
progression with the median duration to cirrhosis reduced from 36 years for 
women to 26 years for men. A protective role for oestrogen, possibly by 
inhibiting the proliferation of stellate cells and fibrogenesis is proposed as an 
explanation for this difference. 
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The influence of ethnicity on the likelihood of spontaneous viral clearance has 
been described and may in part relate to IL28B polymorphism. The evidence 
for racial differences in terms of fibrosis progression is less robust. A 
retrospective examination of 112 African Americans and 243 non/African 
Americans suggested that significantly fewer African Americans had cirrhosis 
in the 3rd (18 vs 31%, P ≤ 0.05) and 4th (22 vs 51%, P ≤ 0.05) decades of 
exposure, though there was no difference in the overall mean fibrosis grade 
[140].  There were no differences in sex or alcohol consumption to explain the 
observations, though the study was not controlled for other potential 
confounders.  Host genetic factors will clearly account for some of the 
variability in disease progression. IL28B polymorphism has been shown to 
influence biochemical and histological levels of inflammation in the post liver 
transplant setting, but not fibrosis progression [151]. An initial genome wide 
scan which included 24,823 candidate single nucleotide polymorphisms 
(SNPs) in 433 biopsy proven chronic HCV patients, identified 100 potential 
SNPs  associated with an increased risk of advanced fibrosis, though the 
association only held for two in the validation cohort [152]. Further study by 
the same group identified a seven gene signature, termed the “cirrhosis risk 
score” (CRS), which consisted of those markers most predictive for developing 
cirrhosis. The CRS had an area/under/the/ROC curve (AUC) of 0.75 in the 
training cohort and 0.73 in the validation cohort [153]. The CRS has been 
further validated in cohorts of patients from Italy, Belgium and Germany [154/
155]. Variations in genes encoding key cytokines involved in human 
fibrogenesis, in particular inheritance of high TGF/ß1 and angiotensinogen 
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producing genotypes have been found to be associated with fibrosis 
progression [156].   
 
The route of transmission of HCV has been proposed as an important factor in 
disease progression. In a large French study of 5,749 patients a significant 
increase in the prevalence of cirrhosis was found in transfusion recipients 
(23.4%) compared to the IDU group (7.0%) [157]. This difference was 
independent of age at infection and duration of disease. The authors proposed 
that that this difference could be due to either the HCV genotype or an 
increased amount of injected viral inoculum associated with blood transfusion.  
 
Necroinflammatory activity at liver biopsy has been shown in some [112, 158/
159] but not all studies [111, 113] to be an independent predictor of fibrosis 
progression. Fontaine et al [158] found that of those patients with a low initial 
activity (METAVIR A0/A1) 13.3% had an increase in fibrosis compared to 
43.8% if there was a high initial activity index (METAVIR A2/3) (P < 0.01). 
Cirrhosis developed in all patients with a high grade of necroinflammation on 
initial biopsy, when followed/up for at least 10 years [159]. The location of 
activated hepatic stellate cells has also been shown to correlate with areas of 
necroinflammatory injury further supporting an association [160].  




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In the absence of cirrhosis, the majority of individuals with Chronic HCV are 
asymptomatic or have mild non specific symptoms[161]. The most frequent 
complaint is fatigue, with other less common manifestations include nausea, 
anorexia, myalgia, arthralgia, weakness, and weight loss. Fatigue is a common 
complaint and in a study of HCV patients without cirrhosis versus healthy 
blood donors, fatigue was the most commonly reported symptom in both 
groups (62% vs 70%) [162]. Symptoms are rarely incapacitating and may be 
difficult to ascribe to liver disease; nevertheless, chronic HCV may lead to a 
decrease in the quality of life [163/164], which may in part be accounted for by 
awareness of infection[165], and which can be improved following successful 
treatment [166].         
Extrahepatic manifestations are seen in 1/2% of patients with chronic HCV 
[167/168] and may be a direct consequence of HCV infection or secondary to 
the resulting immune stimulation. A mixed cryoglobulinaemia is the most 
common and was 11 times more frequent in a US Veterans HCV cohort than in 
a control population [167]. Immune complex deposition in various organs leads 
to fatigue, rash, arthralgia, Raynaud’s phenomenon, vasculitis, renal disease 
and peripheral neuropathy. Other conditions possibly associated with HCV 
include a membranoproliferative glomerulonephritis, porphyria cutanea tarda, 
lichen planus, vitiligo, non/Hodgkins lymphoma, autoimmune thyroiditis, 
Sjögrens syndrome and a seronegative arthritis.  
 

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The “disease burden” is the impact of a disease on the health of a population 
and includes its effect on longevity (mortality and years of life lost because of 
premature death); morbidity, including impairment of health and quality of life; 
and finance, including direct healthcare expenditure and indirect costs related 
to loss of income from premature deaths or disability. In terms of HCV; 
Morbidity in the advanced stages of the disease may include the development 
of hepatocellular carcinoma together with complications of portal hypertension 
and liver failure, including ascites, variceal haemorrhage and hepatic 
encephalopathy. Experts have estimated that HCV accounts for 20% of cases 
of acute hepatitis, 70% of cases of chronic hepatitis, 40% of cases of cirrhosis, 
60% of cases of hepatocellular carcinoma (HCC) and 30% of liver transplants 
in industrialised countries [169]. Though it is suggested that the seroprevalence 
of HCV infection peaked in the United States in 2001 and will fall by half by 
2030 [27], the same modelling points to the proportion of patients with 
cirrhosis reaching 45% in 2030 and the total number with cirrhosis to peak in 
2020. Hepatic decompensation and liver cancer will be expected to continue to 
increase for a further 10 to 13 years after the peak in cirrhosis. Similar 
modelling for an English population suggests a doubling in the number of 
patients with HCV related cirrhosis and HCC between 2005 and 2015. The 
number of HCV infected people living with compensated cirrhosis is predicted 
to increase from 3705 (95% CI 2820/4975) in 2005 to 7550 (95% CI 5120/
11640) in 2015 while those with decompensated cirrhosis or HCC will increase 
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from 1150 (95% CI 1055/1250) to 2540 (95% CI 2035/3310) [170]. These 
projections point to an increasing burden associated with HCV over the coming 
years.  
 
Mortality statistics are often based on death certification and their quality is 
dependent on the accuracy with which the death certificate is completed. In a 
study of mortality rates in a UK cohort of HCV infected patients, HCV was 
mentioned on 23% of death certificates and only on 52% of those dying of liver 
disease [171]. Matching records from a sentinel surveillance scheme and death 
records suggested that the true number of deaths in the UK from HCV is 185/
257% higher than recorded in mortality statistics [172]. Mortality data based on 
death certification data alone will, therefore, invariably underestimate mortality 
associated with HCV, though trends over time may still be of interest. The 
number of deaths in England due to end stage liver disease  or HCC with any 
mention of HCV on the death certificate increased from 81 in 1996 to 230 in 
2008 [34]. Analysis of HCV related mortality rates in the US over a similar 
period (1995/2004) showed a 123% increase in mortality during the study 
period (1.09 per 100,000 persons to 2.44 per 100,000) [173]. In the last year of 
study there were 7427 HCV related deaths (mean age 55 years) corresponding 
to 148,611 years of potential life lost.   
         
A more accurate estimation of the mortality attributable to HCV comes from 
linkage studies that match persons within population [174/175] and clinic 
databases [171, 176/177] with national registries of deaths. The standardised 
mortality ratio (SMR) was 3 times higher than expected in a cohort of 2285 
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HCV patients identified from a secondary care database (Trent HCV study). 
Excess deaths were liver and drug/use related with a pattern between age and 
cause of death, with murder, suicide, and drug overdose mortality peaking 
between 36 and 42 years, while deaths from cirrhosis occurred at a median age 
of 51.4 and liver cancer 63.7. Age, sex, antiviral therapy (protective) and liver 
fibrosis were predictors of all cause mortality while age, antiviral therapy, liver 
fibrosis and mean alcohol consumption predicted a liver/related death [171]. 
The largest population study included 75834 persons with HCV (and 2064 with 
Hepatitis B co/infection) notified to the New South Wales, Australia health 
department between 1990 and 2002. 5.3% of HCV infected patients died 
during the study period (7.1% with co/infection) and the all/cause mortality 
was again approximately three times that expected (SMR 3.1 [95% CI 3.0/
3.2]). The all/cause mortality in Hepatitis B co/infected patients was higher 
still, with an SMR of 5.6 (95% CI 4.8/6.6). The liver/related SMR was 16.8 
(95% CI 15.4/18.3) and 32.9 (95% CI 23.1/46.7), and the drug use/related 
SMR was 19.3 (95% CI 18.1/20.5) and 24.7 (95% CI 18.2/33.5) in mono/
infected and co/infected patients respectively [174]. There was again a bimodal 
distribution of death with younger people dying of lifestyle related problems 
and a later peak from liver disease. Both these studies may have 
underestimated mortality relating to HCV, in that they both excluded deaths in 
the first 6 months [174] or year [171] after diagnosis without a corresponding 
adjustment in the time at risk which remained from the time of diagnosis. 
Authors of the Australian study showed that correction of this methodological 
flaw slightly increased the observed SMRs [178]. A similar threefold increase 
in mortality was seen in a study of HCV infected and non/infected US blood 
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donors, including a significantly increased mortality from liver disease, drug 
and alcohol use, trauma/ suicide and perhaps unexpectedly cardiovascular 
causes [179].          
  
A higher mortality was seen for 20163 HCV infected persons and 4637 HIV 
co/infected persons living in Scotland between 1991 and 2005 [175]. The all 
cause SMR was 5.5 (95% CI 5.5/5.7) and 33.8 (95% CI 28/36.1), and the mean 
age at death 45.4 years and 38.4 years for mono/infected and HIV co/infected 
patients respectively. The majority of deaths were related to drug/use (30%), 
but liver disease contributed significantly (26%) and was ahead of circulatory 
(11%) and neoplastic (8%) causes.  

Assuming an average life expectancy in Northern European populations of 
mid/70s for men and mid/80s for women then collectively mortality data 
suggests a reduction in overall life expectancy in HCV infected individuals of 
8/12 years [180].  

The morbidity associated with HCV and the burden for people living with the 
condition can be described in terms of “years of healthy life lost to disability” 
(YLDs). Disability refers to any departure from a state of perfect health and 
YLDs are weighted according to the severity of the condition.  Using data 
collected by the WHO[181] it is suggested that across the WHO European 
region HCV caused 200,104 YLDs in 2002, with 96% due to HCV related 
cirrhosis. The “disability adjusted life year” (DALY) is a time based measure 
that combines years of life lost due to premature mortality and years lost due to 
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time lived in a state of less than full health. 1.2 million DALYs were lost due to 
HCV in the WHO European region in 2002, which corresponds to 134.54 
DALYs per 100,000 residents. HCV related cirrhosis accounted for 81% of lost 
DALYs and the overall figure for HCV was similar to that for HIV/ AIDS and 
stomach cancer [182]. 
 
Linkage studies of HCV notifications and hospital admission records also 
demonstrate an increase in hospitalisation associated with HCV. In the New 
South Wales, Australia cohort described earlier, rates of hospital admission 
were 42% higher than expected. Standardised Hospitalisation ratios were 
calculated using rates of hospital admission for the New South Wales 
population by 5 year age group, sex and calendar year of hospitalisation. The 
greatest excess was in 15/19 year olds (Standardised Hospitalisation ratio, 
SHR, 3.8 [95% CI 3.4/4.2]). Lifestyle factors accounted for the highest 
absolute and relative rates in young adults while liver disease contributed the 
greatest burden in older adults [183]. In a similar study of a Scottish cohort the 
any diagnosis SHR when adjusted for age, sex and social deprivation was 3.4 
(95% CI 3.3./3.5) and for liver related admissions 41.3 (95% CI 39.6/43)[184].  
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Hepatocellular cancer (HCC) is the third most common cause of cancer death 
in the world (approximately 600,000 deaths/ year). The poor prognosis means 
that the number of deaths is almost the same as the number of cases [185]. 
Chronic HCV is a major risk factor for HCC and together with Hepatitis B 
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accounts for 80% of HCC worldwide [186]. Markers of HCV infection are 
found in 44/66% of HCC cases in Italy [187/189], 27/58% in France [190], 60/
75% in Spain [191] and 80/90% in Japan [192]. In a meta/analysis of 21 case 
control studies HCC was increased 17/fold (95% CI 14/22) in HCV infected 
patients [193].  
 
HCC is currently one of the fastest growing causes of cancer/related deaths in 
many developed countries, with age/adjusted incidence rates in the US having 
increased more than 2 fold from 1985 to 2002 [194/195]. Much of the increase 
in HCC observed in the developed world can be ascribed to HCV infection 
[196/197]. In several European countries the age standardised death rate from 
HCC correlates with the seroprevalence of HCV [198]. In a study of persons ≥ 
65 years from the US SEER/medicare database the incidence of HCV related 
HCC increased by 226% between 1993 and 1999 compared to a 67% increase 
for HBV related HCC [199]. Incidence rates for HCC in Japan tripled between 
1970 and 2000 and the proportion due to HCV increased from 49% of cases in 
1982, to 61% in 1990, and 81% in 2003 [200]. Since 1995 the rate of the rise in 
HCC in Japan has slowed and this may predict future trends in HCC incidence 
elsewhere given the different temporal trends in HCV transmission between 
regions described earlier.   
 
The HCV virus unlike HBV is not able to integrate into the genome of the 
infected cell. It typically, therefore, causes HCC via the indirect route of 
chronic inflammation, cell death, proliferation and cirrhosis. HCV related 
HCCs are, therefore, almost exclusively found in patients with cirrhosis and the 
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majority occur 25/30 years after the onset of infection [106, 201]. The rare 
cases of HCC in HCV infected patients without cirrhosis raises the possibility 
of a direct pathway mediated through viral protein expression, with the 
transforming potential of NS3  and core/protein described [202]. The rate of 
HCC development in HCV infection is 1/3% after 30 years [203]. Once 
cirrhosis is present then an annual rate of 1/4% is observed [204], though as 
high as 7% is reported in Japan [205]. Prospective studies in Europe have 
shown too few HCC in non/cirrhotic patients to calculate an incidence rate 
[206/207], but in Japan the incidence per 100 person years rises with 
incremental increases in liver fibrosis (F0/1: 0.4, F2: 1.5, F3: 5.1 and F4: 6.9 
per 100 person years) [208]. The annual incidence of HCC in the Hepatitis C 
Antiviral Long/term Treatment against Cirrhosis (HALT/C) study [209] was 
1.4% in the cirrhotic group and a surprisingly high 0.8% in the non/cirrhotic 
group, though all patients entered in this study had significant fibrosis (Ishak 
fibrosis stage 3/6).  
 
There are a number of risk factors and co/factors that influence the likelihood 
of developing HCC in association with HCV infection.  Those factors that 
accelerate fibrosis progression which were described earlier will shorten the 
time to cirrhosis and consequently also to HCC. These include age (2/4 fold 
increase in HCC in those over 55 years [210/211]) and male sex (2/3 fold 
increase over females [212]).  Co/infection with HBV significantly increased 
the risk of HCC in the Italian Brescia HCC study, with an OR 165 (95% CI 81/
374) for HBV/ HCV co/infection compared to 17 for HCV and 23 for HBV 
alone [213]. Markers of prior HBV infection (anti/HBc and/or anti/HBs) are 
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also associated with a 2 fold excess risk of HCC in patients with HCV cirrhosis 
[205]. The Brescia HCC study together with others have also showed a synergy 
between HCV and alcohol in the pathogenesis of HCC, with a 2/4 fold excess 
risk in those consuming greater than 60/80g of alcohol/ day [214/215].  Type 2 
diabetes is associated with a 1.5 fold increase in the risk of HCC in the 
presence of other major risk factors for HCC such as HCV, but also alcohol 
and HBV [216]. The increased risk associated with diabetes may simply reflect 
the increased prevalence of steatohepatitis in the diabetic population as hepatic 
steatosis is known to increase the risk of HCC in conjunction with HCV [217]. 
Type 2 diabetes is also associated with hyperinsulinaemia which may act as a 
potential hepatocarcinogen [218]. Caucasians are 2/3 times less affected by 
HCC than African Americans who in turn are 2/3 times less affected than 
Asians, Pacific Islanders and Native Americans in the United States [194]. 
While much of the race difference probably relates to prevalence and 
acquisition times for the major HCC risk factors (HCV/ HBV), these ethnic 
differences are also observed within the HCV infected population. In a case 
control study of 464 patients with HCV and cirrhosis (207 cancer patients and 
257 controls) the cancer risk was increased significantly among Asians 
(adjusted OR, 4.3 [95% CI, 2.1/9.0] for men, and 4.6 [95% CI, 1.2/18.5] for 
women) and somewhat increased among African/American men (adjusted OR, 
2.4 [95% CI, 0.9/6.3]) [219]. It is less clear whether hepatic iron is associated 
with an increased risk of HCC in HCV with studies both in support [220] and 
against [221] hepatic iron being more frequently increased in HCV patients 
with HCC compared to those who are HCC free. 

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 End/stage HCV accounts for more than 40% of liver transplants in Europe and 
North America [222]. Between 1990 and 2000 there was a 5/fold increase in 
the number of orthotopic liver transplant recipients with HCV in the US and 
the proportion of recipients with HCV increased from 12 to 37% [223]. More 
than a third of patients transplanted for HCV will have HCC [224].  Recurrent 
HCV post transplantation is universal in patients who are viraemic before 
transplantation and the natural history follows an accelerated course compared 
to the pre/transplant setting. Most patients will develop histological features of 
acute hepatitis C between 4 and 12 weeks post transplant [225], associated with 
a steep rise in HCV viral load [226]. Within 5 years of transplantation, 10/30% 
of patients will have progressed to cirrhosis [227] and this increases to more 
than 40% after 10 years [222].  Once cirrhosis develops the rate of 
decompensation is also higher at more than 40% at 1 year and 70 % at 3 years 
[228/229] compared to less than 5% and 10% in the non/transplant setting 
[211]. Patient survival following the onset of allograft failure is less than 10% 
at 3 years [229] compared to greater than 60% following decompensation in 
the non/transplant patient [211]. A small number of patients (2/5%) will 
develop a severe cholestatic form of recurrent HCV infection with histological 
features that include intrahepatic cholestasis and biliary ductal proliferation. 
Most such cases rapidly progress to allograft failure and death within the first 
year after transplantation.  
 
The long term outcome for HCV positive liver transplant recipients is poorer 
than for patients transplanted for other indications. There is a decreased graft 
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and patient survival for HCV positive recipients beyond 5 years post 
transplantation [230/231]. Patient survival at 3 years in US transplant centres 
was 78% for HCV positive recipients and 82% for HCV negative recipients 
(HR 1.14 95% CI 1.05/1.23, P<0.001) between 1991 and 2001. In Europe, 7 
year graft and patient survival was 51% and 55% for HCV positive recipients 
and 67% and 70% for HCV negative recipients [227]. There is some evidence 
to suggest that fibrosis progression may be linear for the first few years post 
transplant, but that accelerated progression is observed beyond 5 years [232].  
 
As in the pre/transplant setting there are a number of factors associated with 
the accelerated progression of fibrosis in recurrent HCV. It is typically donor 
factors together with the management of immunosupression and not recipient 
factors that influence the rate of progression. Recipient variables, including 
age, sex, HLA type and ethnicity do not appear to significantly affect the 
severity of HCV recurrence [233]. As described earlier the age of the liver 
infected with HCV and not necessarily the patient’s age has most bearing on 
fibrosis progression. A median rate of fibrosis progression of 0.6 Ishak[110] 
fibrosis stages/ year in donors younger than 40 years was observed compared 
to 2.7 fibrosis stages/ year where the donor was older than 50 years. This 
equated to a reduction in the time to cirrhosis from 10 years to 6.7 years [117]. 
In another series with a median follow/up of 3 years only 14% of patients who 
received a donor organ from a donor less than 30 years developed cirrhosis, 
compared to 45% where the donor was aged 31/59 years and 52% if more than 
59 years [234]. A number of viral factors including genotype, and quasispecies 
emergence have been variably reported to impact on the severity of recurrent 
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HCV [233], but only a high viral load at the time of transplantation appears to 
hold a strong association [235/236]. Infection with Cytomegalovirus (CMV) 
and Human herpesvirus 6 post transplantation has been repeatedly and strongly 
associated with an increased severity of recurrence [237/238], even after 
adjusting for covariables such as degree of immunosuppression [239].   
 
Donor factors are to some degree amenable to modification or selection. The 
treatment of the donor liver following harvesting can influence the post 
transplant course of recurrent HCV. Both the length of cold (cooling post 
procurement surgery to implantation) [240]  and warm ischaemic times 
(implantation to reperfusion via portal vein) [241] correlate with the severity of 
recurrent disease and graft survival, as do poor quality grafts either from non/
heart beating donors or as a result of preservation injury leading to biliary 
complications [242]. On the other hand the use of HCV positive donors does 
not worsen progression or survival [243]. The choice of immunosuppression is 
also amenable to modification with bolus steroid therapy [236] and T cell 
depleting therapies [244/245] both associated with an accelerated disease 
course when used to treat rejection. Steroid sparing immunosuppression 
protocols have to date, however, failed to demonstrate a benefit [246/247] and 
most practitioners will maintain patients on a low dose of steroids with the 
addition of Azathioprine. Ciclosporin based protocols may also be beneficial as 
it possesses weak antiviral activity, though this is only against genotype 1b 
[248], while tacrolimus enhances HCV replication [249].  
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There is also an economic and utilisation of healthcare resources burden 
associated with HCV. Using computer modelling of the NHANES III HCV 
cohort, the calculated direct medical costs relating to HCV in the US are 
estimated to be $6.5/13.6 billion for the period 2010/19. Additional indirect 
costs relating to premature death and disability from decompensated cirrhosis 
and HCC were $21.3 and $54.2 billion respectively [250]. Analysis of a US 
insurance claims database (2002/6), showed HCV patients to have significantly 
higher healthcare expenditure ($20,961 vs $5451) and hospitalisation (24% vs 
7%) compared to age, sex and plan enrolment matched controls [251]. Analysis 
of hospital admission and prescription data shows an accelerated growth in 
healthcare resource utilisation due to HCV. Over an 8 year period (1994/2001) 
there was a 200% increase in hospitalisation associated with a 3/4 fold increase 
in complications relating to HCV infection [252]. Other studies confirm a high 
number of hospitalisations and physician visits associated with HCV [253/
254].   

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According to the results of modelling of HCV seroprevalence and 
complications, treatment of all infected patients in 2010 could reduce risk of 
cirrhosis, decompensation, cancer, and liver/related deaths by 16%, 42%, 31%, 
and 36% by 2020 [27]. Treating just 10 or 50% of the HCV population will 
result in a 6 and 26% reduction in morbidity and a 4 and 20% fall in mortality 
respectively by 2030 [255]. A significant barrier to this goal is that the majority 
of HCV infection is undiagnosed. There are an estimated 200,000 HCV 
infected patients in England, but at the time of the Department of Health’s 
2004 Hepatitis C Action plan only 38,000 diagnosed cases were reported [256]. 
By the end of 2008 this number had increased to 69,865  [34]. Similarly in 
Scotland it is estimated that two/thirds of chronically HCV infected individuals 
are undiagnosed and that two/thirds of this group are former IDUs [257]. This 
may in part be due to a lack of awareness and knowledge of HCV among both 
at risk groups and healthcare professionals. Results of a survey of primary care 
physicians in New Jersey, United States suggested insufficient knowledge 
regarding viral hepatitis risk factors [258]. In another survey of 1412 US 
primary care physicians only 70% reported that they tested for HCV in all 
patients with risk factors and only slightly more (78%) tested all patients with 
elevated liver enzymes for HCV [259]. In the United Kingdom the Royal 
College of General Practitioners have issued guidance on prevention and 
diagnosis of HCV in primary care [260]. The majority of new HCV infections 
in industrialised countries are through IDU. In a sample of young (15/30 years) 
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IDUs from five US cities (HCV seroprevalence of 34.1%), 72% of anti/HCV/
positive and 46% of anti/HCV/negative IDUs were not aware of their HCV 
serostatus. Those IDUs who knew they were anti/HCV/negative were less 
likely than those unaware of their status to share needles or other injecting 
paraphernalia, but knowledge of a positive test result was not associated with 
safer injection practices[261]. Within another sample of street recruited IDUs 
unaware of their HCV infection status, 61% tested positive [262].  

Given the prevalence of undiagnosed HCV infection, there may be a role for 
population or targeted screening for HCV. France introduced a voluntary, 
anonymous, cost/free screening programme, supported by a media campaign 
that led to a 20% increase in testing per year between 1998 and 2002. By the 
end of 2002 approximately 60% of all new cases of HCV were diagnosed 
through screening [263]. In Japan there is nationwide testing for anti/HCV at 5 
year intervals in those over the age of 40 years [200]. The US preventive 
service task force concluded, however, that there was insufficient evidence on 
which to recommend either population or targeted screening of high risk 
groups [264/265]. Independent review of the evidence supports targeted testing 
in high prevalence groups, but nationwide population screening is unlikely to 
be cost effective [266/267].  
 
Targeted screening of 4998 individuals from the Asian community, living in 
England showed an overall seroprevalence of HCV in this population of 1.6%, 
but it varied by country of birth being 0.4%, 0.2%, 0.6% and 2.7% in people of 
this ethnic group born in the UK, India, Bangladesh and Pakistan, respectively 
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[268]. A study of opportunistic testing and counselling of 30/54 year old 
attendees at a primary care practice in an area of high HCV seroprevalence and 
drug use in Scotland identified 584 eligible attendees, of which 117 (28%) 
accepted testing. The overall seroprevalence of anti/HCV was 13% (15/117) of 
which the majority (13/15) were current or former IDUs. The authors 
concluded that targeted testing of current and former IDUs would be a more 
effective intervention [269]. Dried blood spot and oral fluid testing have both 
been found to be useful methods with which to conduct public health 
surveillance for HCV among IDUs [270], a group in whom it can be difficult to 
obtain blood samples through conventional phlebotomy. The sensitivity and 
specificity of a commercial dried blood spot test is of the order of 99% in 
detecting anti/HCV [271]. In a controlled study of HCV testing in 22 specialist 
drug clinics and 6 prisons there was a 14.5% increase in uptake of testing in the 
intervention sites offering dried blood spot testing [272].  
 
 
There remain barriers to treatment even in those with a positive anti/HCV test. 
Between 2000 and 2002, 256 individuals tested positive for HCV through a 
single Public Health laboratory. Less than half were subsequently referred to an 
appropriate specialist clinic and only 10% started treatment. The route of 
testing influenced whether patients were referred for specialty care with 64.3% 
of positive tests performed in primary care leading to referral, compared to 
42.4% from drug and alcohol units and just 18.4% from prisons. Only 68/125 
(54%) of patients referred went on to attend their clinic appointment [273]. 
Prison outreach clinics have become a popular means of addressing 
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deficiencies in the testing and treatment of a population with a high HCV 
seroprevalence. Of 41 HCV RNA positive patients identified by a prison 
outreach clinic led by specialists from Southampton University Hospitals Trust 
only 6 were deemed eligible for treatment due in a large part to 
contraindications, particularly psychiatric disease, but also to logistical reasons 
such as the movement of prisoners [274]. Interrogation of the department of 
Veterans database identified 113927 HCV infected patients during the period 
1999/2003. The prescription rate for antiviral therapy was 11.8%. Non/
treatment was associated with increasing age, non/white race, drug and alcohol 
abuse/ dependence and co/morbid illnesses [275]. When questioned, the 
majority (72%) of US primary care physicians would refer an HCV/positive 
patient with elevated aminotransferases to a specialist, but only 28% would do 
so if the aminotransferases were normal [259]. 

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The immediate goal of HCV treatment is to achieve a sustained virological 
response (SVR), defined by the continued absence of HCV RNA 6 months 
after completion of therapy. Several studies have demonstrated that this 
response is durable in more than 99% of patients receiving the current standard 
of care [276/279]. There were attempts to treat HCV even before identification 
of the virus. Interferon α was shown to be of benefit in the treatment of chronic 
non/A, non/B hepatitis in 1986 [280], though trials in the mid 1990s of 
interferon monotherapy administered by subcutaneous injection three times a 
week were associated with an overall SVR of only 6/10% [281/282]. The 
addition of the broad spectrum antiviral agent ribavirin, a guanosine nucleotide 
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analogue subsequently increased the SVR rate to more than 30% [283/284]. 
Combination therapy has been further refined by the substitution of standard 
interferon with pegylated interferon, where polyethylene glycol is covalently 
attached to interferon in order to increase its half life. Pegylated interferon 
together with ribavirin forms the current standard of care for chronic HCV and 
is associated with an SVR in approximately 50% of patients [285/287]. 
 
Despite these advances in the treatment of HCV, the mechanisms by which 
interferon and ribavirin achieve viral clearance are not fully understood.  
Interferon α has potent antiviral activity but does not act directly on the virus. 
Instead it binds to cell receptors, which in turn leads to the induction of 
interferon stimulated genes which confer antiviral activity within the cell [288]. 
The mechanisms by which the virus can evade the action of interferon include 
inhibition of the transcription of interferon induced antiviral genes by the HCV 
core protein [289/290] and inhibition of the interferon amplication loop by 
HCV NS3/4A protease [289, 291]. Ribavirin monotherapy has no appreciable 
effect on HCV viral load [292], but augments the antiviral action of interferon 
and appears to be particularly important in reducing the risk of relapse after 
completion of treatment. Ribavirin has a small direct effect on HCV RNA 
replication by binding to the nucleoside binding site of polymerases. It is also 
able to induce mutation in the virus, possibly pushing it towards a threshold of 
error catastrophe, appears able to alter T helper cell response, down regulates 
interferon inhibitory pathways and inhibits the host inosine monophosphate 
dehydrogenase (IMPDH) leading to depletion of  the intracellular GTP pool 
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necessary for viral RNA synthesis [293]. It is unclear though, whether any or 
all of these constitute its main mechanism of action in vivo [288]. 
 
As well as only achieving success in approximately half of patients, current 
therapy for HCV is associated with significant side effects that lead 10/20% of 
patients to prematurely discontinue treatment [294]. Fatigue, fever, headache 
and myalgia are common and were experienced by more than half of patients 
treated in the registration trials for pegylated interferon and ribavirin [285/
287]. More serious side effects include depression, witnessed in 20/30% of 
patients and probably precipitated principally by an effect of interferon on 
serotonin activity [295]. Interferon also induces neutropenia and 
thrombocytopenia, while ribavirin leads to a dose dependent haemolytic 
anaemia. Dose reduction is required during treatment in 32/42% of cases and 
in the majority of instances is explained by laboratory abnormalities [295]. 
There are also a number of contraindications to the use of interferon and 
ribavirin, including severe concurrent disease or recipients of renal, heart or 
lung transplants. Ribavirin is teratogenic and, therefore, contraindicated in 
pregnancy and in those patients with an inability to practice birth control. 
Conditions known to be exacerbated by interferon including autoimmune 
hepatitis, active psychiatric illness and untreated hyperthyroidism also 
represent contraindications [296].  
 



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There are a number of factors known to influence the response to interferon 
based therapies and, therefore the likelihood of an SVR. Table 1.4 illustrates 
some of the more important patient and viral factors associated with an SVR in 
patients treated with pegylated interferon and ribavirin.  Host factors, as 
described earlier can have a major impact on disease progression while the 
virus has little bearing. Both host and virological factors help predict treatment 
response, but here (at least until recently) the virus has been felt to be the major 
determinant. Though the underlying functional mechanism is unknown, viral 
genotype is an important predictor of SVR, with rates of 41/52% for Genotype 
1 and 76/84% for genotypes 2 and 3 [285/287]. The odds ratio associated with 
non/1 genotypes was 3.25 (95% CI, 2.09/5.12) in the randomised controlled 
trial conducted by Fried et al [286]. The degree of viral quasi/species 
complexity [297/298] and the number of mutations within specific regions of 
the genome are also associated with the likelihood of an SVR [299/301]. 
Quasi/species diversity may in  part  explain  why  early  intervention with 
interferon monotherapy for acute HCV was associated with an SVR rate of 
100% while delaying treatment for a year reduced the SVR to 53% [302], 
suggesting non/response to interferon is acquired during chronic infection.  
The baseline viral load is also an independent predictor of SVR, with an odds 
ratio for ≤400,000 iu/ml vs. >800,000 iu/ml of 3.01 (95% CI, 2.15 / 4.20, 
P<0.001) and for >400,000 to 800,000 iu/ml vs. >800,000 iu/ml of 1.64 (95% 
CI, 1.10 /2.46, P=0.02) in the study by Shiffman and colleagues [303].  
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Response to treatment is also characterised by the viral kinetic profile with 
responders typically displaying a biphasic decay of viraemia. A rapid initial 
decline reflects blocking of viral production and elimination of free virions, 
while the subsequent slower decline represents clearance of virus infected cells 
[304/305]. A Rapid Virological Response (RVR) is defined as undetectable 
HCV RNA at week 4 of treatment and in a retrospective analysis of 1383 
patients was shown to correlate with a high probability (88/100%) of SVR 
[306]. The presence of RVR generated an odds ratio of 5.47 (95% CI, 3.97/
7.52) for predicting SVR in the multiple logistic regression analysis. 
Identification of virological factors associated with improved SVR rates, has 
allowed the length of treatment to be tailored to reflect the likelihood of a 
successful outcome. Consideration should be given to shortening the length of 
treatment in genotype 1 infection where there is the combination of a low 
baseline viral load (<600/800,000) together with a RVR as more than 75% of  
patients will achieve an SVR after 24 weeks treatment [307/309].  Shortening 
treatment to 16 weeks in genotype 2/3 patients with a RVR and a baseline viral 
load of <800,000 iu/ml also has relatively little impact on the SVR rate 
achieved [303]. Early Virological Response (EVR) is defined as a viral load 
decline of ≥ 2 log10 (partial EVR) or undetectable at week 12 (complete EVR). 
Less than 3% of patients who fail to achieve an EVR will have an SVR [286, 
310] and treatment should, therefore, be stopped at week 12 when the 
requirements for EVR are not met. Genotype 1 patients with a complete EVR 
have an SVR of 80% compared to 17% in those with only a partial EVR after 
48 weeks treatment. Extending treatment to 72 weeks in those patients with a 
partial EVR increased the SVR rate to 29% suggesting a role for extended 
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treatment in slow virological responders (partial EVR and undetectable HCV 
RNA at 24 weeks) [311]. Less than 2% of patients with a partial EVR who still   
have detectable virus at week 24 will achieve an SVR and this should again 
lead to the stopping of treatment [310, 312].  
 
A number of host factors are concerned with the response to treatment. The 
best results from interferon based therapies are seen in those less than 40/45 
years, with a normal BMI and who consume minimal alcohol. Younger age 
correlates significantly with SVR with an odds ratio for ≤ 40years of between 
1.4 (95% CI; 1.1/1.9, P=0.005) [313] and 2.6 (95% CI; 1.72/3.95, P<0.001) 
[286] in clinical trials. A high BMI is inversely correlated with SVR [311, 314] 
and weight ≤ 75kg was associated with an odds ratio of 1.91 (95% CI; 1.27/
2.89, P=0.002) in the study by Fried and colleagues [286]. Shiffman et al [303] 
likewise found the odds ratio for SVR in those whose weight was ≤ 80kg 
compared to patients weighing > 80kg was 1.75 (95% CI; 1.37/2.24, P 
<0.001). These were both trials of pegylated interferon alfa/2a which is 
administered weekly in a standard dose of 180g. Trials of pegylated alfa/2b 
did not find either weight or BMI to be independent predictors of SVR, though 
here the dose is weight based which may negate any effect of obesity on SVR 
[315/316]. 
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In an earlier trial of pegylated interferon alfa/2b weight was an independent 
predictor of SVR [285], though this predated the introduction of weight based 
Ribavirin dosing which is now standard practice with both forms of pegylated 
interferon. The data for an effect of alcohol consumption on SVR is less robust, 
being based on limited data from relatively few patients; in part due to the fact 
clinical trials of antiviral therapy generally exclude patients with other potential 
causes of liver disease such as alcohol. A consumption dependent decrease in 
response to treatment with standard interferon has been demonstrated [318] and 
it has also been observed that patients who drink alcohol in the 12 months 
before treatment are more likely to discontinue treatment as compared to non/
drinkers (40% vs 26%, P=0.002), though in this prospective multicentre trial 
patients who did finish treatment had comparable response rates to non/
drinkers [319].  
 
Response rates to interferon based therapy appear to be lower in patients with 
HIV/ HCV co/infection. SVR rates range from 14/29% in genotype 1 and 44/
73% in genotype 2 and 3 infection [320/322]. HIV co/infected patients are 
more likely to discontinue therapy, in part due to increased susceptibility to the 
haemolytic effects of ribavirin in those patients taking highly active 
antiretroviral therapy (HAART) [322/323].  
  
A negative correlation between male sex and SVR was observed in both 
pegylated interferon registration trials, though the correlation did not remain 
significant in the multivariate analyses [285/286]. Sex was no longer 
significant once weight was taken in to account in one study [285]. Ethnicity 
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also has a significant impact on response to treatment with numerous studies 
demonstrating that African Americans having a reduced likelihood of SVR 
[317, 324/331]. Even with the more potent pegylated interferon regimens 
significant differences in SVR rates remain for African Americans as compared 
to non/African Americans (19/28% vs 39/52%) [317, 324, 331], an 
observation that is independent of genotype, socio/demographic characteristics  
or compliance to treatment. Hispanic Americans also appear to have poorer 
SVR rates compared to white patients [325, 332], while individuals of south 
east Asian extraction have in smaller numbers been shown to achieve better 
SVR rates [333].  
 
Recent reports from genome/wide association studies point to a genetic basis 
for much of the observed differences in treatment response between ethnic 
groups. Three published analyses examining US [334], Japanese [335] and 
Australian [336] populations described single nucleotide polymorphisms 
(SNPs) in the vicinity of the IL28B gene, which encodes Interferon / λ3 as 
being highly predictive of response to pegylated interferon and ribavirin in 
genotype 1 infection. The C allele at polymorphism rs12979860 is positively 
associated with SVR (OR 5.79 [95% CI; 2.76/12.57, P= 9.0 x 10/6]) [337] and 
a subsequent intention to treat analysis confirmed a 2/3 fold increase in SVR 
for C/C patients of all ethnic groups [338]. The favourable C/C allele is less 
frequent in African Americans (16%) as compared to Caucasians (39%), but 
IL28B polymorphism is only felt to explain approximately half the observed 
difference in SVR rate as African Americans with the C/C allele still have a 
lower response than Caucasians with the same genotype (53% vs 82%) [334].   
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SNP rs8099917 was identified in the Japanese and Australian studies as being 
most significant and this was replicated by Rauch 	
 who identified it as 
being independently associated with treatment failure (OR 5.19 [95% CI; 2.90 
– 9.30, = 3.11 × 10 − 8]) [339]. The original studies of IL28B polymorphism 
were in genotype 1 patients, but subsequent studies confirm the relevance to 
genotype 2 and 3 infection. In a study of 213 genotype 2 and 55 genotype 3 
patients in which pegylated interferon and ribavirin were given for 12 weeks in 
those with an RVR and 24 weeks in those without; 82% of patients with the 
C/C allele had an SVR compared to 75% for C/T and 58% for T/T (P=0.0046 
for trend) [340]. The difference between IL28B genotypes was greatest among 
patients who did not have an SVR.  The mechanisms of how IL28B 
polymorphism affects HCV suppression are unknown, but there is some 
evidence that IL28B may influence the expression of interferon stimulated 
genes (ISGs). A high baseline expression of ISGs in liver tissue is known to be 
associated with a poor response to interferon based therapy [341/343] and non/
C/C IL28B genotypes have been shown to exhibit higher levels of ISGs than 
the C/C genotype [344].   
 
Histological and biochemical factors are also important in predicting the 
response to treatment. Advanced fibrosis or cirrhosis are major predictors of 
non/response [345], across all genotypes (cirrhosis vs no cirrhosis: OR 0.58 
(95% CI 0.47/0.73, P <0.0001) [315]. The absence of significant fibrosis on the 
other hand is associated with an increased likelihood of SVR (OR 2.15 (95% 
CI; 1.62/2.81, P<0.001) [303]. In a study aimed at assessing the efficacy of 
treatment in cirrhosis, data collated from three randomised controlled trials of 
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peglylated interferon alfa/2a was examined. SVR rates for genotype 1 and 4 
patients with cirrhosis were 33% compared to 60% if there was no bridging 
fibrosis or cirrhosis, for genotype 2 and 3 infection the figures were 57% and 
76% [346]. The absence of steatosis on liver biopsy is also strongly correlated 
with SVR [134, 316].  
 
Baseline levels of ALT have been shown in one study of genotype 2 and 3 
infected patients to be correlated with SVR [303], though this has not been 
confirmed elsewhere [286, 315]. An association between low pre/treatment 
levels of gamma/glutamyl transferase (GGT) and SVR has also been 
demonstrated with an odds ratio (5.7 [95% CI; 3.2/10.0, P <0.0001]) similar to 
that of genotype [347]. GGT levels have been shown to closely relate to levels 
of hepatic steatosis and fibrosis, as well as to insulin resistance [348/349]. The 
latter is associated with a poor treatment response, particularly in genotype 1 
patients [138, 317, 350]. Concurrent treatment with Metformin has been shown 
to improve insulin sensitivity during antiviral therapy, but only female patients 
saw a statistically significant improvement in SVR [351].  
 
The nature of previous failure to achieve an SVR with antiviral therapy also 
predicts the likelihood of a response with retreatment. This is an increasingly 
important area of treatment as by 2015 the number of non/responders to either 
standard or pegylated interferon with ribavirin seeking retreatment is expected 
to exceed treatment naive patients [352]. The EPIC/3 study [353] enrolled 
2333 chronic HCV infected patients with significant fibrosis (≥ F2) who had 
previously failed to achieve an SVR with interferon and ribavirin therapy. 
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Patients were retreated with pegylated interferon and ribavirin for 48 weeks 
regardless of genotype. There was a higher SVR in previous responder/
relapsers as compared to non/responders (38% vs 14%) and in patients whose 
previous treatment had been with standard interferon rather than pegylated 
(25% vs 17%). The likelihood of SVR remained dependent on genotype and 
hepatic fibrosis with SVR rates less than 5% for genotype 1 infected patients 
with cirrhosis who had been previous non/responders to pegylated interferon 
based therapy. In contrast a genotype 2/3 infected patient with F2 fibrosis, who 
had previously been a responder/relapser with peglyated interferon and 
ribavirin had a chance of SVR as high as 75% with 28 weeks therapy. The 
REPEAT study [354/355] evaluated higher doses and a longer duration of 
pegylated interferon alfa/2a and ribavirin in previous non/responders to 
pegylated interferon alfa/2b therapy, in a predominantly (>90%) genotype 1 
infected population. Higher SVR rates were achieved with 72 weeks treatment 
as compared to 48 weeks (16% vs 8%, P=0.0006). The HALT/C study [356] 
randomised patients who had previously failed to respond to pegylated 
interferon to either low dose maintenance interferon or no treatment for 3.5 
years. No benefit in terms of disease progression was seen for maintenance 
interferon.  
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Achieving an SVR is the immediate target of therapy, but long term efficacy 
depends on treatment improving wellbeing, halting disease progression and 
improving outcomes in terms of liver failure, HCC and death. Successful 
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treatment has been shown to lead to an improvement in fatigue and the 
presence of cryoglobulin, though many patients still complain of persistent 
fatigue despite a virological response [357]. A 9 year follow/up study of 455 
patients, 384 of whom who received standard interferon based therapy 
examined the long/term outcome of treatment. The frequency of HCC and liver 
transplantation or death was similar for both untreated patients and treatment 
non/responders showing no overall benefit to receiving treatment.  Non/
responders, however, had an 11 fold increased risk of developing HCC and an 
8.8 fold increased risk of death as compared to patients with an SVR. The risk 
of hepatic decompensation was also much reduced in those patients with an 
SVR at 10 years (3% vs 35%, P<0.001) [358]. A decreased risk of HCC 
following successful interferon therapy has also been seen in other studies 
[359/361].  
 
An important question has been whether antiviral therapy still confers long 
term benefits in patients who already have significant hepatic fibrosis at the 
time of treatment. There is some evidence to suggest that treatment can be 
associated with regression of fibrosis [362] and reduction in portal pressure in 
patients with cirrhosis [363]. A retrospective analysis of 568 patients with 
cirrhosis who received pegylated interferon and ribavirin demonstrated that 
those patients with an SVR had a higher survival (98% vs 86%, P=0.005) and a 
higher probability of remaining free of decompensation (97.3% vs 66.7%, 
P<0.001) at 5 years. Fewer patients had developed a HCC at 5 years, though 
the difference was not statistically significant (4% vs 16%, P=0.09) [364]. 
Another retrospective analysis of 317 patients with bridging fibrosis or 
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cirrhosis did show failure to achieve an SVR to be an independent predictor of 
HCC development with a 4.72 fold higher rate of HCC among non/responders 
[365]. There has been limited study of the benefits of treatment in patients with 
cirrhosis and a prior history of hepatic decompensation. Iacobellis et al studied 
129 consecutive patients with decompensated cirrhosis (mean Child/Pugh 
score approximately 8) of which 66 agreed to 24 weeks of treatment with 
pegylated interferon and ribavirin. Those who declined treatment formed the 
control group. The SVR rate was 43.5% for genotype 2 and 3 patients and 7% 
for those with genotype 1. Though the SVR rate was low there were no deaths 
among those patients who achieved an SVR during a median 30 months 
follow/up compared to 32.2% in the control group and 20.8% of non/
responders [366].  
 
In a systematic review of studies examining the long term health outcomes and 
costs associated with antiviral therapy for HCV, treatment with pegylated 
interferon and ribavirin was shown to prolong life, improve long term health 
related quality of life and be cost effective in the treatment of treatment naïve 
and non/responders/ relapsers with HCV [367]. In a further economic analysis, 
antiviral therapy for HCV was felt to be comparable in terms of cost 
effectiveness to other well accepted medical interventions including 
haemodialysis, screening for colon cancer and treating HIV infection and 
hypertension [368]. 
 


 59 
-.9.9*/)+0+04*31)
3*0101
Given that only approximately half of patients achieve an SVR with current 
therapy, there is a pressing need for new, more efficacious therapies. Ideally 
new drugs should be more potent, less toxic and allow a shorter duration of 
therapy. One avenue has been to further refine interferon and ribavirin based 
therapy. Taribavarin is a pro/drug of ribavirin that appears to be associated 
with less anaemia, but unfortunately efficacy is only at best equivalent to 
ribavirin [369/370]. Alternative forms of interferon have also been investigated 
including daily consensus interferon and albinterferon (interferon alfa fused to 
human albumin). Neither drug has entered common practice, though 
albinterferon which can be administered fortnightly due to its extended half life 
appears to have similar efficacy to pegylated interferon with less impairment of 
quality of life [371/372]. More recently there has been interest in IFN/λ1 (also 
known as interleukin/29), which has functional similarities to IFN/α. The 
expression of the IFN/λ receptor is more restricted than that of IFN/α, 
however, being only expressed on hepatocytes.  This suggests the potential for 
reduced adverse events and a phase 1b study has evaluated 4 weeks of 
treatment with IFN/λ1 alone and in combination with ribavirin. Antiviral 
activity was demonstrated with 29% of treatment naïve patients achieving an 
RVR and 86% having at least a 2 log10 drop in HCV RNA with minimal 
constitutional and haematologic effects [373]. Whether this translates to 
acceptable SVR rates remains to be seen, but with receptors restricted to 
hepatocytes there will be a risk of relapse as a result of HCV replication in 
peripheral blood mononuclear cells.  
 
 60 
A more productive approach has been the development of new drugs that target 
steps in the HCV life cycle including entry into the host cell, proteolytic 
processing, viral replication and the assembly and release of new virions. 
Designated Directly Acting Antiviral (DAA) drugs, these new compounds 
potentially represent a significant advance in the treatment of HCV. The most 
promising targets are two viral enzymes required for viral replication; the 
NS3/4A protease and NS5B polymerase. NS5B functions as an RNA 
dependent polymerase and is key to the synthesis of complementary minus/
strand RNA. Two types of HCV polymerase inhibitors (nucleoside and non/
nucleoside analogues) have been under development. Mericitabine is a 
nucleoside analogue polymerase inhibitor with high in/vivo potency, a high 
genetic barrier to resistance and which to date has not been associated with any 
severe adverse effects. A planned interim analysis of week 12 data from the 
PROPEL study demonstrates that the addition of Mericitabine 1000mg bd for 
the first 12 weeks of 48 weeks treatment with pegylated interferon/ ribavirin is 
associated with an RVR of 62% vs 18% and and cEVR of 80% vs 49% [374]. 
Preliminary data from a phase IIb study (JUMP/C) of Mericitabine in 
combination with pegylated interferon and ribavirin demonstrates virological 
suppression is achieved in 91% of patients at week 24 compared to 62% of 
patients receiving pegylated interferon and ribavirin alone[375].  Unfortunately 
a number of other promising agents in this class including Valopictabine 
(NM283), R/1626 and HCV/796 have been withdrawn because of  safety 
concerns and an unfavourable risk/benefit profile[376].  
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The NS3/4A serine protease inhibitors are the class of DAA molecules that 
look set to first reach clinical practice. The NS3 protein and its co/factor NS4A 
form a serine protease that is required to cleave proteins from the HCV 
polyprotein before viral replication can occur. The two drugs within this class 
that are furthest in development are telaprevir and boceprevir. PROVE 1 (US) 
[377] and PROVE 2 (Europe) [378] were phase 2b studies of telaprevir in 
treatment naïve genotype 1 infected patients. PROVE 1 had 3 arms in which 
telaprevir was given for 12 weeks together with 12 (T12PR12), 24 (T12PR24) 
or 48 (T12PR48) weeks of pegylated interferon and ribavirin. The SVR rate for 
the T12PR24 and T12PR48 arms were 61% and 67% as compared to 41% in 
the control arm (pegylated interferon and ribavirin for 48 weeks). The 
improvement in SVR was despite a higher rate of discontinuation in the 
telaprevir group, mostly due to rash. PROVE 2 also showed that 12 weeks of 
telaprevir together with 24 weeks of pegylated interferon was associated with 
an SVR rate of 69%, but that efficacy was lost in the study arm without 
ribavirin (SVR 36%). PROVE 3 [379] incorporated similar study arms in the 
re/treatment of genotype 1 infected patients who had previously failed to 
achieve an SVR with pegylated interferon and ribavirin. In a difficult to treat 
population, that included 17/20% of patients in the telaprevir arms with 
cirrhosis, 51% of patients who received telaprevir for 12 weeks and pegylated 
interferon and ribavirin for 24 weeks achieved an SVR. The efficacy of 
boceprevir was assessed in treatment naïve genotype 1 infected patients in the 
SPRINT 1 study [380]. There were 4 boceprevir study arms, all of which had 
significantly higher SVR rates than the control arm (pegylated interferon and 
ribavirin for 48 weeks). Pegylated interferon and ribavirin for 4 weeks 
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followed by both drugs together with boceprevir for a further 44 weeks was 
associated with an SVR rate of 75%. SPRINT 2 enrolled 938 non black and 
159 black patients and demonstrated an SVR with 4 weeks lead in with 
pegylated interferon and ribavirin followed by 24 weeks of pegylated 
interferon, ribavirin and boceprevir (PR4, PRB 24) of 67% in non blacks and 
42% in blacks compared to 40% and 23% with standard therapy [381]. 
RESPOND 2 confirmed efficacy for boceprevir in the treatment of previous 
treatment failures with significantly higher SVR rates for both boceprevir arms 
(PR4, PRB 32 = 59%, PR4, PRB 44 = 66%) than controls (PR 48 = 21%) 
[382].  
 
Both telaprevir and boceprevir significantly improve cure rates in difficult to 
treat genotype 1 infected patients. The error prone nature of the HCV RNA 
dependent RNA polymerase means, however, that drug resistance will 
inevitably occur in patients treated with drugs directed against specific HCV 
enzymes. The NS3/4A serine protease inhibitors and non/nucleoside 
polymerase inhibitors have a relatively low genetic barrier to resistance. The 
dominant mutation seen with telaprevir (A156S) [383/384] is at the same 
position as the mutation selected most frequently with boceprevir (A156T) 
[385] and cross resistance has already been confirmed. While extremely 
promising, enthusiasm for these drugs needs to be tempered by the major threat 
of drug resistance.   
 
Nucleoside analogue polymerase inhibitors and protease inhibitors have also 
been studied in combination. The INFORM/1 study examined an IFN sparing 
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regime combining Mericitabine and Vaniprevir. After 14 days patients with 
genotype 1 infection had an average reduction in HCV RNA of 5.1 log 10 
IU/ml in the higher dose arm [386]. This represented the first proof of concept 
that IFN sparing regimes may be effective in treating HCV.  
 
There are many other areas of drug development in HCV therapy, including 
targeting the cellular immune response. Agents such as toll/like receptor 
agonists can promote an effective host immune response by inducing/ 
modulating cytokine response [387]. The immunosuppressant agent, 
cyclosporin A has been shown to suppress HCV replication [388]. This is 
mediated through specific blockade of cyclophilins, important host factors in 
RNA replication. Non/immunosuppressive cyclosporin A analogues which 
inhibit either cylcophilin A (Debio/025) or cyclophilin B (NIM/811) have been 
shown to suppress HCV replication in vitro. NS5A is a non/structural protein 
which interacts with a number of cellular proteins, including cyclophilin A. A 
small molecule inhibitor (BMS/790052) of NS5A has been the subject of a 
phase 1 study in which a single dose led to a 3.3 log10 reduction in mean viral 
load at 24 hours[389]. Another target is NS4A, a co/factor for NS3 protease, 
but unfortunately concerns regarding nephrotoxicity have led to cessation of 
development of ACH/806, an initial drug in this class [390].  
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The aim of the studies comprising this thesis is to examine the natural history 
of Hepatitis C (HCV) in a cohort of patients followed up longitudinally as part 
of the Trent HCV cohort study (established in 1991 with the aim of studying 
the epidemiology and natural history of HCV infection in a defined and 
representative area of the UK). The initial three data chapters examine the 
natural history of HCV infection within groups of patients with differing 
degrees of liver disease. Starting with patients, perceived to have mild disease 
(those with a persistently normal ALT), moving onto those with severe fibrosis 
on liver biopsy and finally to those who have developed Hepatocellular 
carcinoma as a result HCV infection. The final two data chapters examine the 
influence of ethnicity and thrombocytopenia on the success of treatment with 
Pegylated Interferon and Ribavirin. 








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The Trent HCV cohort study was established in 1991, with 3 main research 
objectives: 
/ To address the epidemiology of HCV infection in a defined and 
representative area of the UK (Trent Health Care region: population 5.1 
million – See Figure 1.1).  
/ To study the natural history of HCV infection 
/ To devise optimal strategies for the management of HCV infected 
patients 
The Trent HCV study group developed following an initiative by the Trent 
centre of the National Blood Authority (NBA) in response to the introduction 
of HCV antibody screening of donated blood. They arranged for referral of 
antibody positive donors to one of seven clinics (merger of centres now means 
five hospital trusts) which collaborated in collecting detailed epidemiological 
data on these patients in a central database. Subsequently the study group 
collected identical data on any antibody positive patient referred to one of the 
centres.  The study has been funded since 1991 variously by the National blood 
Authority, the Department of Health, and the pharmaceutical industry. The 
study has approval from a Multi/centre Research Ethics Committee. 
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The study is currently run by a multidisciplinary group of specialists in 
hepatology, infectious diseases, pathology, virology, epidemiology and blood 
transfusion (current membership is listed in Appendix 1). It is the largest 
cohort of HCV infected patients in the UK, and is felt to be highly 
representative of HCV infection in the country at large, as none of the 
participating clinics operate as a tertiary referral centre for areas outside the 
region. The study population reflects those referred to secondary care and this 
will not necessarily mirror a primary care population.  As described in Chapter 
1.5.1 a significant proportion of HCV infected patients remain undiagnosed 
and there are a number of barriers to those with a diagnosis accessing 
secondary care. There are no resources within the Trent study for the screening 
of patients for HCV, even amongst high risk populations, though individual 
centres may in some instances run outreach clinics in prisons and drug 
rehabilitation centres from which patients may be recruited.  There is also no 
attempt to recruit patients identified through the central laboratories as having a 
positive HCV antibody. The population studied does as previously alluded  to,  
have a significant bearing on the natural history of HCV and the Trent study 
cohort should be though of as reflecting the natural history of HCV infection 
within a secondary care cohort.   
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All patients referred to one of the participating clinics (Derby, Leicester, 
Lincoln, Nottingham and Sheffield) with a diagnosis of HCV infection are 
invited to enrol in the study, with informed consent. Participation in the study 
is open to all patients referred to these clinics and as none of the centres are 
tertiary referral centres to which patients are referred from outside the Trent 
region, it is likely that the majority of patients in the study will reside in the 
Trent geographical region illustrated in Figure 1.1. The patient’s postcode is 
recorded at the time of enrolment, but entry to the study does not require this to 
be within the Trent region. A detailed epidemiological questionnaire is 
administered by interview with trained personnel and the patient derived data is 
stored on a centralised database. Basic demographic data collected includes 
place of birth and ethnicity (categorised according to the definitions used in the 
2001 national census). Risk factor data are categorised hierarchically as: 1) 
injecting drug use, 2) receipt of blood (pre/1991) or blood product (pre/1986) 
transfusion, 3) other risk factor (born abroad, non/professional tattoo, 
professional tattoo pre/1982), 4) none of the above risk factors, and 5) risk 
factor data missing. Duration of infection is estimated on the assumption that 
infection was acquired at the first exposure to risk (e.g first year of IDU or date 
of blood transfusion). Information is also collected on past alcohol 
consumption (history of heavy alcohol consumption defined as > 50g per day 
for most days over a period of 6 months) at enrolment and subsequently on 
alcohol consumption over the week prior to each clinic attendance.  
Liver histology was scored by a single pathologist (Dr J Underwood) and using 
the Knodell Histological Activity Index (HAI) [391] during the early years of 
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the study, but in recent years biopsies have being scored by the local 
pathologist at each centre using the Ishak modified HAI [110]. Hepatic 
steatosis is scored from 0 (none) to 3 (extensive). Training in the use of the 
Ishak modified HAI and sharing of cases to assist in standardising scoring has 
been employed in order to reduce inter/observer error. The scoring of the Ishak 
Modified HAI is shown in Table 1.5.  
 
The current recommendation for evaluation of chronic viral hepatitis is that 
liver biopsies should be at least 20mm in length and contain at least 11 portal 
tracts [392]. Synchronous  biopsies with a mean length greater than 2 cm show 
minimal variation in stage [393], while smaller biopsies, each with only 4/5 
portal tracts differ in staging by two or more categories in 20% of cases [394].  
Smaller biopsies are likely to underscore disease while biopsy specimens 
obtained from the subcapsular region are prone to overestimating the stage of 
disease as increased stroma, including septum formation and perhaps even 
nodularity, may be within the spectrum of normal [395]. Unfortunately there is 
no recording of the size or adequacy of the liver biopsy within the study 
database and, therefore, there is the potential that some biopsies will have been 
under or over scored.   
 
Patient management was up until 1998 according to an agreed protocol 
(Interferon therapy recommended to those with a total Knodell score [391] ≥ 6 
on liver biopsy), and subsequently has been in line with national guidelines 
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[396/397]. Initially those patients who declined treatment or had a Knodell 
score < 6 had a repeat liver biopsy after an interval of 2 years.  Laboratory data 
is captured from the participating centres’ own pathology reporting systems 
and regularly downloaded to the study database. Patients with known human 
immunodeficiency virus infection or inherited coagulation disorders are 
identifiable within the cohort but excluded from analysis as the natural history 
may differ in these groups.
 
Patients are flagged with the National Health Service Central Register 
(NHSCR). This system covers nearly all residents of England and Wales and 
has reciprocal links to the equivalent Scottish register. It identifies deaths, 
cancer registrations and emigrations and forwards the information monthly to 
the study group. When a death is identified by the NHSCR, information 
forwarded includes a copy of the death registration data and coroner’s findings 
where relevant. 
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Absent 0 
Mild (focal, few portal areas) 1 
Mild/ moderate (focal, most portal areas) 2 
Moderate (continuous around < 50% of tracts or septa) 3 
Severe (continuous around > 50% of tracts or septa) 4 
!./)5+/0/$1 
Absent 0 
Focal confluent necrosis 1 
Zone 3 necrosis in some areas 2 
Zone 3 necrosis in most areas 3 
Zone 3 necrosis + occasional portal/central bridging 4 
Zone 3 necrosis + multiple portal/central bridging 5 
.	$*5300501$/$1E*3301*/)$*51/)5*,,*01/
Absent 0 
One focus or less per x 10 objective  1 
Two to four foci per x 10 objective 2 
Five to ten foci per x 10 objective  3 
More than ten foci per x 10 objective 4 
.0*51/)5*,,*01/
Absent 0 
Mild, some or all portal areas 1 
Moderate, some or all portal areas 2 
Moderate/ marked all portal areas  3 
Marked all portal areas 4 
*=1,+,/$1/)5*,,*0$ F-<
	1%1
No fibrosis 0 
Fibrous expansion of some portal areas, with or without short fibrous septa 1 
Fibrous expansion of most portal areas, with or without short fibrous septa 2 
Fibrous expansion of most portal areas, with occasional portal to portal bridging 3 
Fibrous expansion of portal areas, with marked bridging as well as portal / central 4 
Marked bridging (portal to portal and/or portal/central) with occasional nodules 5 
Cirrhosis, probable or definite 6 
*=1,+,)1%1$ F:

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Patients are flagged with the National Health Service Central Register 
(NHSCR). This system covers nearly all residents of England and Wales and 
has reciprocal links to the equivalent Scottish register. It identifies deaths, 
cancer registrations and emigrations and forwards the information monthly to 
the study group. When a death is identified by the NHSCR, information 
forwarded includes a copy of the death registration data and coroner’s findings 
where relevant.  
 
The epidemiology of those patients recruited to the Trent HCV study between 
1st September 1991 and 1st December 1998 has previously been described [33]. 
During this period there were a total of 2546 patients who were found to be 
anti/HCV positive by one of the diagnostic laboratories serving the region, of 
which 44% had been recruited into the study. There were relatively more 
females (32 vs 27%, P=0.004) in the study cohort than amongst the total anti/
HCV positive population, together with a slight shift in the age distribution 
towards an older population. The majority of those patients not enrolled in the 
study had not been referred to or attended an outpatient appointment at one of 
the participating clinics. No information, however, is recorded on the consent 
to participate rate of those approached with a view to entering the study. 
Consistent with the development of the study, 50% of new patients in 1991/
1993 were referred by the NBA, while this route of referral had reduced to 2% 
in 1997.  95 % of the study population were Caucasian and approximately two/
thirds of patients had a history of intravenous drug abuse. The infecting 
genotype was 1 (47%), 2 (10%), 3 (39%), 4 (1%) and 5 (2%). Past markers of 
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hepatitis B infection (antibody to hepatitis B core antibody) were positive in 
37% of patients.  

As of August 2011, there were 3612 patients in the study database of which 
2041 have had at least one liver biopsy and 1255 have received pegylated 
interferon based treatment. 850 patients have more than 5 years follow/up since 
the date HCV infection was discovered, of which 457 patients have more than 
10 years. Data from the initial patient questionnaire and subsequently from the 
hospital notes and IT systems is entered into the study database by data entry 
clerks, with the number employed having fluctuated over the years depending 
on the health of the study's funds. Regular data review meetings are held to 
highlight areas with missing data and to prioritise certain data fields that are 
relevant to current or planned research. The quality of the data entered into the 
study database is the subject of periodic validation audits of random sets of 
casenotes.     


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Alanine aminotransferase (ALT) is a frequently used serum marker of liver 
injury. Evidence from data on volunteer blood donors, however, suggests that 
20/40% of Hepatitis C (HCV) RNA positive patients will have a normal ALT 
level at the time of diagnosis [162, 398/399]. A proportion of these patients 
will have a persistently normal ALT (PNALT), usually defined as two or three 
consecutive measurements within the normal range over a 6/month period 
[296, 400]. There is conflicting evidence, however, on whether these patients 
represent a subgroup with mild disease and at low risk of disease progression 
[401/403]. Few longitudinal studies have specifically looked at HCV patients 
with PNALT [404/406] and of those that have, some estimate fibrosis 
progression on the basis of a single biopsy [404], or do not include a 
comparison group of patients with an elevated ALT [405]. There is also 
controversy on what constitutes a normal ALT, with some proposing that the 
upper limit of normal is set too high because the cohorts used to establish the 
normal range included apparently health individuals with unrecognised fatty 
liver disease. A threshold of 40U/L may, therefore, fail to identify some 
patients with significant liver disease [407].  
 
2.21,
The aim of this study was to examine the natural history of HCV infected 
patients with a persistently normal ALT. It examines the likelihood of the ALT 
remaining normal for two groups of patients with PNALT, defined using either 
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a threshold of 30U/L or 40U/L. It also examines the risk of disease progression 
as compared to patients with an elevated ALT.  

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 At the time of this study (2007) the Trent HCV study cohort included 2184 
HCV RNA positive patients for which there were over 27,000 separate ALT 
measurements recorded on the database. All laboratories in the participating 
centres have an upper limit of normal for ALT of 40IU/L. All treatment/naïve 
patients were included and divided according to whether they had either an 
elevated ALT, defined as at least one ALT > 40 in the 6 months following 
diagnosis (n=1140) or a PNALT. Two definitions of PNALT were used, either 
an ALT ≤ 30 (n=43) or an ALT ≤ 40 (n=87) on 2 or more occasions (at least 
one month apart) in the 6 months following diagnosis. Patients with a PNALT 
≤ 30 will by definition also be included in the PNALT ≤ 40 group.  

2.6.2	55#+3 
Entry into the study was defined as the date on which the patient was 
diagnosed with HCV. Follow/up for this study was until the date of death or 
transplantation, last recorded clinic visit or initiation of antiviral therapy. ALT 
measurement and liver biopsy were performed as part of routine clinical care 
and the latter was scored by a histopathologist at each participating centre 
using the Ishak disease severity score [110]. The likelihood of the ALT 
remaining normal in PNALT patients was assessed by scrutiny of ALT values 
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taken after the initial 6 month definition period for PNALT. Liver histology 
was considered for analysis when the first biopsy was within one year of 
diagnosis (PNALT ≤ 30: 28/43 (65%), PNALT ≤ 40: 59/87 (68%) and 
Elevated ALT: 628/1140 (55%)). Fibrosis progression in those patients with 
paired biopsies (PNALT ≤ 30: n=11 (26%), PNALT ≤ 40: n=15 (17%), 
Elevated ALT: n= 164 (14%)) was expressed as Ishak fibrosis points per year. 
Patients with cirrhosis (Ishak stage 6) on the initial biopsy, and who could not 
therefore progress, were excluded from this analysis, as were patients who 
received antiviral therapy between the two biopsies. Analysis of mortality was 
restricted to those patients with an Ishak score of 0, 1 or 2 on the initial liver 
biopsy.  
 
2.6.60*0101$*5*/*51 
Continuous variables were compared using the Mann/Whitney U/test. 
Categorical variables were compared using the chi/squared test or Fisher’s 
exact test. A two/tailed P value of < 0.05 was considered significant. Statistical 
analysis using life tables was used to estimate the likelihood that the ALT 
remained normal at 1, 3, and 5 years and to calculate the survival probability 
following discovery of HCV in those patients with mild disease (Ishak fibrosis 
stage 0, 1 or 2). Kaplan/Meier plots were used to express the proportion of 
patients maintaining a PNALT and to display survival curves for patients with 
both PNALT and an elevated ALT. Multiple logistic regression analyses was 
performed with PNALT as the dependent variable and included age at 
diagnosis, sex and those variables from the univariate analysis with a P value < 
0.1.  
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One thousand one hundred and forty patients with at least one elevated ALT in 
the first 6 months from diagnosis were identified, compared to 87 with a 
PNALT ≤ 40 IU/L and 43 with a PNALT ≤ 30 IU/L. The remaining patients in 
the cohort had either no ALT measurements available (n=615) or a single 
normal value (n=342) during the definition period and were not included in the 
study.  Of the 1140 patients with an elevated ALT, 97 subsequently had a 6/
month period prior to any treatment in which the ALT was ≤ 40 on 2 or more 
occasions (at least one month apart) and no elevated ALT. The median follow 
up was 61, 36 and 21 months in the PNALT ≤ 30, PNALT ≤ 40 and elevated 
ALT group respectively. Initiation of antiviral treatment marked the end of 
follow/up and was more common in group with an elevated ALT (49%) than in 
either the PNALT ≤ 30 (19%) or PNALT ≤ 40 (28%) group (P < 0.001). When 
initiation of antiviral treatment was removed from the list of potential 
endpoints, the period of follow/up remained shorter for patients with an 
elevated ALT as compared to PNALT ≤ 30 patients (61 vs 42 months, P=0.02). 
 
2.8.-*01/00*15
 
Table 1 shows the baseline characteristics of patients in the study at point of 
diagnosis with HCV. Patients in both PNALT groups were more likely to be 
female (P < 0.001) and to have a lower body mass index (BMI) (P < 0.001) 
than patients with an elevated ALT. In the multivariate analysis (Table 2) both 
female sex and a lower BMI remained independent predictors of having a 
PNALT. Other parameters including age,  estimated duration of disease,  route 
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Results presented are median (range) 
Unless indicated no statistically significant difference between PNALT groups and elevated 
ALT group 
a,b, e, f Significant difference between groups with P < 0.001 (X2 test) 
c,d, h, j Significant difference between groups with P < 0.001 (Mann Whitney  test) 
e,f Significant difference between groups with P <0.001 (X2 test) 
g Significant difference between groups with P = 0.004(Mann Whitney  test) 
I Significant difference between groups with P = 0.006 (Mann Whitney  test) 
 PNALT ≤ 30 
(n=43) 
PNALT ≤ 40 
(n=87) 
Elevated ALT 
(n=1140) 
 
Age (years) 
 
36 (19/64) 
 
36 (19/64) 
 
36 (15/86) 
 
Sex / Male:Female (% male)  
 
18:25 (42%) a 
 
41:46 (47%)b 
 
809:329 (71%)a,b 
 
Ethnicity (White) 
 
39 (91%) 
 
79 (91%) 
 
993 (89%) 
 
Main risk factor 
                    IVDU 
                    Blood Transfusion 
 
 
32 (74%) 
4 (9%) 
 
 
65 (77%) 
11 (13%) 
 
 
746 (68%) 
130 (12%) 
 
Estimated duration of infection 
(years)  
 
14 (3/40) 
 
14 (2/40) 
 
14 (0/63) 
 
Genotype  
                     1 
                     2 
                     3 
 
 
16 (55%) 
4 (14%) 
 9 (31%) 
 
 
26 (45%) 
7 (12%) 
23 (40%) 
 
 
352 (42%) 
70 (8%) 
385 (46%) 
 
Hepatitis B status  
                    HBsAg positive  
                    HBcAb positive 
 
 
0 
9 (33%) 
 
 
0 
13 (23%) 
 
 
36 (4%) 
216 (33%) 
 
Drinks alcohol 
 
n=37 
19 (51%) 
 
n=78 
45 (58%) 
 
n=972 
553 (57%) 
 
Average alcohol consumption  
(units/week) 
 
n=33 
0.6 (0/155) 
 
n=69 
1.5 (0/189) 
 
n=926 
2.5 (0/248) 
 
Past or present history of excess 
alcohol  
(>50g/d for at least 6 months) 
 
 
12 (36%) 
 
 
31 (42%) 
 
 
461 (50%) 
 
BMI (kg/m2) 
 
22.0 (17/34)c 
 
22.7 (16/35)d 
 
25 (15/47)c,d 
 
Subsequent antiviral therapy  
 
6/32 (19%)e 
 
20/72 (28%)f 
 
458/ 932 (49%)e,f 
 
Necroinflammatory score on 
 biopsy (Ishak) 
n=25 
2 (0/5)g 
n=55 
2 (0/7)h 
n=586 
3 (0/15)g,h 
 
Fibrosis score on biopsy (Ishak) 
 
n=27 
0 (0/3)i 
 
n=58 
0 (0/6)j 
 
n= 620 
1 (0/6)i,j 
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Variable 
 
OR (95% CI) 
 
P value 
 
PNALT ≤ 40 IU/L  
Age at diagnosis (per year) 0.98 (0.94 – 1.02) n.s 
Sex / (Female) 3.09 (1.70 – 5.60) <0.001 
BMI (per point) 0.91 (0.85 – 0.98) 0.009 
Estimated duration of infection 
 at diagnosis (per year) 
1.002 (0.998 – 1.005) n.s 
   
PNALT ≤ 30 IU/L   
Age at diagnosis (per year) 0.99 (0.94 – 1.05) n.s 
Sex / (Female) 2.92 (1.21 – 7.04) 0.017 
BMI (per point) 0.83 (0.74 – 0.94) 0.003 
Estimated duration of infection 
 at diagnosis (per year) 
 
1.001 (0.996– 1.006) n.s 
 
































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of infection, genotype and a history of heavy alcohol consumption were similar 
between the groups.   
 
2.8.210/$)*/,*5
 
Figures 1 demonstrates the proportion of patients in whom the ALT remains 
persistently normal over time. In those patients with a PNALT ≤ 30, the 
proportion in whom the ALT had remained persistently ≤ 30 by 1, 3 and 5 
years was 69.8%, 42.2% and 37.5%. For patients with a PNALT ≤ 40 the 
proportion in whom the ALT had remained persistently ≤ 40 at 1, 3 and 5 years 
was 68.9%, 41.7% and 35.4%. 


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Figure 2.1 demonstrates that the majority of patients who initially fulfilled the criteria 
for PNALT ultimately have an abnormal ALT. By 3 years less than half of patients 
could still be described as having a persistently normal ALT 
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The proportion of patients having a liver biopsy within one year of diagnosis 
was higher in the PNALT ≤ 40 group (68%) than those with an elevated ALT 
(55%) (P=0.02). There was no statistical difference in the frequency of liver 
biopsy between PNALT ≤ 30 patients (65%) as compared to the elevated ALT 
group.  Figures 2a and 2b illustrate the distribution of the Ishak 
necroinflammatory and fibrosis score on liver biopsies performed within 1 year 
of HCV diagnosis. Patients in both PNALT groups had a significantly lower 
necroinflammatory (PNALT ≤ 30: 2.12 ± 1.27 vs 3.34 ± 2.16, P =0.004; 
PNALT ≤ 40: 2.05 ± 1.41 vs 3.34 ± 2.16, P <0.001) and fibrosis score (PNALT 
≤ 30: 0.63 ± 0.84 vs 1.80 ± 2.05, P =0.006; PNALT ≤ 40: 0.83 ± 1.47 vs 1.80 ± 
2.05, P <0.001) on their initial biopsy, than patients with an elevated ALT. 
Significant levels of fibrosis (Ishak fibrosis score ≥ 3) were seen in 29.6% of 
patients with an elevated ALT, as compared to 3.7% (P=0.002) and 8.3% 
(P<0.001) of  patients with PNALT ≤ 30 and PNALT ≤ 40 respectively.  


Figure 3a and 3b illustrate the change in the necroinflammatory and fibrosis 
score in those patients with paired biopsies. The median interval between 
biopsies was 31 months in both PNALT groups and 28 months in the group 
with an elevated ALT (Table 3). There was no statistically significant 
difference between the groups in regard to the proportion of patients having a 
second biopsy, with 10/28 (36%), 14/59 (24%) and 148/628 (24%) having had 
a repeat biopsy within 5 years of their initial biopsy and prior to the onset of 
therapy. The rate of fibrosis progression was 0.33 ± 0.94 Ishak fibrosis points/ 
year for PNALT ≤ 30 patients, 0.35 ± 0.82 for PNALT ≤ 40 patients and 0.19 ± 
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0.48 for those with an elevated ALT. There was no statistically significant 
difference in either the interval between biopsies or the rate of fibrosis 
progression between the PNALT patients and those with an elevated ALT.  
The majority of patients with paired biopsies had an Ishak fibrosis score of 0, 1 
or 2 on the initial biopsy. Restricting the analysis of fibrosis progression to 
only these patients did not alter the result. In all, fibrosis progressed in 5/11 
(45%) patients with PNALT ≤ 30, 8/15 (53%) with PNALT ≤ 40 and 59/164 
(36%) patients with an elevated ALT. 1/11 (9.1%), 2/15 (13.3%) and 22/164 
(13.4%) patients respectively had an increase in fibrosis score of ≥ 2 points 
between biopsies.  


When the PNALT patients with paired biopsies (n=15) were compared to the 
PNALT group as a whole (n=87), no statistically significant difference in terms 
of age, sex, ethnicity, main risk factor, or history of heavy alcohol use was 
identified. There was also no difference in the Ishak necroinflammatory or 
fibrosis score on the first biopsy. On the other hand, those patients with an 
elevated ALT and paired biopsies (n=162) had a significantly lower Ishak 
necroinflammatory (2.8 ± 1.8 vs 3.3 ± 2.2 P=0.002) and fibrosis score (0.6 ± 
1.0 vs 1.8 ± 2.1 P<0.001) on the first biopsy than the elevated ALT group as a 
whole (n=1140). There was also no difference in the Ishak necroinflammatory 
(2.76 ± 1.90 vs 2.75 ± 1.81 P=0.971) and fibrosis score (0.78 ± 1.27 vs 0.54 ± 
0.85 P=0.160) on the first biopsy between patients who had fibrosis 
progression and those who did not.  This was true for both the elevated ALT 
and PNALT groups. Those patients with an elevated ALT and paired biopsies 
were also more likely to be female (P=0.005).  
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Both Figure 2.2a and 2.2b illustrate that on an initial liver biopsy the majority 
of patients with either a PNALT or elevated ALT have mild Ishak 
necroinflammatory and fibrosis scores, but that there are proportionately more 
patients with higher scores amongst patients with an elevated ALT. 
Statistically patients with PNALT has significantly lower scores for both 
necroinflammation and fibrosis. 
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
Figures 2.3a and 2.3b illustrate that there was both progression and regression 
of inflammation between paired liver biopsies in those with PNALT and those 
with an elevated ALT. There was no statistical difference in the rates of 
progression when the PNALT and elevated ALT patients were compared 


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 PNALT ≤ 30 
(n=11) 
PNALT ≤ 40 
(n=15) 
Elevated ALT 
(n=162) 
 
Age (years) 
 
33.8 ± 9.2 
34 (23/56) 
 
34.9 ± 9.3 
35 (23/56) 
 
38.1 ± 10.4 
35 (23/56) 
 
Sex / Male:Female (% Male) 
 
3:8 (27%) 
 
 
5:10 (33%) 
 
97:65 (60%)  
 
Estimated duration of infection 
(years) 
 
11.8 ± 5.2 
10 (5/19) 
 
13.1 ± 5.9 
12 (5/22) 
 
15.2 ± 8.7 
16 (1/36) 
 
Ever Heavy alcohol drinker  
(>50g/d for at least 6 months) 
 
 
4 (44%) 
 
 
5 (39%) 
 
 
55 (43%) 
 
BMI (kg/m2) 
 
22.1 (18/30) a 
 
21.9 (18/26) b 
 
25.5 (17/37) a, b 
 
 
	10%13
 
Ishak necroinflammatory score 
 
2.5 ± 1.4 
2 (0/5) 
 
2.2 ± 1.4 
2 (0/5) 
 
2.8 ± 1.9 
2 (0/12) 
 
Ishak stage 
 
0.8 ± 1.0  
1 (0/3) 
 
0.6 ± 0.9 
0 (0/3) 
 
0.6 ± 1.0 
0 (0/5) 
$/%13
 
Ishak necroinflammatory score 
 
2.9 ± 1.8 
3 (1/6) 
 
2.7 ± 1.7 
2 (1/6) 
 
3.3 ± 2.3 
3 (0/14) 
 
Ishak stage 
 
 1.3 ± 1.6  
 1 (0 /4) 
 
1.2 ± 1.4 
1 (0/4) 
 
1.1 ± 1.6 
1 (0/6) 
 
 
Interim between biopsies 
(months) 
37.3 ± 19.2 
31 (12/85)  
35.6 ± 16.6  
31 (12/85) 
 
34.4 ± 15.4  
28 (12/111) 
Fibrosis progression (points/ yr) 0.33 ± 0.94 
0 (/0.5/3) 
0.35 ± 0.82 
0.29 (/0.5/3.0) 
0.19 ± 0.48 
0 (/0.9/2.6) 
 
Results are Mean ± Standard deviation and Median (Range) 
a,b Significant difference between groups with P = 0.002 (Mann Whitney test) 
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No cases of Hepatocellular carcinoma (HCC) were recorded in the group of 
patients with a PNALT. 4/437 (0.9%) patients with an elevated ALT were 
diagnosed with HCC after a median of 46.5 months. Analysis of mortality of 
patients was restricted to patients with an Ishak fibrosis score of 0, 1 or 2 on 
the initial biopsy.  
 
Figure 2.4 illustrates survival from the date of diagnosis for the three groups of 
patients. There was no difference in the survival probability at 5 years, with 
95.2%, 97.6% and 95.9% of patients with a PNALT ≤ 30, PNALT ≤ 40 and an 
elevated ALT respectively being alive. 
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It has been proposed that those HCV infected patients with a PNALT represent 
a subgroup with mild, slowly progressive disease [403/404, 406]. This study 
looked at whether a PNALT, defined as a normal ALT on 2 or more occasions 
(at least one month apart) in the 6 months following diagnosis, predicts that the 
ALT will subsequently remain normal. It also examined the risk of disease 
progression as compared to patients with an elevated ALT. In accordance with 
recent evidence suggesting that the standard reference range for ALT fails to 
identify a significant proportion of patients with liver disease [407], it also 
explores the natural history of patients with a PNALT using a standard 
threshold of 40 U/L for ALT and a lower level of 30 U/L. This evidence is 
supported by a study in which a fall in ALT was noted in patients with a 
“normal” ALT level after achieving a SVR with treatment [408]. The PNALT 
≤ 30 U/L group included 25 women, 58% of the total. It was decided not to 
adopt the Prati et al [407] definition of a normal ALT for a woman of ≤ 19 U/L 
and for a man of  ≤ 30 U/L, as only five of the twenty five women in this group 
would have been included.  
 
Patients with PNALT were more likely to be female and to have a lower Body 
Mass Index (BMI) than those with an elevated ALT. The predominance of 
female patients amongst those with a PNALT has been reported 
previously[403, 405/406, 409] and is consistent with evidence from non HCV 
infected patients, that points to the fact that ALT levels are on average 30% 
lower in women [407]. The same study and others have also shown a strong 
correlation between ALT and BMI, even after adjustment for other potential 
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confounders, such as age and alcohol [407, 410/411]. An increased frequency 
of genotype 2 among patients with PNALT has been previously reported [409, 
412]. In line with several other groups [403/404, 406] this study found no 
difference in the seroprevalence of genotype 2, though the number of patients 
with this genotype was small. 
 
Using a standard definition of PNALT [296], 87 patients with an ALT 
persistently ≤ 40 U/L were identified, included in which were 43 patients in 
whom it was persistently ≤ 30 U/L. In contrast there were 1140 patients with at 
least one ALT > 40 U/L in the six months following diagnosis. This study was 
not designed to assess the prevalence of PNALT in HCV infected patients, but 
87/ 1227 (7%) is significantly lower than the 20/50% reported by some groups 
[162, 398/399, 413]. Patients in this study represent those referred to secondary 
care from within a geographically determined area of the UK. It is to be 
expected that many of these patients were diagnosed with HCV following the 
discovery of an elevated ALT. It is, therefore, likely that our population 
underestimates the true prevalence of a PNALT in HCV infected patients.  
 
This study has also shown that the majority of patients with a PNALT will 
ultimately have an elevated ALT. Within five years of the initial definition 
period for PNALT over 60% of patients with PNALT ≤ 30 U/L and PNALT ≤ 
40 U/L group had a recorded ALT of greater than 30 U/L and 40 U/L 
respectively. This is in concordance with other studies that suggest 20/50% of 
patients with PNALT develop an abnormal ALT with extended follow/up 
[414/415]. Some groups suggest that a more stringent definition of PNALT is 
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needed in order to identify patients where there is a genuine PNALT.  The 
Italian Association for the Study of the Liver recommend that the ALT be 
normal on tests conducted every 2/3 months for a minimum of 18 months 
before advocating a diagnosis of PNALT [416].  The data presented here 
shows that the attrition rate in both PNALT groups continued beyond 18 
months and did not plateau even after five years, suggesting that very few 
patients maintain a PNALT throughout the course of their disease. This is 
consistent with evidence suggesting that the ALT fluctuates during the course 
of HCV infection [417].  A significant proportion (8.5%) of the patients who 
initially had an elevated ALT subsequently had a period where the ALT 
remained persistently normal for at least 6 months. Had HCV been diagnosed 
at that time then these patients would have been labelled as having a PNALT. 
The natural history of HCV would seem, therefore, to be one of fluctuating 
ALT levels, with many patients having periods where the ALT remains within 
normal limits.    
 
In line with previous studies this study demonstrates that patients with PNALT 
have lower Ishak fibrosis and necroinflammatory scores on their first liver 
biopsy than patients with an elevated ALT [401, 413, 415]. This is despite 
patients with PNALT having a similar estimated duration of infection and 
frequency of liver biopsy as those with an elevated ALT. As has already been 
mentioned, patients with PNALT are more likely to be female and to have a 
lower BMI. The demographics of patients with PNALT are, therefore, in 
keeping with previous descriptions of HCV infected patients with a low risk of 
disease progression [111, 131]. 
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Finally, this study has examined whether there was any biopsy/assessed 
difference in fibrosis progression between the PNALT groups and patients with 
an elevated ALT. The PNALT and elevated ALT patients with paired liver 
biopsies had similar necroinflammatory and fibrosis scores on their first 
biopsy. This reflects the fact that the repeat biopsy patients with an elevated 
ALT are a selected sub/group of the total cohort of patients with a raised ALT 
where a decision not to treat was taken after the first biopsy. We found that 
fibrosis progressed at a similar rate between paired biopsies in those with 
PNALT as compared to patients with an elevated ALT. Of the previous 
longitudinal studies that have specifically looked at HCV patients with 
PNALT, some estimate fibrosis progression on the basis of a single biopsy 
[404], or have not included a comparison group of patients with an elevated 
ALT [405]. Hui et al [406] compared fibrosis progression between liver 
biopsies and suggested that fibrosis progressed at a slower rate in the patients 
with a PNALT. The definition of PNALT used, however, incorporated an 
upper limit of normal for ALT of 59 IU/ml, which makes direct comparison 
difficult. In the present study no difference between the groups in terms of the 
number of patients in whom the Ishak fibrosis score increased by ≥ 2 points 
was observed. Such an increase is considered to be indicative of fibrosis 
progression rather than to any potential sampling error [418]. Patients with a 
PNALT would seem, therefore, to be as much at risk of disease progression as 
those patients with an elevated ALT who start with similar necroinflammatory 
and fibrosis levels. It might be argued that a median interval between biopsies 
of 31 months in the PNALT group and 28 months in the group with an elevated 
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ALT, may be too short to demonstrate significant fibrosis progression. Given 
that fibrosis progression in Ishak points per year was higher in the PNALT 
groups than in those with an elevated ALT, it seems unlikely that a longer 
median interval between biopsies would result in an increased rate of 
progression in the elevated ALT group. 
 
Those patients in whom the risk of death or HCC was assessed, were by design 
those with initially mild disease (Ishak fibrosis score 0, 1 or 2 on the initial 
biopsy).  The frequency of these events was, therefore, low and no discernable 
difference between the patients with a PNALT and those with an elevated ALT 
was demonstrated. There is evidence that HCV with a normal ALT can still be 
associated with liver related morbidity. In a study of 519 patients in whom the 
average ALT value was < 40IU/L over 10 years, the 5 and 10 year cumulative 
incidence of HCC was 2.0% and 11.2% respectively [419]. 
   
This study has examined the natural history of patients with a PNALT using a 
large geographically determined population of patients with HCV infection. 
The results suggest that the majority of patients with a PNALT will have had 
an abnormal ALT within 3 years of follow/up. These patients also demonstrate 
similar rates of fibrosis progression as a sub/group of HCV infected patients 
with an elevated ALT who are re/biopsied prior to any institution of therapy. 
They, therefore, warrant the same consideration with regard to treatment and 
the need for liver biopsy as patients with an elevated ALT.  Earlier studies of 
standard interferon monotherapy in patients with a normal ALT were 
associated with a flare in serum ALT in nearly 60% of patients, leading to the 
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recommendation against treatment in these patients [420]. More recent studies 
show the efficacy of peginterferon and ribavirin in patients with a normal ALT 
is similar to that of patients where the ALT is elevated [421/422] and that 
treatment associated flares in ALT are not a significant feature [423].  
 
Non/invasive methods of assessing liver fibrosis, including transient 
elastography and Doppler indices have been studied in a small number of 
patients with PNALT [424/426]. Liu et al [425] suggested that the splenic 
arterial pulsatility index was the most discrimatory of the non/invasive 
methods in predicting significant fibrosis (>F2). On the other hand Sebastiani 
et al [426] found that the performance of biochemical markers of liver fibrosis 
was poorer in patients with a normal ALT as compared to those with an 
elevated ALT. With ALT seemingly an unreliable indicator of disease 
progression, however, these modalities and other non/invasive investigations 
for fibrosis warrant further study to assess whether they are able to provide 
patients with information on disease severity and progression in order to allow 
an informed decision with regard to antiviral therapy. 




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The seroprevalence of HCV infection is believed to have peaked in first decade 
of the 21st century [27]. Disease progression over many decades, however, 
means that the proportion of patients with cirrhosis will not peak until 2020 
[27, 170], and the complications of HCV will continue to increase for many 
years thereafter. A better understanding of the clinical course and prognosis for 
patients with advanced liver disease secondary to HCV will, therefore, become 
increasingly important. Epidemiological studies of disease progression have 
shown that the patient population selected has an important bearing on the 
results [427]. The majority of studies examining the natural history of cirrhosis 
secondary to HCV have come from tertiary referral centres, have included 
predominantly those infected following blood transfusion and are largely from 
an era before the advent of effective therapy [210/211, 428/429]. With the 
elimination of blood as a route of transmission in the majority of western 
countries, patients who acquired hepatitis C from injecting drug use are now 
the main source of new referrals.  
 
6.21,
The aims of this study were to describe the natural history of HCV with severe 
fibrosis within a broad patient population that typifies those patients currently 
attending hepatitis clinics.  
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At the time of this study (2005) there were 2003 HCV RNA positive patients 
enrolled into the Trent HCV study, of which 1003 had at least one liver biopsy 
with an Ishak disease severity score. For this study all chronically HCV/
infected patients with a liver biopsy (the index biopsy) prior to January 1st 2002 
demonstrating severe fibrosis (defined as Ishak stage ≥ 4) were included 
(n=155). Patients were then excluded if they had 1) evidence of hepatocellular 
carcinoma (HCC) at or within 6 months of entry into the study (n=1); or 2) co/
existing liver disease that could potentially have caused severe fibrosis (n=4: 3 
with active HBV infection, 1 haemachromatosis). The final cohort (n=150) 
contained 3 patients with a positive HBV surface antigen, but an undetectable 
HBV DNA. Nineteen patients had evidence of decompensated liver disease 
(defined below) prior to the index biopsy.  
    
6.6.2	55#3
Entry into the study was defined as the date of the index biopsy. Follow/up was 
until the date of death or liver transplantation, or the last recorded clinic visit 
prior to data collection. Data on patients were gathered from the Trent HCV 
study database and from review of hospital records, including laboratory 
databases. Baseline laboratory values were accepted if within 6 months of the 
index biopsy and were used in conjunction with the clinical information to 
calculate a retrospective Child/Pugh grade.  The primary endpoint was death or 
liver transplantation, with death judged as being related to HCV infection if it 
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was associated with a progressive impairment of liver function, acute variceal 
haemorrhage, or the result of HCC.  Secondary endpoints were HCC 
(diagnosed by imaging modalities) and decompensation, defined as the first 
appearance of jaundice (bilirubin > 50 mol/l with no other identifiable cause), 
ascites (proven by paracentesis or imaging), endoscopically proven variceal 
haemorrhage, or hepatic encephalopathy.     
 
109/150 patients had received at least one course of antiviral therapy, with 92 
(84%) starting treatment after the index biopsy. A sustained virological 
response (SVR) was defined as a lack of detectable HCV RNA 6 months after 
completing therapy.   
      
6.6.60*0101$*5*/*51
 Survival analyses were performed using Life Tables to estimate 1, 3, and 5 
year survival. Kaplan/Meier plots were used for the survival curves and Cox 
proportional hazards for predictors of death. In the Cox models survival 
analyses were calculated using death or liver transplant as the outcome. All 
variables were included in at least one model. Tests for proportionality were 
performed.        
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Tables 3.1 shows the baseline characteristics of the 150 patients, split into 
those with no prior history of decompensation (n=131, Group A), and those 
with clinical evidence of decompensation prior to the index biopsy (n=19, 
Group B). Overall, the median length of follow/up was 51 months (range 1/
185).  
+3
 
Within Group A, 69% were male. Median age at the time of index biopsy was 
48 years (range 30/76), with a median estimated duration of infection of 22.2 
years.  Alcohol intake at biopsy varied considerably between individuals, with 
10 (8%) patients consuming in excess of 80g/day.  The majority of patients 
reduced their alcohol intake following the index biopsy, with the mean 
consumption falling from 22.7 to 7.8g/day.   
 
Treatment data are shown in Table 3.2. An SVR was achieved in 32/101 (32%) 
patients (23% genotype 1 patients compared with 37% of genotype 2 or 3), 
with 28%, 33%, and 33% of patients with Ishak stage 4, 5, and 6 respectively 
having an SVR. 

 99 
*%56.- !*51/$4**$0101$)040+33+5*01/*00401,)
041/=I%131/*553*01/0*/04104*/104+071/$)
31$,3/*01/.






 100 
+3!
 
The main differences between Groups A and B were in alcohol consumption 
and in the severity of the underlying liver disease (Table 3.1). At the time of 
the index biopsy, mean daily alcohol consumption was more than twice that of 
Group A patients. 16/19 (84%) Group B versus 65/131 (50%) Group A patients 
were Ishak stage 6 and more were Child/Pugh grade B (24% vs 6%) and C 
(18% vs 0%).  

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6.8.20*510'170*/35*/0*01/ 
During follow/up 50 (33%) patients reached the defined end/points of death 
(n=40) or liver transplantation (n=10), 33 (25%) from Group A and 17 (89%) 
from Group B.  
+3
 
Within Group A there were 25 (19%) deaths, 19 (76%) of which were directly 
attributable to HCV infection (n=16), or had HCV infection as a contributing 
factor (n=3). The probability of survival without the need for transplantation 
was 97%, 88%, and 78% at 1, 3, and 5 years (Table 3.3). The median interval 
from biopsy to either death or transplantation was 42 months (range 1/109).  
 
+3!
The outcome was worse for the 19 Group B patients.  15 died, whilst 2 
underwent liver transplantation, after a median interval of 22 months (range 7/
158). 

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Note: Values in parentheses represent standard errors unless shown as a percentage  
* patients were excluded from the cohort if they developed HCC within the first 6 months of 
biopsy 
 1 year 3 years 5 years 
 
Survival  0.97 (0.02) 0.88 (0.03) 0.80 (0.035) 
 
Survival with native liver 0.97 (0.02) 0.88 (0.03) 0.78 (0.04) 
 
Cumulative probability of Liver 
transplantation 
 
0/124 (0%) 3/109 (2.8%) 7/63 (11.1%) 
Cumulative probability of HCC and/ 
or decompensation 
8/124 (6.5%)* 15/115 (13.0%) 25/76 (32.9%) 
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Hepatocellular carcinoma (HCC) and/or decompensation was diagnosed in 
33/131 (25%) Group A patients, after a median of 41 months (range 1 – 106). 
The cumulative probability of HCC and/or decompensation was 6.5%, 13%, 
and 32.9% at 1, 3, and 5 years respectively (Table 3.3). Of the 13 patients with 
HCC, 5 underwent liver transplantation, with the diagnosis having been made 
before surgery in all cases. At the end of the study 9/13 HCC patients had died, 
including 4 of the 5 transplanted patients. The median interval from diagnosis 
of HCC to death was 7 months (range 23 days to 48 months).  
 
Decompensation occurred in 26 (20%) Group A patients (6 of whom also 
developed HCC), with jaundice (n=6), ascites (n=9), encephalopathy (n=3), 
variceal haemorrhage (n=5), or more than one of the above (n=3). The median 
interval between biopsy and the first episode of decompensation was 29 
months (range 1/92).  Subsequent to this, 15 patients died and 3 underwent 
liver transplantation. Following the first episode of decompensation, the 
cumulative probability of survival without liver transplantation in Group A 
patients was 55%, 26%, and 19% at 1, 3, and 5 years respectively. The median 
interval between the first episode of decompensation and death/transplantation 
was 10.2 months (range 0/91).   
 



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Two patients developed HCC. All patients in Group B had by definition 
suffered a decompensation event prior to the index biopsy and further analysis 
on subsequent events was not performed. 
 
6.8.8	*$0$5*01/&104+717*5
Analyses of factors correlating with death or liver transplantation were 
performed for Group A patients. In univariate analysis, age, Child/Pugh grade, 
treatment with either standard or pegylated interferon combined with ribavirin, 
and a response to antiviral treatment (SVR or relapser) were all significantly 
associated with survival. Figure 3.1a shows the effect of antiviral treatment on 
the probability of survival without liver transplantation. Laboratory 
measurements associated with an increased probability of death or 
transplantation were an elevated serum Bilirubin or Immunoglobulin M or A, 
and a low Albumin (Table 3.4). The platelet concentration at the time of the 
index biopsy was significantly lower in those Group A patients with Ishak 
stage 6 as compared to Ishak stage 4 (129.2 vs 186.5; P = 0.002). Despite this 
the Ishak stage (4, 5 or 6) did not influence the probability of survival (figure 
3.1b). In multivariate analysis, elevated IgA or IgM levels were independent 
factors predictive of death or liver transplantation, whilst combination antiviral 
therapy was associated with survival (Table 3.5). 
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Figure 3.1 (a) demonstrates that patients who achieved a sustained virological 
response (SVR) or were responder/relapsers following therapy had an 
improved survival when compared to patients who did not receive antiviral 
therapy. 




















 105 


	1&+6.-%43%*%1510)+717*5104+05170*/35*/0*01/
3/1/&/4*>0*&*00401,)041/=%131/04104/
371+71/$)$,3/*01/+3

.  
 
Figure 3.1 (b)  demonstrates that all patients with significant liver fibrosis on 
biopsy have a similar survival probability, regardless of whether their Ishak 
stage on liver biopsy  was 4, 5 or 6. 
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Variable 
No. of 
patients 
 
OR (95% CI) 
 
P value 
 
Age  (per year) 
        
        131 
          
         1.04 (1.01/1.08) 
    
     0.013 
 
Sex   Female  
          Male 
         
41 
90 
          
reference 
0.83 (0.40 –1.73) 
 
 
ns 
 
Ethnic group:                White  
                         Indian subcontinent 
                         Black 
                         Other 
       
         106 
15 
6 
2 
 
reference 
         1.17 (0.40 / 3.38) 
         1.48 (0.20 /11.06) 
         1.56 (0.21 / 11.69) 
 
      
       ns 
ns 
ns 
 
Route of infection:      No known risk factor 
                                    Intravenous drug use 
                                    Blood product transfusion 
 
 
18 
61 
22 
 
reference 
0.73 (0.26/2.06) 
1.36 (0.45/ 4.09) 
 
 
ns 
ns 
 
Past or present history of alcohol consumption > 80g/d        No 
 Yes 
 
87 
39 
 
reference 
1.20 (0.55 – 2.60) 
 
 
ns 
 
Genotype:                       1 
                          3 
 
        
         38 
56 
 
 
reference 
0.80 (0.32 / 1.97) 
 
 
 
ns 
 
 
Ishak stage:                 4  
                                    5 
                                    6 
 
23 
42 
65 
 
reference 
0.68 (0.23 – 2.07) 
0.96 (0.35 – 2.65) 
 
 
ns 
ns 
 
Ishak necroinflammatory score (per point) 
 
114 
 
1.06 (0.95/1.19) 
 
ns 
 
Hepatitis B status:            HBsAg and HBcAb neg 
                            HBsAg neg HBcAb pos 
                            HBsAg pos 
 
         80 
46 
3 
 
                  reference 
1.01 (0.45 – 2.29) 
2.62 (0.33 – 20.61) 
 
       ns 
ns 
ns 
 
Immunoglobulins (per unit increase)*         IgG 
                                                                     IgM 
                                                        IgA 
 
        111 
110 
111 
 
           1.05 (0.98 / 1.13) 
1.33 (1.17 / 1.52) 
1.59 (1.25/2.02) 
 
       ns 
<0.001 
<0.001 
 
Antiviral therapy:           No therapy  
                                        IFN monotherapy (includes PEG =3) 
                                        Standard IFN + Ribavirin 
                                        PEG/IFN + Ribavirin 
 
         29 
26 
28 
48 
 
reference 
0.53 (0.23/1.23) 
0.31 (0.11 – 0.91) 
0.10 (0.03 – 0.39) 
 
 
ns 
0.03 
0.001 
 
Response to antiviral therapy: No treatment 
                                                Non responder/ withdrawn/ died 
                                                Relapser    
                                                Sustained viral response 
 
         30 
49 
20 
32 
 
                  reference 
0.46 (0.20 / 1.05) 
0.16 (0.03 – 0.73) 
0.18 (0.05 – 0.65) 
 
 
       ns 
0.02 
0.009 
 
Bilirubin (g/L)* per g 
 
129 
 
1.04 (1.01 – 1.07) 
 
0.018 
 
ALT (iu/L)* per iu 
 
130 
 
1.00 (0.10/1.01) 
 
ns 
 
Albumin (g/ L)* per g 
 
127 
 
0.90 (0.85 – 0.96) 
 
0.002 
 
Platelets (x 109/L)* per unit 
 
117 
 
1.00 (0.99/1.00) 
 
ns 
 
Child pugh grade                        A 
                                       B 
 
104 
7 
 
reference 
3.07 (1.03 – 9.19) 
 
 
0.04 
 
* Laboratory values refer to the result nearest to the index biopsy (providing within 6 months of biopsy). The Child/
Pugh grade was calculated retrospectively based on these results where available. 
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Variable 
 
Number of  
Patients 
 
 
OR (95% CI) 
 
P value 
 
 
Standardised  
Relative risk 
(standard 
deviation) 
Age (per year) 131 1.02 (0.98 – 1.07) ns  
Sex – (Male) 131 (90) 1.12 (0.40 – 3.11) ns  
Immunoglobulin A 111 1.36 (1.05 – 1.77) 0.02 1.59 (1.51) 
Immunoglobulin M 110 1.42 (1.16 – 1.73) 0.001 1.74 (1.6) 
Antiviral therapy: 
          No therapy  
          IFN monotherapy  
          (includes PEG =3) 
          Standard IFN + Ribavirin 
          PEG/IFN + Ribavirin 
 
          29 
26 
 
28 
48 
 
reference 
0.43 (0.13 – 1.38) 
 
0.26 (0.07 – 1.03) 
0.05 (0.01 – 0.32) 
 
 
ns 
ns 
 
0.05 
0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


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This prospective study provides a clearer picture of the prognosis for 
individuals with chronic HCV infection complicated by severe hepatic fibrosis. 
By investigating a geographically determined population this study avoids 
much of the selection bias associated with this type of study. The aim was to 
examine the natural history in a group of patients that typify those attending 
hepatitis clinics and patients have, therefore, been included irrespective of their 
alcohol consumption. 
  
The principal findings concern survival to death or transplantation and the 
cumulative probability of both HCC and decompensation. Those patients with 
prior evidence of decompensation were evaluated separately leaving 131 
patients in the main analysis; these were similar in age and sex to other studies 
[210/211, 428/430]. The median estimated duration of HCV infection (22.2 
years) is also consistent with the literature [111, 113]. In other respects, 
however, the patient population differed markedly from those of previous 
studies. The patients in each of these previous studies were predominantly 
blood transfusion recipients [210/211, 428/430], whereas almost half of the 
patients in this study acquired HCV through injecting drug use. This group has 
been under/represented in some previous studies, with the Eurohep series [211] 
including just 2% of such patients. Those studies that have focused on patients 
infected with HCV through injecting drug use have mainly included patients 
with mild disease [101].   
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The most important difference, however, is in the inclusion of patients who 
consumed excess alcohol. At entry to the study 10 (8%) Group A and 7 (37%) 
group B patients were consuming in excess of 80g/day of alcohol. Heavy 
alcohol use (> 50g/day) is associated with increased fibrosis[120], however, 
neither alcohol consumption at the time of biopsy or past heavy alcohol use 
were prognostic factors in this study. Mean alcohol consumption fell by 
approximately two thirds following the index biopsy, with only one patient in 
Group A continuing to drink in excess of 80g/day and only 6 at moderate levels 
(>32g/d for men or > 24g/d for women). These findings suggest that if patients 
diagnosed with severe fibrosis reduce their alcohol consumption, subsequent 
prognosis is not influenced by their prior alcohol intake. This underlines the 
importance of encouraging HCV infected patients to reduce their alcohol 
consumption, particularly those with advanced disease.  
 
At the end of the study a quarter of those patients in Group A had died or 
undergone liver transplantation, with the majority of deaths judged to be 
related to HCV. Following a diagnosis of severe hepatic fibrosis (Ishak stage 
>4), the likelihood of the patient being alive at 5 years was 80%; lower than in 
some series [211], but consistent with the findings of a French study, which 
included a similar number of patients with an alcohol consumption of > 
80g/day [210]. Following the first appearance of decompensation, the 
cumulative probability of survival fell to 19% at 5 years. This is lower than the 
approximately 50% 5 year survival previously reported [211, 428, 431], but 
two of these studies only reported on patients who remained HCC free [211, 
428], while the third included only those patients where the diagnosis of  HCC 
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was subsequent to the decompensation. Our study examined survival following 
decompensation irrespective of whether the patient also had HCC and the order 
in which they were diagnosed.  
 
Hepatitis C is suggested to be an important cause for the increase in incidence 
of HCC in developed countries [197, 199, 432].  The cumulative risk of HCC 
in group A patients was 15.4% at 5 years, comparable with the 7/13.5% 
previously reported [210/211, 428/430]. The median estimated duration of 
infection prior to the diagnosis of HCC was 30 years.  Prior HBV infection is 
suggested as a risk factor for the development of HCC in HCV infection [433], 
however, a similar proportion of patients who did not develop HCC had a 
positive HBcAb in this study.  
 
Baseline patient and laboratory characteristics were assessed for their ability to 
define prognosis using Cox’s model. Univariate analysis showed that age, 
together with indicators of poor liver function (Bilirubin, Albumin and the 
Child/Pugh grade) were prognostic factors for survival. An elevated serum 
immunoglobulin M or A was also associated with a worse outcome in both 
univariate and multivariate analyses. Hypergammaglobulinaemia is a feature of 
cirrhosis, with reduced antigen clearance by Kupffer cells thought to be the 
stimulus [434/436], suggesting it may result from rather than contribute to 
cirrhosis.  
 and animal studies, however, demonstrate that 
immunoglobulins stimulate the proliferative activity of hepatic stellate cells 
leading to increased fibrosis [437/438]. Elevated levels of immunoglobulins 
have been reported in patients with HCV [439], with immunoglobulin A, G and 
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total immunoglobulin levels also shown to be independent predictors of hepatic 
fibrosis [440]. Previous natural history studies have not featured elevated 
immunoglobulins as potential prognostic factors, but neither do they appear to 
have included measurement of immunoglobulins in their design [111/113, 210/
211, 428/429]. This study can not discern whether the observation that raised 
Immunoglobulin levels are associated with a worse prognosis results from 
immunoglobulin induced stimulation of hepatic stellate cells or that raised 
levels are simply a surrogate marker for declining liver function.  
 
The proportion of patients who received antiviral therapy was higher (78% in 
Group A) than in previous studies. Advanced fibrosis is independently 
associated with a lower rate of SVR in response to combination antiviral 
therapy [285/286]. Treatment naïve patients in this study who received 
Pegylated Interferon and Ribavirin had an SVR of 39%, only marginally lower 
than for advanced fibrosis patients in the published trials [285/286]. Treatment 
was associated with survival in both univariate and multivariate analyses. An 
undetectable HCV RNA at the end of treatment was also associated with 
survival in the univariate analysis. A potential bias is that the untreated group 
may include some patients judged too unwell for treatment. Untreated patients 
were more likely to be Child/Pugh grade B at biopsy (13% vs 5%), genotype 1 
(44% vs 33%), and to consume > 80g/day of alcohol (17% vs 6%), suggesting 
that the treating physician may have been more inclined to recommend 
treatment if the course of treatment was shorter and the likelihood of success 
greater. It is noteworthy, however, that treated patients with a viral response, 
whether sustained or not, faired better than non/responders. This suggests that 
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interruption of viral replication, even if only temporary, is associated with an 
improved prognosis, possibly through  a reduction in liver fibrosis and 
inflammation [441/442], which in turn may reduce portal hypertension[443].  
 
Unlike previous studies that looked only at cirrhotic patients, this study 
included patients with a spectrum of severe liver disease, from portal fibrosis 
with marked bridging (Ishak stage 4) to probable (Ishak stage 5) or definite 
cirrhosis (Ishak stage 6). The Ishak stage did not, however, significantly impact 
on the probability of survival, suggesting progression to severe fibrosis is 
universally associated with a poor prognosis. Sampling error is an inherent 
problem to staging HCV on liver biopsy [418, 444]. In 4 of the 19 patients with 
prior decompensation, the subsequent index biopsy did not demonstrate 
definite cirrhosis. This could be interpreted as evidence of sampling error, 
though an alternative explanation is that decompensation was secondary to 
alcoholic hepatitis, given that all 4 patients previously consumed alcohol in 
excess of 80g/ day. The significant difference in the mean platelet 
concentration between Group A patients with Ishak stages 4 and 6, at the time 
of the index biopsy, suggests that these are distinct groups of patients and that 
mis/scoring through sampling error was not a significant problem. Physicians 
need, therefore, to be aware that those patients with bridging fibrosis but not 
yet definite cirrhosis, are also at significant risk of morbidity and mortality 
from liver disease in the short as well as long term. Extending the study to 
include patients with Ishak stage 3, would have incorporated a further 73 
patients. During an average of more than six years follow/up, six of these 
patients died, but none through HCV/related causes. No patients were 
 113 
diagnosed with HCC or underwent transplantation. This suggests that Ishak 
stage 4 is the threshold at which significant morbidity and mortality from liver 
disease occurs.  
 
The whole cohort also included a number of patients with evidence of 
decompensation prior to the index biopsy (Group B). Patients with advanced 
liver disease will often present with complications before a defining biopsy has 
been performed and this is, therefore, an important group to consider. Not 
surprisingly, these patients had a worse prognosis, with 89% of patients 
compared with 25% in Group A having died or undergone liver transplantation 
by the end of the study.  
 
In conclusion, this prospective study examined the natural history of severe 
hepatic fibrosis secondary to HCV in a geographically determined population. 
It demonstrates a worse prognosis than has been reported from earlier studies 
using more selected patient populations. It also confirms that once 
decompensation develops, HCV infection is associated with a high mortality 
rate. Indicators of poor synthetic liver function and hypergammaglobulinaemia 
were found to be important prognostic factors for mortality, while combination 
antiviral therapy was associated with an improved survival. The results from 
this study add to our understanding of the natural history of HCV infected 
patients with severe hepatic fibrosis. It also demonstrates the importance of 
using data collected from a broad patient population when planning the 
allocation of resources to the management of hepatitis C.  

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HCC is recognised as an increasing cause of morbidity and mortality in HCV 
infected patients [199/200]. HCV related HCC almost exclusively occurs in 
those patients with cirrhosis [106, 201], where approximately 3.7% of patients 
will develop HCC each year [445]. Those patients who present with 
symptomatic disease will usually have an advanced tumour that is not 
amenable to curative therapy. Such patients have a median survival with 
supportive care alone of just 5.4 months [446]. Tumours identified at an earlier 
stage may be amenable to curative treatment through resection, transplantation 
or local ablative therapies. Routine periodic screening of patients with HCV 
related cirrhosis is, therefore, recommended in UK [447], European [448] and 
US [449] guidelines in order to diagnose more patients at an earlier stage of 
disease. This recommendation is based not on randomised controlled trials of 
surveillance versus no surveillance, as these are lacking, but on observational 
studies that suggest that HCC detected during formal surveillance are smaller, 
more often uninodular  and more likely to be amenable to curative treatment as 
compared to those where the diagnosis is as a result of symptoms or incidental 
[450]. Surveillance programmes vary, but generally incorporate one or both of 
α/fetoprotein (AFP) and ultrasound at an interval of between 3 and 12 months. 
The recommended interval is based on evidence showing that the period 
between undetectable HCC and a 2 cm lesion is 4/12 months [451].   
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The aims of this study were to:  
/ Examine the opportunity for and effectiveness of surveillance in the early 
diagnosis of HCC in HCV associated cirrhosis  
/ Explore factors associated with an increased risk of developing HCC within a 
population with cirrhosis secondary to HCV.  
 
8.6*01/0*/,04 

8.6.-0+3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At the time of this study (2007) the Trent HCV study cohort included 2184 
HCV RNA positive patients, from which 46 patients with an additional 
diagnosis of HCC were identified. Information on HCC diagnosis and 
treatment and in particular whether the diagnosis was made as a result of 
surveillance was ascertained from review of the patient’s hospital records. 
These were unavailable in 6 cases. Additional clinical and laboratory data were 
extracted from the study database. 
 
Patients were judged to have had appropriate surveillance for HCC if they had 
both an AFP and ultrasound scan at intervals of not longer than 6 months, as 
recommended in guidance from the British Society of Gastroenterology [447]. 
HCC were felt to have been diagnosed at an early stage if their dimensions fell 
within the Milan criteria [452] (a single solitary lesion not greater than 5cm in 
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diameter or up to 3 nodules with none more than 3cm in diameter, together 
with no evidence of vascular invasion). 
 
A further 129 patients with biopsy proven cirrhosis (Ishak stage 6) but no 
evidence of HCC were identified. Data at the point of diagnosis with cirrhosis 
was taken from the study database and compared to similar data for those 
patients who subsequently developed HCC. 
 
8.6.20*0101$*5*/*51 
Continuous variables were compared using the Mann/Whitney U/test. 
Categorical variables were compared using the chi/squared test or Fisher’s 
exact test. A two/tailed p value of < 0.05 was considered significant. Survival 
analyses from the point of diagnosis with HCC were performed using Life 
Tables to estimate 1, 3, and 5 year survival. Kaplan/Meier plots were used for 
the survival curves.  
 
Multiple logistic regression analyses included all HCV infected patients with 
cirrhosis and were performed with diagnosis of HCC as the dependent variable 
and included age at diagnosis, sex and those variables from the univariate 
analysis with a p value < 0.1.  
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The majority of the 46 patients with HCC were male (78%), with a median age 
at diagnosis of 60.5 years (range: 42/ 83 years). The median estimated duration 
of HCV infection at the time of diagnosis with HCC was 24.5 years. Forty five 
percent of patients were current smokers and a further 20% were ex/smokers. 
An existing diagnosis of diabetes was present in 20% of patients at the time of 
diagnosis with HCC.   
          
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The opportunity for and effectiveness of surveillance was assessed in the 40 
patients for whom the hospital notes were available for review. Seventy five 
percent of patients (30/40) had been diagnosed with cirrhosis at least 6 months 
prior to the diagnosis of HCC and as such there was an opportunity for 
surveillance. Of these a third (10/30) had a minimum of AFP and ultrasound 
every 6 months (appropriate surveillance), while a further 14 patients (47%) 
had inconsistent surveillance. In total, therefore, 80% of patients had evidence 
of some form of surveillance.    
 
HCC was diagnosed as a result of surveillance in 14 patients (35%), 58% of 
those who were having some form of surveillance and 70% of patients who had 
appropriate surveillance. Thirty (75%)  patients diagnosed with HCC had an 
ultrasound within 6 months of diagnosis, on which HCC was evident in 26/30 
(87%) of cases. The median AFP at diagnosis was 54 ng/ml (range 4 / 
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400,000), with 21% of patients having a normal AFP and 18% a level ≥ 400 
ng/ml.  
 
For 6 patients it was not possible from either the hospital records or radiology 
reports to accurately stage the tumour and, therefore, to ascertain whether it fell 
within the Milan criteria.  Forty four percent of the remaining patients had 
HCC that fell within the Milan criteria. Patients who were receiving some form 
of surveillance (55%) or appropriate surveillance (63%) were more likely than 
those receiving no surveillance (20%) to have earlier stage tumours. When 
HCC was diagnosed as a result of surveillance 85% (11/13) were within the 
Milan criteria, compared to 17% (3/18) when the diagnosis was incidental or 
the result of symptoms (P<0.001).  All patients with an AFP ≥ 400 ng/ml (n=5) 
had tumours whose dimensions fell outside of the Milan criteria compared to 
11/26 (42%) where the AFP was < 400 ng/ml.  
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Survival from the time of diagnosis with HCC was 55%, 31% and 19% at 1, 3 
and 5 years. Survival was not significantly different in those who received 
surveillance, but having a potentially curative treatment [liver transplantation 
(n=9), resection (n=2), radiofrequency ablation (n=6) or alcohol injection 
(n=3)] was associated with a 84%, 62% and 33% survival at 1, 3 and 5 years 
compared to a 1 year survival with palliative treatments (n=20) of 37% and no 
survivors beyond 34 months (P<0.001) (Figure 4.1).   



 120 
	1&+8.-*%*%1510)+717*53/1/&/404/004
3*01/0$17*/),)+7155*/$.





Figure 4.1 (a) illustrates that patients receiving HCC surveillance had a similar 
survival probability to those who were not receiving any form of surveillance.
 121 
	1&+8.-%%*%1510)+717*53/1/&/404043*01/0
$17*30/01*55$+*0170*0,/03*551*0170*0,/0

 
 
Figure 4.1 (b) demonstrates that patients who were suitable for some form of 
potentially curative therapy (liver transplantation, surgical resection, 
radiofrequency ablation or alcohol injection) had an improved survival 
probability as compared to those patients for whom only palliative therapies 
were possible. 
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Table 4.1 compares the 46 patients with HCC to 129 patients with cirrhosis, 
but who had not developed HCC at the time of the study. The data presented is 
taken from the point at which the patient was diagnosed with cirrhosis. 
Smoking history and information on the presence or not of diabetes which was 
described earlier for the patients with HCC is not recorded on the study 
database and was, therefore, not available for the 129 patients with cirrhosis, 
but no HCC. Patients with HCC were older at the time of diagnosis with 
cirrhosis (57 vs 46 years, P<0.001), had a higher serum IgG level (20.6 vs 17.0, 
P=0.007) and a lower albumin (32.4 vs 36.5, P=0.001).  
 
Factors associated with the development of HCC in the univariate analysis 
included advancing age (OR 1.07 [95% CI; 1.04/1.10, P<0.001]), the estimated 
duration of infection (OR 1.06 [95% CI; 1.01/1.11, P =0.03]) and higher levels 
of IgG (OR 1.09 [95% CI; 1.02/1.17, P=0.03]). Treatment with pegylated 
interferon and ribavirin (OR 0.35 [95% CI; 0.15/0.81, P=0.01]) together with 
an SVR (OR 0.24 [95% CI; 0.07/0.88, P=0.03) were shown to be protective, as 
was Sheffield steatosis score 1 vs 0 (OR 0.18 [95% CI; 0.05/0.61, P =0.006]) 
(Figure 4.2). Those variables that were statistically significant in the univariate 
analysis were further considered in multivariate analysis, but none were 
statistical significant in the adjusted model.   
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HCC (n=46) 
 
Cirrhotics 
(n=129) 
 
P value 
 
Age at diagnosis with cirrhosis 
 
57 (38/78) (n=42) 
 
46 (15/79) 
 
P<0.001  
 
Male  
 
36 (78%) 
 
92 (71%) 
 
ns 
 
Ethnic group        
          White 
          Indian subcont 
          Black 
          Other 
 
 
36 (78%) 
3 (7%) 
5 (11%) 
2 (4%) 
 
(n=128) 
102 (80%) 
18 (14%) 
4 (3%) 
4 (3%) 
 
 
ns 
 
Main risk factor    
          IVDU 
          Blood Tx 
          Other 
          No known risk factor 
 
 
14 (34%) 
13 (32%) 
7 (17%) 
7 (17%) 
 
(n=126) 
54 (43%) 
21 (17%) 
29 (23%) 
22 (18%) 
 
 
ns 
 
Ever heavy drinker 
 
25 (61%)  (n=41) 
 
60 (57%)  (n=105) 
 
ns 
 
Genotype         
                         1  
                         2 
                         3 
                         4 or 5 
 
(n=24) 
7 (29%) 
3 (13%) 
12 (50%) 
2 (8%) 
 
(n=113) 
36 (32%) 
8 (7%) 
64 (57%) 
5 (5%) 
 
ns 
 
Ishak necroinflammatory score 
 
5.7 ±  5.0  (n=22) 
 
4.8 ±  2.5  (n=79) 
 
ns 
 
 
Sheffield steatosis score     0 
                                            1 
                                            2 
                                            3 
 
(n=21) 
14 (67%) 
4 (19%) 
1 (5%) 
2 (10%) 
 
(n=77) 
24 (31%) 
38 (49%) 
9 (12%) 
6 (8%) 
 
 
ns 
 
Hep B status       HBsAg  
                            HBcAb  
 
0  (n=45) 
15 (47%) (n=32) 
 
6 (6%) (n=109) 
 31 (43%) (n=73) 
 
ns 
 
BMI  
 
25.9 ±  3.5  (n=11) 
 
27.4 ± 5.8(n=79) 
  
ns 
 
Estimated duration of infection  
 
24.7 ± 8.9  (n=23) 
 
21.2  ± 10.3 (n=81) 
 
ns 
 
Immunoglobulins    IgG 
                                IgA 
                                IgM 
 
20.6 ± 7.6  (n=35) 
4.2 ± 2.4  (n=35) 
2.1 ± 2.0  (n=35) 
 
17.0 ± 5.9  (n=72) 
3.9 ± 3.2  (n=72) 
2.1 ± 1.3  (n=72) 
 
P=0.007  
ns 
ns 
 
Antiviral therapy:           No therapy  
                                        Standard IFN monotherapy  
                                        Standard IFN + Ribavirin 
                                        PEG/IFN + Ribavirin 
 
22 (48%) 
11 (24%) 
3 (7%) 
10 (22%) 
 
45 (35%) 
11 (9%) 
14 (11%) 
59 (46%) 
 
treatment 
vs  no 
treatment 
ns 
 
Response to antiviral therapy:  
                Non responder/ withdrawn/ died 
                Relapser    
                Sustained viral response 
 
 
(n=22) 
16 (73%) 
3 (14%) 
3 (14%) 
 
 
(n=80) 
33 (42%) 
20 (25%) 
26 (33%) 
 
SVR vs 
no SVR 
 
ns 
 
Bilirubin  
 
37.6 ± 99.3  (n=33) 
 
19.1 ± 14.1  (n=98) 
 
ns  
 
ALT        
 
116 ± 63 (n=33) 
 
118.7 ± 71.8 (n=101) 
 
ns 
 
GGT       
 
249.1 ± 318.3  (n=30) 
 
151.1 ± 158.4  (n=79) 
 
ns 
 
Albumin   
 
32.4 ± 6.0  (n=30) 
 
36.5 ± 5.5  (n=94) 
 
P=0.001  
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Variable 
 
OR (95% CI) 
 
P value 
 
Age  (per year) 
          
         1.07 (1.04/1.10) 
    
    < 0.001 
 
Sex   Female  
          Male 
          
reference 
1.45 (0.65 –3.22) 
 
 
ns 
 
Ethnic group:                White  
                         Indian subcontinent 
                         Black 
                         Other 
 
reference 
         0.47 (0.13 / 1.70) 
         3.54 (0.90 /13.92) 
         1.42 (0.25 – 8.07) 
 
      
       ns 
ns 
ns 
 
Route of infection:      No known risk factor 
                                    Intravenous drug use 
                                    Blood product transfusion 
 
 
reference 
0.82 (0.29/2.29) 
1.95 (0.65/ 5.82) 
 
 
ns 
ns 
 
Ever heavy drinker (> 80g/d)                                     No 
                                                                                    Yes 
 
reference 
1.17 (0.56 – 2.45) 
 
 
ns 
 
Genotype:                       1 
                          3 
 
 
reference 
0.96 (0.35 / 2.67) 
 
 
 
ns 
 
 
Ishak necroinflammatory score (per point) 
 
1.16 (0.96/1.39) 
 
ns 
 
Sheffield steatosis score                 0 
                                                        1 
                                                        2 
                                                        3  
 
reference 
0.18 (0.05/0.61) 
0.19 (0.02/1.67) 
0.57 (0.10/3.23) 
 
 
0.006 
ns 
ns 
 
Hepatitis B status:            HBsAg and HBcAb neg 
                            HBsAg neg HBcAb pos 
                            HBsAg pos 
 
                  reference 
1.21 (0.52 – 2.79) 
0 (0– ∞) 
 
       ns 
ns 
ns 
 
BMI 
 
0.95 (0.83/1.08) 
 
ns 
 
Estimated duration of infection 
 
1.06 (1.01/1.11) 
 
0.03 
 
Immunoglobulins (per unit increase)         IgG 
                                                                    IgM 
                                                       IgA 
 
           1.09 (1.02 / 1.17) 
1.03 (0.80 / 1.32) 
            1.04 (0.91/1.18) 
 
      0.03 
ns 
ns 
 
Antiviral therapy:           No therapy  
                                       Standard IFN monotherapy  
                                       Standard IFN + Ribavirin 
                                       PEG/IFN + Ribavirin 
 
reference 
2.05 (0.77/5.45) 
0.44(0.11 – 1.69) 
0.35 (0.15 – 0.81) 
 
 
ns 
ns 
0.01 
 
Response to antiviral therapy: No therapy 
                                                Non responder/ withdrawn/ died 
                                                Relapser    
                                                Sustained viral response 
 
                  reference 
1.01 (0.46 / 2.22) 
0.16 (0.08 – 1.17) 
0.24 (0.07 – 0.88) 
 
 
       ns 
ns 
0.03 
 
Bilirubin  
 
1.00 (0.98 – 1.02) 
 
ns 
 
ALT  
 
1.00 (0.99/1.00) 
 
ns 
 
GGT 
 
1.00 (1.00/1.00) 
 
ns 
 
Albumin  
 
0.96 (0.91 – 1.02) 
 
ns 

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This study describes 46 HCV infected patients with hepatocellular carcinoma 
identified from the Trent HCV study. The proportion of male patients (78%) 
and the median age at diagnosis (60.5 years) are similar to other case series of 
patients with HCC [453].  An estimated duration of HCV infection of 24.5 
years prior to the diagnosis of HCC is also in keeping with our understanding 
of the natural history of HCV [106, 201]. Sixty five percent of patients were 
current (45%) or ex/smokers (20%) at the time of diagnosis with HCC. Studies 
that have explored the association between smoking and HCC suggest it is not 
independently associated with an increased risk of HCC, but further increases 
the risk of HCC in both HBV and HCV infected patients.  A meta/analysis of 6 
studies demonstrated a multiplicative interaction between HCV and smoking 
[454].  In a Japanese series there was a significantly increased risk of HCC for 
both current (OR 9.6 [95% CI; 1.50 – 61.36]) and ex/ smokers (OR 7.8[95% 
CI; 1.09/56.15]) infected with HCV [455]. Diabetes has also been shown to 
increase the risk of HCC, both independently and in synergy with HCV.  
Twenty percent of patients with HCC in the current series also had a diagnosis 
of diabetes. In a large cohort of US patients from veteran’s association (VA) 
medical centres the incident rate for HCC was 2.39 vs 0.87 per 10,000 person 
years (P<0.0001) in diabetic and non/diabetic subjects respectively. Diabetes 
was associated with a hazard ratio for HCC of 2.16 (95% CI; 1.86/2.52, 
P<0.001) [456]. Another large study included 2061 patients with HCC and 
6183 non/cancer controls identified through the SEER/Medicare database. 
Forty three percent of the patients with HCC had diabetes compared to 19% of 
the non/cancer patients. This represented a 2/3 fold increased risk of HCC in 
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diabetics, independently of other risk factors. The odds ratio for HCC in HCV 
infected patients without diabetes was OR 24.4 compared to OR 36.9 in HCV 
infected patients with diabetes [457]. The synergistic relationship is supported 
by the study of Chen et al which demonstrated a 3.5 fold increased risk for 
HCV infected patients with diabetes compared to those without diabetes [458].  

Regular screening for HCC in patients with cirrhosis secondary to HCC is 
recommended in British [447], European [448] and US [449] guidelines. In a 
2002 survey of gastroenterologists working in the UK, three/quarters 
undertook formal surveillance for HCC [459]. The findings were similar in an 
analogous US study [460]. Three quarters of the patients with HCC in the 
current study were known to have cirrhosis at least 6 months prior to the 
diagnosis of cancer and as such had the opportunity for surveillance. Some 
form of surveillance took place in 80% of patients, though only a third had 
appropriate surveillance, as recommended in guidance produced by the British 
Society of Gastroenterology. In a study of 13002 patients diagnosed with HCV 
related cirrhosis in VA medical centres in the US, 42% received at least one 
surveillance test within the first year, but the number having surveillance then 
declined over the subsequent 2/4 years of the study. Of those patients with at 
least 2 years follow/up, only 12% were still receiving routine surveillance, with 
a further 58.5% having tests on an inconsistent basis [461]. A retrospective 
study of 1480 HCV infected patients (US – VA medical centres) who 
developed HCC between 1998 and 2007 showed that annual surveillance with 
both AFP and ultrasound was observed in only 2% of patients[462]. An issue 
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with surveillance programmes is patient uptake and 3/18% will fail to comply 
with the programme [463].  
 
Surveillance programmes generally utilise one or both of AFP measurement 
and ultrasound. AFP is produced by immature hepatocytes and can, therefore, 
be detected in the blood at times of liver regeneration or in the presence of 
HCC which are made up of transformed, often immature hepatocytes. 
Unfortunately the sensitivity of AFP as a diagnostic tool is rather restricted by 
the fact that non/AFP secreting tumours constitute approximately 20% of HCC 
[447] and a raised AFP can be seen during a flare in viral hepatitis [448]. A cut 
off for AFP of 20 ng/ml has a sensitivity of 41/65% and a specificity of 80/
94% [464].  In the current study 21% of HCC had a normal AFP at diagnosis. 
Ultrasound as a diagnostic tool performs somewhat better with a sensitivity of 
35/84% and a specificity of 92/98% [450]. The performance of ultrasound is 
dependent on the size of the lesion with a sensitivity of 75% for lesions greater 
than 5cm and less than 20% for lesions below 2cm in diameter [465]. In the 
present study ultrasound identified the lesion in 87% of patients who had an 
ultrasound at the time of or in the 6 months preceding the diagnosis of HCC.  
 
Those that dispute the effectiveness of HCC surveillance argue that there is a 
lack of high quality randomised controlled trials (RCT) demonstrating that it 
improves patient outcomes [466/467]. A single RCT of surveillance using 6 
monthly ultrasound and AFP in exclusively HBV infected Chinese patients has 
shown an improvement in mortality at 5 years in those receiving surveillance 
with a mortality ratio of 0.63 (95% CI 0.41/0.98). The mortality benefit was 
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attributed mainly to the detection of tumours at an earlier stage [468]. 
Diagnosing tumours at an earlier stage may make them more amenable to 
treatment, but it also introduces the potential for lead/time bias in any observed 
survival benefit. Observational studies have also demonstrated that tumours 
detected by surveillance are more likely to be solitary, at an early stage and be 
amenable to potentially curative treatment. Adjusted analysis to take into 
account lead time bias in these studies still shows that surveillance is associated 
with improved survival [469/471]. A study of 240 HCV infected patients with 
cirrhosis demonstrated that the proportion of patients with lesions that were 
solitary, early stage and amenable to curative therapy was 66%, 83% and 80% 
respectively in those diagnosed as a result of surveillance and 24%, 24% and 
27% in those detected outside of a surveillance programme or scheduled doctor 
visits [472]. Those HCC detected as a result of surveillance tests in the present 
study were more likely to fall within the Milan criteria than those diagnosed 
outside of regular surveillance (85% vs 17%) and receiving a potentially 
curative treatment was associated with a better survival. Thirty percent of 
patients who were having appropriate surveillance with AFP testing and 
ultrasound every 6 months did not, however, have their tumour diagnosed as a 
result of a surveillance test and simply receiving surveillance was not 
associated with an improvement in mortality in this study. In the study of 1480 
infected patients with HCC described earlier, the presence of either AFP or 
ultrasound surveillance during the 2 years preceding HCC diagnosis was 
associated with a lower mortality risk [462].  In a systematic review and 
economic analysis of HCC surveillance the most effective form of surveillance 
was AFP testing and ultrasound at 6 month intervals. Assuming a maximum 
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willingness to pay for a quality adjusted life year (QALY) of £30,000 the 
optimum surveillance strategy was dependent on the aetiology of cirrhosis. For 
patients with HCV cirrhosis the most cost effective strategy was triage with 
AFP testing every 6 months [450].  
 
US data taken from the SEER database between 1992 and 1996 show that 
regardless of treatment the median survival following the diagnosis of HCC 
was 0.64 years with a 1 and 5 year survival of 23 and 6% respectively [473]. 
Trent HCV study patients faired slightly better with a 1, 3 and 5 year survival 
of 55, 31 and 19% following the diagnosis of HCC,  though these figures are 
significantly less than the 86%, 49% and 24% observed for HCV infected 
patients in the study of Trevisani et al [474]. The latter study also demonstrated 
that prognosis from HCC was independent of the aetiology of cirrhosis [474].   
 
This study also examined the characteristics of patients diagnosed with HCC as 
compared to HCV infected patients with cirrhosis who had not developed 
HCC. A multivariate model did not identify any factors that were 
independently associated with developing HCC. In the univariate analysis an 
increase in the patient’s age and the duration of HCV infection were associated 
with an increased risk of HCC. Patients over the age of 55 years have 
previously been recognised to have a 2/4 fold increased risk of HCC [210/
211]. The risk also increases with the length of infection with the mean 
estimated duration of infection in this study of 24.7 years typical of the time 
from acquisition of infection to cancer observed in previous studies [106, 201].  
Increases in IgG levels were also associated with an increased risk of HCC. As 
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outlined in an earlier chapter raised immunoglobulins may be a surrogate 
marker for a more advanced stage of disease and also possibly stimulate the 
proliferative activity of hepatic stellate cells leading to increased fibrosis [437/
438]. Hepatic steatosis may also have been expected to be associated with an 
increased risk of HCC as has been shown elsewhere [217], and given the 
increased risk that has been described with diabetes [456/458]. Chen et al have 
also shown that HCV infected patients with a BMI ≥ 30 have a 4/fold increased 
risk of HCC [458]. In the current study BMI did not confer an increased risk of 
HCC and patients with mild steatosis (stage 1) were at less risk of HCC than 
patients with no steatosis. The latter result is hard to explain except that 28.6% 
of patients with steatosis stage 1 had an SVR following antiviral therapy 
compared to 18.4% of those with no steatosis. This may be because of the 
higher frequency of genotype 3 infection (58% vs 48%), though neither 
association was statistically significant.  
 
Both combination therapy with pegylated interferon and ribavirin, and a SVR 
were associated with a lower risk of HCC. Several studies have shown that 
interferon based therapy decreases the risk of progression to HCC [360/361, 
475/477], particularly in those who achieve an SVR [478/479]. Recent 
evidence suggests this benefit is even seen in those patients who already have 
cirrhosis at the point of treatment [365, 453]. 
 
A major limitation of this study is the small number of patients with HCC 
found within the Trent HCV study cohort.  This in particular effects the 
conclusions that can be drawn from the comparison with cirrhotic patients 
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without evidence of HCC. This study may have missed factors associated with 
a small increased risk of HCC given that wide confidence intervals are a 
characteristic of small studies. There was also a lack of data on smoking 
history and diabetes in the cirrhotic patients without HCC. This data is not 
recorded in the Trent study database and searching the hospital records of all 
the cirrhotic patients was not felt to be productive, given the small number of 
HCC patients and reservations regarding the size of the study. This study also 
only addressed the performance of a single AFP level at the time of HCC 
diagnosis. It would be interesting to look at trends in AFP levels to see whether 
an increasing trend rather than an absolute cut/off value best predicts the 
presence of HCC.  
 
In conclusion this study could not demonstrate any factors in cirrhotic patients 
that were independently associated with an increased risk of HCC in a 
multivariate model. Advancing age and duration of disease were associated 
with an increased likelihood of HCC and combination therapy with pegylated 
interferon and ribavirin, together with an SVR were protective in the univariate 
analysis. It has also shown that the majority of patients with HCC have 
previously been recognised as cirrhotic and there is, therefore, an opportunity 
for surveillance. Guidance on HCC surveillance was, however, only variably 
applied in the Trent region and there was no survival benefit to having 
surveillance. The majority of HCC were diagnosed at an advanced stage, but 
were more likely to be diagnosed at an earlier stage if detected as a result of 
surveillance. Survival was significantly improved where patients had a 
potentially curative treatment. While lead time bias may contribute to the 
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improvement in survival this results suggests that we need to develop strategies 
that more reliably diagnose HCC at an earlier stage than current practices 
allow. 
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Host factors such as age, sex, alcohol consumption and immunodeficiency 
have been shown to influence disease progression and/ or the outcome of 
treatment in Hepatitis C (HCV) infection [111, 113, 125]. Ethnicity is an 
important host variable, known to influence disease manifestations and 
progression in many diseases [480/482]. Its importance compared to other host 
factors in HCV infection is less clear.  
 
African Americans appear to have lower response rates with interferon based 
therapies as compared to white patients [325/330]. On the other hand they are 
reported to have slower progression of fibrosis as compared to Non/African 
Americans [140, 483]. The picture for Asian patients with HCV is less clear 
with Asian Americans whose origins are mainly in South East Asia seeming to 
have a similar [329] or more favourable response to treatment [484], while a 
United Kingdom Asian population, the majority of whom originated from the 
Indian sub/continent, had a poor response to treatment as compared to white 
patients in one study [485]. 
 
9.21,
The aims of this study were to investigate the natural history of Hepatitis C 
infection and the outcome of therapy in an Asian population originating from 
the Indian subcontinent and to compare disease progression and sustained 
virological response rates following antiviral therapy with a group of white 
patients.   
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At the time of this analysis (2009), the Trent HCV study cohort included 2451 
HCV RNA positive patients of which 2364 have a known ethnic group. Of 
these, 2123 were white and 120 Asian (Pakistani 83, Indian 36 and 
Bangladeshi 1).  Disease progression was calculated on the basis of fibrosis 
stage/ duration of infection, in those patients who had both a liver biopsy prior 
to therapy and an estimated duration of infection.  
 
491 White and 55 Asian patients had completed a course of treatment with 
Pegylated Interferon and Ribavirin and had a known treatment response. 51/55 
Asian patients had a recorded genotype of which 46 (90.2%) were genotype 3. 
A comparison of treatment outcome was, therefore, restricted to the 224 White 
and 46 Asian genotype 3 infected patients who had received Pegylated 
Interferon and Ribavirin.  
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SPSS v16 was used for all statistical analyses. Continuous variables were 
compared using the Mann/Whitney U/test. Categorical variables were 
compared using the chi/squared test or Fisher’s exact test. A two/tailed P value 
of < 0.05 was considered significant. Multiple logistic regression analyses 
(forwards, likelihood ratio, inclusion at p < 0.1) were performed with a 
sustained virological response (SVR) as the dependent variable. 
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Table 5.1 shows the baseline characteristics of the 2123 White and 120 Asian 
patients in the study cohort. There was a greater proportion of female patients 
(43.3% vs 30.5%, P=0.003) and Genotype 3 infection (79.2% vs 42.8%, P < 
0.001) within the Asian group. There was also a significant difference in 
alcohol consumption with only 15.5% of Asian patients reporting they drank 
alcohol as compared to 56.6% of whites (P< 0.001). A past or present history 
of excess alcohol (> 50g/d for at least 6 months) was noted for 51.4% of white 
and 6.5% of Asian patients (P<0.001).  Elicit use of intravenous drugs (77%) 
was the main risk factor for infection in whites, while place of birth (i.e. being 
born abroad, 67%) was the most common in the Asian patients. 
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
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1173 (55.3%) White and 76 (63.3%) Asian patients had at least 1 liver biopsy 
prior to receiving antiviral therapy. There was no significant difference in the 
proportion of liver biopsy (P=0.089). Of those biopsied, 1052 White and 69 
Asian patients had at least an Ishak fibrosis stage recorded on the study 
database (Table 5.2).  
 
Asian patients undergoing liver biopsy were older (43.9 ± 13.6 vs 37.9 ± 10.6 
years, P < 0.001) and more likely to be female (46.4 vs 29.1%, P=0.004) than 
their White counterparts. The Ishak necroinflammatory (4.3 ± 2. 5 vs 3.4 ± 2.1, 
P<0.001), Ishak fibrosis score (3.0 ± 2.3 vs 1.8 ± 2.0, P = 0.001) and Sheffield 
steatosis scores (0.9 ± 0.9 vs 0.6 ± 0.8, P=0.016) were all significantly higher 
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in Asian patients. When analysis of steatosis score was restricted to genotype 3 
patients there was no significant difference (1.0 ± 0.9 vs 0.9 ± 0.9, P = 0.369). 
The duration of infection at the time of liver biopsy was significantly longer in 
White patients (9.9 ± 8.1 vs 16.7 ± 9.6 years, P=0.002), with the major caveat 
that duration of infection could only be estimated in a minority of Asian 
patients (n = 18) due to their only risk factor being their country of birth. Only 
72 White and 2 Asian patients had more than one biopsy prior to therapy and, 
therefore, fibrosis progression was calculated on the basis of fibrosis stage on 
first biopsy/ duration of infection (points/ year). The rate of fibrosis 
progression (0.25 ± 0.31 vs 0.16 ± 0.54 points/year, P=0.068) was similar for 
both groups of patients (Table 5.2).   
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224 White and 46 Asian genotype 3 patients had completed a course of 
Pegylated Interferon and Ribavirin therapy. Patients within the Asian group 
were again more likely to be female (50% vs 32%, P=0.027), but were of 
similar age at the time of treatment (43.3 ± 11.7 vs 42.5 ± 9.3 years, P=0.878).  
Table 5.3 shows the outcome of therapy for both Asian and White patients. 
There was no significant difference in the number of patients achieving an 
SVR (78.3 vs 67.9%, P=0.162), though a greater proportion of white patients 
were responder relapsers (4.3 vs 18.8%, P=0.016).  








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Sex / Male:Female (% male)  
 
1476:647 (69.5%)  
 
68:52 (56.7%) 
 
P=0.003  
 
Age (years) at date of discovery 
 
36.0 ± 11.5 
35 (1/82) 
 
 
38.8 ± 13.1 
38.5 (10/73) 
 
P=0.024 (mw) 
 
Main risk factor 
                    IVDU 
                    Blood Transfusion 
                    Other 
                         / Born abroad 
            Not IVDU, Blood,       
tattoo or sex 
 
n=2038 
1571 (77%) 
214 (11%) 
141 (7%) 
               / 24 (1%) 
114 (6%) 
 
n=101 
10 (10%) 
17 (17%) 
72 (71%) 
             / 68 (67%) 
4 (4%) 
 
 
IVDU vs Not 
IVDU 
P<0.001 
 
Genotype  
                     1 
                     2 
                     3 
                     4 
                     5 
                     6 
 
n=1557 
730 (46.9%) 
133 (8.5%) 
        666 (42.8%) 
19 (1.2%) 
8 (0.5%) 
1 (0.1%) 
 
n=96 
15 (15.6%) 
3 (3.1%) 
76 (79.2%) 
1 (1%) 
1 (1%) 
0 
 
 
G1 vs not G1 
P<0.001 
 
Hepatitis B status  
                    HBsAg positive  
                    HBcAb positive 
 
 
43 (2.7%)   (n=1559) 
407 (32.0%) (n=1273) 
 
 
4 (4.5%) (n=89) 
19 (33.3%) (n=57) 
 
 
P=0.308 
P=0.829 
 
Drinks alcohol 
                     Yes 
                      No    
 
n=1862 
1053 (56.6%) 
809 (43.4%) 
 
n=97 
15 (15.5%) 
82 (84.5%) 
 
 
P<0.001 
 
Past or present history of excess 
alcohol  
(>50g/d for at least 6 months) 
 
 
n=1763 
907 (51.4%) 
 
 
n=92 
6 (6.5%) 
 
 
P<0.001 
 
 
BMI (kg/m2) 
 
n=1247 
25.4 ± 4.9 
24.6 (14.5/61.7) 
 
 
n=76 
26.2 ± 4.3 
25.8 (19.7/35.5) 
 
 
P=0.041 (mw) 
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Sex / Male:Female (% male)  
 
746:306 (70.9%) 
 
37:32 (53.6%) 
 
P=0.004  
(Chi square) 
 
Age (years) 
 
37.9 ± 10.6** 
37 (16/85) 
 
43.9 ± 13.6 
45 (20/79) 
 
P<0.001 
 
Ishak score 
 
N=991 
5.1 ± 3.6 
4 (0/21) 
 
N=64 
7.3 ± 4.2 
4 (1/15) 
 
P<0.001 
 
Ishak necroinflammatory score 
 
N=991 
3.4 ± 2.1 
3 (0/17) 
 
N=64 
4.3 ± 2.5 
4 (1/15) 
 
P=0.001 
 
Ishak stage 
 
N=1052 
1.8 ± 2.0 
1 (0/6) 
 
N=69 
3.0 ± 2.3 
3 (0/6) 
 
P<0.001 
 
Sheffield steatosis score 
 
N=872 
0.6 ± 0.8 
0 (0/3) 
 
N=571 
0.9 ± 0.9 
1 (0/3)  
 
P=0.016 
 
Duration of infection (years) 
 
N=901 
16.7 ± 9.6 
15.9 (0.5/52.8)  
 
N=18 
9.9 ± 8.1 
8.7 (0.9/31.5) 
 
P=0.002 
 
Fibrosis progression (stages/yr) 
(Stage/duration of infection) 
 
N=901 
0.16 ± 0.54 
0.07 (0/11.1)  
 
N=18 
0.25 ± 0.31 
0.14 (0/1.1) 
 
P=0.068 
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 White Asian P value 
N 224 46  
SVR  152 (67.9) 36 (78.3) 0.162 
NR 6 (2.7) 3 (6.5) 0.186 
RR 42 (18.8) 2 (4.3) 0.016 
Treatment withdrawn  24 (10.7) 5 (10.9) 0.975 
 
Percentages in parentheses 
SVR (Sustained virological response), NR (Non/Responder), RR (Responder/Relapser) 
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 Number on bar represents number of patients 
 
 
Figure 5.1 demonstrates that for White patients where the numbers were 
greater there was a progressive decline in the percentage of patients achieving a 
sustained virological response (SVR) as the Ishak fibrosis stage increased. This 
correlation was not observed in the Asian group, but the number of patients 
was smaller. When patients were grouped according to the Ishak fibrosis stage, 
the SVR rate amongst Asian patients was observed to be at least that of White 
patients  for each group except Ishak stage 1 (SVR rate for Asian patients was 
50% for 2 patients, i.e 1 did not achieve an SVR). 
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Of those completing therapy, 85 white and 23 Asian subjects had a liver biopsy 
in the 12 months prior to therapy. Unlike the cohort as a whole, Ishak 
necroinflammatory (4.8 ± 3.0 vs 4.0 ± 2.0, P =0.343) and fibrosis scores (3.5 ± 
2.1 vs 3.3 ± 2.1, P =0.706) were similar for both White and Asian patients who 
subsequently had therapy. Figure 5.1 displays the sustained virological 
response depending on Ishak stage and ethnic group.   


On univariate analysis (Table 5.4) increasing age and duration of infection, 
together with levels of fibrosis on biopsy equal and above to Ishak stage 4 were 
associated with a reduction in the likelihood of a sustained virological 
response.  Higher levels of bilirubin, ALT and GGT together with lower levels 
of platelets were also associated with a lack of treatment success.  
         
In the multivariate model (Table 5.5), cirrhosis (Ishak stage 6) was associated 
with a reduction in the likelihood of a sustained virological response as were 
increased levels of GGT.  
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Age  (per year) 
 
270 
 
0.958 (0.932/0.986) 
 
0.003 
 
Sex   Female  
          Male 
 
95 
175 
 
reference 
0.682 (0.390/1.193) 
 
 
0.180 
 
Duration of infection  
 
207 
 
0.958 (0.930/0.986) 
 
0.004 
 
Ethnic group:                White  
                         Asian 
 
224 
46 
 
reference 
1.705 (0.802 –3.627) 
 
 
0.166 
 
Route of infection:      No known risk factor 
                                    Intravenous drug use 
                                    Blood product transfusion 
                                    Other 
 
 
15 
159 
34 
55 
 
reference 
0.345 (0.075/1.589) 
0.220 (0.043/1.131) 
0.375 (0.076/1.854) 
 
 
0.172 
0.070 
0.229 
Drinks Alcohol           
                                     No 
                                    Yes 
 
133 
123 
 
Reference 
0.960 (0.566/1.629) 
 
 
0.879 
 
Past or present history of alcohol consumption > 50g/d         
                   No        
                   Yes 
 
 
147 
102 
 
 
 
reference 
0.583 (0.339/1.003) 
 
 
 
0.051 
BMI (kg/m2) 245 0.977 (0.917/1.041) 0.475 
 
Ishak stage:                  0,1 
                                     2,3 
                                     4,5 
                                       6 
                               No biopsy taken 
 
29 
28 
25 
26 
155 
 
Reference 
0.272 (0.05/1.481) 
0.157 (0.03/0.831) 
0.046 (0.009/0.238) 
0.170 (0.039/0.745) 
 
 
0.132 
0.029 
<0.001 
0.019 
 
 
Ishak necroinflammatory score:    0,1,2 
                                                         3,4 
                                                         5,6 
                                                         7,8 
                                                         ≥ 9 
                                                       No biopsy taken 
          
 
22 
33 
29 
10 
1 
155 
 
reference 
2.122 (0.630/7.079) 
1.086 (0.341/3.456) 
2.286 (0.387/13.505) 
 
1.313 (0.516/3.340) 
 
 
 
0.221 
0.885 
0.362 
 
0.568 
 
Bilirubin 
 
255 
 
0.948 (0.912/0.984) 
 
 
0.005 
 
ALT 255 0.997 (0.994/1.000) 
 
0.07 
Albumin 255 1.093 (1.029/1.160) 
 
0.004 
GGT 
 
189 0.996 (0.993/0.999) 0.011 
Platelets 170 1.006 (1.002/1.011) 0.006 
 


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Variable 
 
OR (95% CI) 
 
P value 
 
 
GGT 
 
0.991 (0.984 – 0.999) 
 
0.036 
Ishak fibrosis score 0,1 Reference  
Ishak fibrosis score 2,3 0.121 (0.005/3.218) 0.207 
Ishak fibrosis score 4,5 0.056 (0.002/1.279) 0.071 
Ishak fibrosis score 6 0.015 (0.001/0.381) 0.011 

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Ethnicity impacts on many aspects of HCV infection; from awareness of the 
disease in the non/infected [486] to perception and knowledge of risk factors in 
those infected [484]; from rates of seroprevalence [481] to rates of testing and 
referral for treatment [275, 487]. Perhaps most importantly patient ethnicity has 
been shown to be an important predictor of disease progression and response to 
treatment in some populations. A number of studies have shown that African 
Americans have an inferior response to treatment as compared to other ethnic 
groups [325/330] and yet may also have a slower rate of fibrosis progression 
than Non/African American patients [140, 483]. The picture for Asian 
populations is less clear with a distinction previously being drawn by some 
groups between patients of South/East Asian origin who may have a more 
favourable response to treatment as compared to White patients [484] and 
patients from the Indian subcontinent where the SVR has been previously 
reported to be inferior [485].  
 
The largest ethnic minority group in the United Kingdom are Asians whose 
origins lie in the Indian subcontinent (India, Pakistan and Bangladesh). This 
study aimed to compare disease progression and treatment outcome in Asian 
and White patients chronically infected with HCV within the Trent HCV 
cohort. It demonstrates significant differences in the epidemiology and 
presentation of HCV infection between these two ethnic groups. Asian patients 
are more likely to be female, older at diagnosis, to drink less alcohol and to 
have genotype 3 infection. Unlike White patients where the predominant risk 
 146 
factor for infection is a history of injecting drug use, the majority of Asian 
patients lack identifiable risk factors, other than their country of birth.  
 
There was a similar frequency of liver biopsy amongst Asian and White 
patients prior to therapy. There were, however, significant differences in the 
severity of the histological manifestations of HCV infection demonstrated. 
Asian patients had significantly higher necroinflammatory, fibrosis and 
steatosis scores as compared to Whites. Asian patients were older at 
presentation as compared to White patients. If we assume that for those 
patients where the only identifiable risk factor was having being born in a 
country with a high seroprevalence of HCV infection, infection was acquired at 
a young age, then Asian patients will also have a longer duration of infection. 
A longer duration of infection and the older age at presentation may explain the 
higher fibrosis scores on biopsy seen in Asian patients, a hypothesis indirectly 
supported by the observation that for the small minority (18/69) of biopsied 
Asian patients with dateable risk factors, the rate of fibrosis progression 
estimated on the basis of the initial biopsy and the estimated duration of 
infection, was not significantly different to that of White patients. The higher 
steatosis score is likely to relate to the predominance of genotype 3 infection in 
Asian patients, particularly given that both Asian and White patients had a 
similar BMI and that there was no significant difference in steatosis score when 
the analysis was restricted to genotype 3 patients. There is a large body of 
evidence linking genotype 3 infection with increased hepatic steatosis [133, 
136].  
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The analysis of response rates to PEG/Interferon and Ribavirin combination 
therapy in previously treatment naïve patients was restricted to patients with 
genotype 3 infection, due to the low number of infections with other genotypes 
in Asian patients receiving treatment. There was no significant difference in 
SVR rates between White and Asian patients and ethnic group was not a 
predictor of treatment response in either the univariate or multivariate analysis. 
Unlike the entire cohort, White and Asian patients receiving combination 
treatment had similar necroinflammatory and fibrosis scores to one another. 
Predictors of treatment response in the univariate analysis were age, duration of 
infection, an Ishak fibrosis score ≥ 4, bilrubin, albumin, platelet count and 
GGT. In the multivariate model only cirrhosis (Ishak fibrosis score 6) and an 
increasing GGT were associated with a reduction in SVR rates. A low GGT 
has previously been shown to be independently associated with improved SVR 
rates [311, 347, 488]. GGT has been shown to correlate with insulin resistance 
and with levels of hepatic fibrosis and steatosis, all of which have been 
demonstrated to impact on SVR [348/349].  
 
There is a single previous published study comparing treatment response in 
HCV genotype 3 infected Asian (Indian subcontinent) and non/Asian patients 
[485]. Patients were treated at the Queen Elizabeth Hospital, Birmingham, UK 
and the Asian population in their catchment area is likely to be similar to our 
own. Overall SVR rates for both Asian (42.1%) and non/Asian (62.1%) 
patients were lower in that study than we have observed. Asian ethnicity was a 
significant determinant of inferior SVR compared with non/Asian in the 
univariate analysis, but no factors achieved statistical significance in their 
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multivariate analysis. There was, however, a significant difference in the 
severity of liver fibrosis between Asian and non/Asian patients in that study 
with 54% of Asian patients having cirrhosis compared to 18% of non/Asian 
patients. In our study there were a similar proportion of cirrhotic patients 
within both the Asian (26%) and non/Asian (23%) group. Given that the 
current study demonstrates that fibrosis stage and not ethnicity is an 
independent predictor of an SVR, it is likely that the previous suggestion that 
Asian patients have an inferior response to treatment reflects the higher 
proportion of Asian patients with cirrhosis in that population, rather than a 
direct effect of ethnicity on treatment response. In a post/hoc analysis of data 
from an open/label parallel study of 1.5 or 1.0 g/ kg/ wk PEG/IFN alfa/2b 
plus Ribavirin for 16/24 weeks published in abstract form, White and Asian 
(both Indian and South East Asian) genotype 2 and 3 patients also had similar 
SVR rates [489].  
 
 Recent data have shown that a single nucleotide polymorphism near the IL28B 
gene, encoding Interferon λ/3 is associated with response to treatment with 
Pegylated Interferon and Ribavirin [97, 334/336]. Patients with the C/C 
genotype are three times more likely to clear HCV relative to C/T and T/T 
genotypes combined. This response is independent of viral genotype [490].  
IL28B genetic variation is associated with initial virological response and C/C 
patients have a significantly greater decline in HCV RNA from day 0/28. 
When stratified for race, IL28B is associated with a higher rapid virological 
response (RVR) in both African Americans and White patients [491]. 
Geographical variation in the IL28B gene supports the notion that Asian 
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patients should have at least as good response rates as their White European 
counterparts, given that both populations, unlike African Americans have a 
high frequency of the C/C genotype [97]. Patients with the C/C genotype have 
also been shown to have a lower GGT [490]. As described earlier a lower GGT 
was an independent predictor of SVR in the present cohort.  
 
There was in fact a non/statistically significant trend towards a superior 
treatment response in Asian patients in the present study as compared to White 
patients. Subsequent ad/hoc analysis of 661 patients (496 White) from two 
multicentre trials of combination therapy (standard interferon and Ribavirin) 
for HCV performed in the USA showed that treatment response was highest 
among Asians (61%), followed by Whites (39%), Hispanics (23%) and African 
Americans (14%) [325]. In a logistic regression model that adjusted for factors 
including genotype, Asian patients continued to be more likely to respond than 
Whites while Hispanics and African Americans were less likely.  The study 
was not able to provide an explanation for the observations. The Asian 
population was also very different to our own with their origins being in South/
East Asia rather than the Indian subcontinent and a predominance of genotype 
1 infection. 
 
The results of this study refutes the idea that Asian patients with Indian 
subcontinent origins have a poorer response to treatment, but confirms that 
there are significant differences in demographics of Asian and White HCV 
infected patients. A limitation of the study is that reliable data was not 
available on compliance with treatment, need for dose reduction and viral load 
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at each stage of treatment, because this was poorly recorded on the database. 
Data was available on end of treatment response (EOTR) and unlike the study 
from Birmingham, UK we have not observed a large proportion of Asian 
patients who relapsed after an initial EOTR. 
 
This study demonstrates that Asian patients infected with Hepatitis C have at 
least as good a response to treatment with Pegylated Interferon and Ribavirin 
as White patients. Asian patients do, however, present to medical services later 
in life, having been infected for longer and with a more severe histological 
injury than White patients. Resources should be directed towards increasing 
awareness of HCV amongst the Asian population, as well as educating primary 
care physicians in recognising that having been born in the Indian subcontinent 
is a risk factor for HCV infection. This should hopefully enable earlier 
identification of infection through opportunistic testing.        
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The platelet count is integrally associated with liver disease. 
Thrombocytopenia occurs in 64/76% of patients with liver cirrhosis and 6% of 
non/cirrhotic patients with chronic liver disease [492]. Both hospital [493/495] 
and community [496/497] based studies illustrate a positive association 
between anti/HCV positivity and thrombocytopenia. There is also a significant 
inverse correlation between the platelet count and the severity of liver disease 
in untreated patients with chronic HCV [498].  
 
Several mechanisms contribute to thrombocytopenia in HCV related liver 
disease. Hypersplenism leads to sequestration and destruction of platelets in the 
spleen[499], but hypersplenism is not a consistent finding in HCV infected 
patients with reduced platelet counts [500/501]. Immune mediated destruction 
of platelets is increased in the context of HCV infection. Elevated titres of 
platelet associated immunoglobulin are detected in as many as 88% of patients 
with chronic HCV and there is an inverse correlation between platelet count 
and platelet survival time [494]. It is suggested that binding of HCV to platelets 
may induce the development of neoantigens on the platelet surface or alter the 
conformation of the platelet membrane promoting autoantibody 
formation[492]. Decreased platelet production also results from direct virus 
induced bone marrow suppression[502] and reduced hepatic production of 
thrombopoietin [503/504]. Thrombopoietin is the primary cytokine governing 
megakaryocyte maturation and platelet production  [505]. It binds to receptors 
on haematopoetic stem cells and megakaryocytes promoting all stages of 
platelet production. It also binds to platelets, enhancing activation and function 
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[506]. Thrombopoietin is produced in hepatocytes and there is an inverse 
correlation between liver fibrosis and thrombopoietin levels [498].  
 
Interferon induced bone marrow suppression leads to an approximately 33% 
reduction in platelet counts in patients treated with pegylated interferon, with 
levels reaching a plateau by the 12th week of treatment [507]. 
Thrombocytopenia is most pronounced in pegylated interferon monotherapy 
and it is suggested that ribavirin induced anaemia may contribute to a reactive 
thrombocytosis, balancing out to a degree interferon induced myelosuppression 
[286]. Successful treatment on the other hand leads to an improvement in 
platelet levels [501, 508]. Product labels for pegylated interferon recommend 
dose reductions for patients with platelet counts between 50 and 100 x 109/L 
and suspension of treatment if levels fall below 20/25 x 109/L [509]. In the 
registration trials of pegylated interferon approximately 4% of patients required 
a dose modification, but less than 1% stopped treatment because of 
thrombocytopenia [285/287, 316]. Fried et al observed severe bleeding in 
association with thrombocytopenia in 1 of 453 patients treated [286]. In a study 
of the efficacy of pegylated interferon and ribavirin in patients with cirrhosis 
and a baseline platelet count of > 75 x 109/L, dose modifications due to 
thrombocytopenia were required in 18/19% (permanent in 8/13%) of patients 
and treatment was discontinued in 2/4% [510].  

Thrombocytopenia and concern regarding the risk of bleeding complications 
may cause the postponement of necessary procedures and therapy, or 
alternatively may result in suboptimal doses of antiviral therapy. Not 
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surprisingly, therefore, there is considerable interest in the pharmacological 
treatment of thrombocytopenia. Eltrombopag is an orally bioavailable low 
molecular weight non/peptide growth factor, that is a selective agonist for the 
thrombopoietin receptor (Mpl). It has been the subject of a phase II study 
examining its efficacy in treating thrombocytopenia in patients with HCV 
related cirrhosis receiving treatment with pegylated interferon and ribavirin. 12 
weeks of treatment was completed by 36/65% of patients treated with 
eltrombopag, compared to just 6% of controls [511]. No study has yet 
answered the question, however, of whether addressing thrombocytopenia with 
pharmacological agents increases the number of patients achieving an SVR.  
 
 
:.21,
This aim of this study was to determine if a reduced platelet count adversely 
affects the likelihood of an SVR using data from the Trent HCV study.
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At the time of this analysis (2008), the Trent HCV study cohort included 2184 
HCV RNA positive patients. An initial 650 patients were identified from the 
study database as having a recorded response to treatment with pegylated 
interferon and ribavirin. The final study population incorporated 357 patients 
with at least one recorded platelet count (3505 individual platelet counts, range 
1/35) taken during treatment. The majority of patients (87%) had a pre/
treatment biopsy, though 27 patients had incomplete data on fibrosis stage.  
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SPSS v14 was used for all statistical analyses. Variables including the initial 
and minimum platelet count were assessed for their association with both SVR 
and completion of therapy (without dose reduction) using logistic regression. 
The results were expressed as the odds ratio (OR) and their 95% confidence 
interval (CI). For the multiple logistic regression analysis patients were 
stratified according to genotype. A two/tailed P value of < 0.05 was considered 
significant. The Pearson correlation coefficient was used to measure the 
relationship between the Ishak fibrosis stage and both the initial and minimum 
platelet count. 
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Table 6.1 shows the baseline characteristics of the study population at the start 
of treatment.  The majority of the 357 patients were male (68%), white (87%) 
and acquired HCV through the use of intravenous drugs (60%). Forty one 
percent of patients had a past or present history of consuming in excess of 50g 
of alcohol/ day. Serology indicated prior Hepatitis B infection in 63 patients 
(31% of those with serology), while four patients (2%) had ongoing co/
infection with HBV as evidenced by a positive hepatitis B surface antigen. 
Patients with genotype 3 (52%) outnumbered those with other genotypes (G1 
35%, G2 10% and G4 3%). The majority of patients who had a pre/treatment 
liver biopsy had mild disease (66% stage ≤ 3), while cirrhosis was evident in 
45 (16%) cases.   
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The mean platelet count at the start of treatment was 176 x 109/L. One hundred 
and twenty seven (38%) patients had a platelet count below 100 x 109/L at the 
start of therapy. Overall 78% of patients completed therapy (73% without a 
dose reduction), while 33% of genotype 1 and 67% of genotype 2/3 patients 
achieved an SVR.  Table 6.2a shows the number of patients with an SVR 
according to Ishak stage and initial platelet count. Table 6.2b and 6.2c separate 
patients according to genotype. A patient with genotype 3 infection, fibrosis 
stage 0 or 1 and platelet > 150 x 109/L had an SVR rate of 89%, whereas no 
patients with genotype 1 infection, cirrhosis and a platelet count < 50 x 109/L 
achieved an SVR. Both the initial (r = /0.43, P<0.001) and minimum (r= /0.46,  
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Age  
 
43.3 ± 10.7 
 
Male  
 
242 (68%) 
 
Estimated duration of infection (years) n=282 
 
20.6 ± 10.7 
 
Ethnic group        
          White 
          Indian subcontinent 
          Black 
          Other 
 
 
310 (87%) 
30 (8%) 
7 (2%) 
8 (2%) 
 
Main risk factor   (n=345) 
          IVDU 
          Blood Tx 
          Other 
          No known risk factor 
 
 
206 (60%) 
56 (16%) 
49 (14%) 
34 (10%) 
 
Ever heavy drinker (past or present history of alcohol 
consumption > 50g/day) (n=336) 
 
135 (41%)   
 
Hep B status (n=205) 
                HBsAg  positive 
                HBcAb positive (HBsAg negative) 
 
 
4 (2%) 
63 (31%) 
 
 
BMI (n=305) 
 
25.6 ± 4.4 
 
Genotype        (n=352) 
                                        1  
                                        2 
                                        3 
                                        4  
 
 
123 (35%) 
35 (10%) 
183 (52%) 
11 (3%) 
 
Ishak necroinflammatory score (mean)   (n=276) 
                
 
3.9 ± 2.1 
 
 
Ishak stage      (n=282) 
                         0,1 
                         2,3 
                         4,5                   
                           6 
 
 
 
108 (38%) 
82 (28%) 
47 (17%) 
45 (16%) 
 
Platelet count at start of  therapy (x 109/ L) 
 
176.3 ± 72.9 
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All (n=330) <50 
(n=37) 
50/100 
(n=90) 
100/150 
(n=107) 
> 150 
(n=96) 
HE- 73/108 (68) 2/3 (67) 15/19 (79) 22/42 (52) 34/44 (77) 
2E6 48/82 (59) 2/6 (33) 12/23 (52) 19/27 (70) 15/26 (58) 
8E9 20/47 (43) 3/8 (38) 9/20 (45) 6/15 (40) 2/4 (50) 
: 15/45 (33) 4/17 (24) 8/20 (40) 2/6 (33) 1/2 (50) 
%13 31/48 (65) 1/3 (33) 7/8 (88) 11/17 (65) 12/20 (60) 
0*5 187/330 (57) 12/37 (32) 51/90 (57) 60/107 (56) 64/96 (67) 
Figures in parentheses are percentage The 27 patients who had a biopsy, but on whom there was incomplete data on 
fibrosis stage are not included 

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All (n=112) <50 (n=13) 50/100 
(n=35) 
100/150 
(n=35) 
> 150 
(n=29) 
HE- 12/34 (35) 0/1 (0) 3/6 (50) 3/14 (21) 6/13 (46) 
2E6 11/31 (36) 1/3 (33) 1/10 (10) 5/9 (56) 4/9 (44) 
8E9 2/16 (13) 0/3 (0) 2/9 (22) 0/4 (0) 0/0  
: 2/11 (18) 0/4 (0) 2/6 (33) 0/1 (0) 0/0  
%13 11/20 (55) 1/2 (50) 3/4 (75) 4/7 (57) 3/7 (43) 
0*5 38/112 (34) 2/13 (15) 13/35 (37) 12/35 (34) 13/29 (45) 
Figures in parentheses are percentage The 27 patients who had a biopsy, but on whom there was incomplete data on 
fibrosis stage are not included 

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All (n=203) <50 (n=24) 50/100 
(n=51) 
100/150 
(n=67) 
> 150 
(n=61) 
HE- 56/87 (84) 2/2 (100) 11/12 (92) 18/25 (72) 25/28 (89) 
2E6 35/48 (73) 1/3 (33) 10/11 (91) 14/18 (78) 10/16 (63) 
8E9 18/30 (60) 3/5 (60) 7/10 (70) 6/11 (55) 2/4 (50) 
: 13/33 (39) 4/13 (31) 6/14 (43) 2/4 (50) ½ (50) 
%13 18/25 (72) 0/1 (0) 4/4 (100) 6/9 (67) 8/11 (73) 
0*5 140/203 (69) 10/24 (42) 38/51 (74) 46/67 (69) 46/61 (75) 
Figures in parentheses are percentage. The 27 patients who had a biopsy, but on whom there was incomplete data on 
fibrosis stage are not included 
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P<0.001) platelet count on treatment showed a negative correlation with Ishak 
stage. 
 
:.6.6	*$0*$1*0104*/*/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/)04*3 
Table 6.3 shows the results of the univariate analysis examining factors 
associated with an SVR and completion of therapy (without dose reduction). 
Increasing age and estimated duration of infection were associated with a 
failure to achieve SVR as was Ishak stage ≥ 4 on biopsy. Patients with cirrhosis 
were less likely to complete therapy than patients with lower stages of fibrosis. 
A higher initial platelet count was associated with both an SVR and completion 
of therapy, while a platelet count of < 50 x 109/L during treatment was 
associated with a failure to complete therapy or achieve an SVR.  
 
In the multivariate model (Tables 6.4a/d) patients were stratified according to 
genotype. sex, age, estimated duration of infection and Ishak stage were 
included in the model along with initial and minimum platelet count. Age at the 
start of treatment (OR 0.95 [95% CI 0.903/0.999, P=0.046]) was the only 
independent predictor of SVR in genotype 1 patients, while the estimated 
duration of infection (OR 0.996 [95% CI 0.994/0.999, p=0.016]) and Ishak 
fibrosis stage (6 vs 0 or 1; OR 0.072 [95% CI 0.021/0.244, P <0.001]) were 
independent predictors of SVR in genotype 2/3 patients. No factors were 
independently associated with completion of therapy in genotype 1 infected 
patients, but Ishak fibrosis stage was associated with completion of therapy in 
genotype 2/3 patients (6 vs 0 or 1; OR 0.208 [95% CI 0.052/0.838, P <0.027]). 
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(%) 
 OR (95% CI) P value OR (95% CI) P value 
 
Age  (per year) 
 
357 
 
0.97 (0.95/0.99) 
 
0.002 
 
1.00 (0.98/1.02) 
 
0.762 
 
Sex        Female 
               Male 
 
115 
242 (68) 
 
reference 
0.74 (0.47/1.16) 
 
 
0.183 
 
reference 
0.97 (0.59/1.61) 
 
 
0.912 
 
Duration of infection  (per 
month) 
 
282 
 
0.997 (0.995/
0.999) 
 
0.002 
 
1.00 (1.00/1.00) 
 
0.709 
 
Past or present history        No 
of alcohol  > 50g/d              Yes 
 
 
201 (59) 
135 (41) 
 
reference 
0.69 (0.45 – 
1.08) 
 
 
0.102 
 
reference 
0.69 (0.42/1.13) 
 
 
0.140 
 
Genotype:                       1 
                                      2,3 
 
123 (36) 
218(64) 
 
reference 
4.30 (2.68/6.89) 
 
 
<0.001 
 
Reference 
3.12 (1.90/5.14) 
 
 
<0.001 
 
Ishak stage:                  0,1 
                                     2,3 
                                     4,5 
                                      6 
                          No biopsy taken 
 
      108 
82 
47 
45 
48 
 
reference 
0.68 (0.37/1.3) 
0.36 (0.18/0.72) 
0.24 (0.11/0.50) 
0.87 (0.43/1.79) 
 
 
 
0.199 
0.004 
<0.001 
0.713 
 
 
reference 
0.85 (0.42/1.71) 
0.63 (0.29/1.37) 
0.50 (0.23/1.08) 
0.65 (0.29/1.45) 
 
 
0.650 
0.239 
0.078 
0.294 
 
Initial  platelets 
 
357 
 
1.005 (1.002/
1.008) 
 
0.002 
 
1.003 (1.000/1.007) 
 
0.049 
 
Minimum platelets 
 
357 
 
1.006 (1.002 /
1.010) 
 
0.004 
 
1.001 (0.997/1.005) 
 
0.564 
 
Normal 
Platelets < 50 
 
105 
39 
 
reference 
0.25 (0.12/0.55) 
 
 
0.001 
 
reference 
0.40 (0.18/0.86) 
 
 
0.018 
 
Normal 
Platelets  <100 
 
105 
138 
 
reference 
0.54 (0.32/0.90) 
 
 
0.018 
 
reference 
1.09 (0.62/1.94) 
 
 
0.763 
Normal 
Platelets < 150 
105 
252 
reference 
0.60 (0.37/0.95) 
 
0.03 
reference 
1.09 (0.65/1.83) 
 
0.733 
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Variable 
 
Number of  
Patients 
 
 
OR (95% CI) 
 
P value 
 
Age at start of treatment 123 0.95 (0.903 – 0.999) 0.046 
Initial platelet count 123 1.006 (0.999/1.014) 0.081 
 
Variable(s) entered on step 1: sex, initial platelet count, minimum platelet count, age at start of treatment, estimated 
duration of infection, Ishak Stage. 

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Variable 
 
Number of  
Patients 
 
OR (95% CI) 
 
P value 
Estimated duration of 
infection    (per month) 
167 0.996 (0.903 – 0.999) 0.016 
Ishak stage 0,1 
2,3 
4,5 
6 
No biopsy 
67 
48 
30 
33 
25 
Constant 
0.426 (0.252/1.191) 
0.359 (0.113/1.143) 
0.072 (0.021/0.244) 
    0.260 (0.073 – 0.930) 
 
0.104 
0.083 
<0.001 
0.038 
 
Variable(s) entered on step 1: sex, initial platelet count, minimum platelet count, age at start of treatment, estimated 
duration of infection, Ishak Stage. 

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Variable 
 
Number of  
Patients 
 
OR (95% CI) 
 
P value 
 
Initial platelet count 123 1.006 (0.999/1.012) 0.090 
 
Variable(s) entered on step 1: sex, initial platelet count, minimum platelet count, age at start of treatment, estimated 
duration of infection, Ishak Stage. 

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Variable 
 
Number of  
Patients 
 
OR (95% CI) 
 
P value 
 
Ishak stage 0,1 
2,3 
4,5 
6 
No biopsy 
67 
48 
30 
33 
25 
Constant 
0.323 (0.090/1.164) 
0.396 (0.090/1.746) 
0.208 (0.052/0.838) 
0.153 (0.037 – 0.635) 
 
0.084 
0.221 
0.027 
0.010 
 
Variable(s) entered on step 1: sex, initial platelet count, minimum platelet count, age at start of treatment, estimated 
duration of infection, Ishak Stage

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The platelet count is a recognised surrogate marker of the severity of liver 
disease and the results of this study confirm that platelet levels show a negative 
correlation with the Ishak fibrosis stage. In HCV infected patients on treatment, 
thrombocytopenia can also result from interferon induced bone marrow 
suppression. Thrombocytopenia may, therefore, prevent some patients 
commencing therapy or force therapy to be curtailed or continued only after a 
reduction in the dose of interferon. Shortening of the duration of therapy or 
reducing the dose of interferon will have a negative impact on the likelihood of 
achieving an SVR. Modifications in drug dosage or temporary cessation of 
therapy have the most impact when made in the first 12 weeks of therapy. 
Individuals who are able to maintain at least 80% of both the pegylated 
interferon and ribavirin dose have an early virological response (EVR) rate of 
80%, compared to 30% when less than 80% of both drugs are taken. Less of 
one drug has a more modest impact with patients taking less than 80% of their 
pegylated interferon but more than 80% of the ribavirin dose having an EVR of 
70% [310].  Seventy eight percent of the 357 patients treated with pegylated 
interferon and ribavirin in the present study completed therapy without the 
need for a reduction in drug dosage. A higher initial platelet count was 
associated with completion of therapy in the univariate analysis.  The only 
factor shown to be independently associated with completion of therapy in the 
multivariate analysis was cirrhosis on liver biopsy, which predicts a failure to 
complete therapy in genotype 2/3 infected patients. Neither the initial platelet 
count nor the minimum platelet count during treatment would appear, 
therefore, to be independent predictors of completion of therapy.  
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Thirty three percent of genotype 1 and 67% of genotype 2/3 infected patients 
achieved an SVR. In those patients with minimal fibrosis on liver biopsy (Ishak 
stage 0 or 1) and a platelet count > 150  x 109/L the SVR rate was 77% 
compared to 24% in cirrhotic patients with a platelet count < 50 x 109/L. Both 
the initial platelet count and minimum count on treatment were associated with 
an SVR on univariate analysis. Neither, however, was independently associated 
with obtaining an SVR, instead the patient’s age in genotype 1 and estimated 
duration of infection and cirrhosis on biopsy in genotype 2/3 patients were the 
factors associated with treatment success in the multivariate analysis. 
 
The severity of fibrosis on liver biopsy has, as described in chapter 1, 
repeatedly been shown to predict the likelihood of a patient achieving an SVR. 
Both the initial and minimum platelet count in this study showed a negative 
correlation with liver fibrosis and, therefore, any association with SVR in the 
univariate analysis may simply reflect worsening levels of liver fibrosis in 
patients with lower platelet levels. An alternative reasoning is that though 
thrombocytopenia correlates with fibrosis stage, thrombocytopenia is as the 
univariate analysis suggests a cause of failure to complete therapy or achieve 
an SVR in patients with cirrhosis. Against this is that less than 1% of patients 
discontinued therapy because of thrombocytopenia in the registration trials of 
pegylated interferon and ribavirin. The investigators in these trials would also 
have been restricted by the product labels which stipulate dose reductions for 
patients with platelet counts between 50 and 100 x 109/L and suspension of 
treatment if levels fall below 20/25 x 109/L. Outside of the confines of a 
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clinical trial many clinicians may be happy to continue with the pegylated 
interferon dose unchanged in patients with lower platelet levels than the 
product label stipulates for dose reduction. If true then this would further 
reduce the impact of thrombocytopenia on SVR rates. 
 
The strength of this study is the large amount of available data on platelet 
counts taken during antiviral treatment. The fact that the majority of patients 
had a pre/treatment biopsy also allows some distinction to be drawn between 
the direct impact of thrombocytopenia on SVR rates and what is simply a 
surrogate for the effect of severe hepatic fibrosis.  The mandatory data fields 
recorded in the Trent study database do not, however, include a reason for a 
reduction in drug dose or cessation of therapy. This is a significant limitation 
for the present study, as the data does not tell us with certainty which patients 
reduced or stopped treatment as a result of thrombocytopenia. Instead we are 
left to draw conclusions from associations between platelet levels and SVR 
rates. Information on any complications resulting from thrombocytopenia is 
also not available.  
 
In conclusion this study did not find the initial or minimum platelet count 
during antiviral therapy to be independent predictors of SVR or completion of 
therapy. Focusing attention on drug therapies designed to increase the platelet 
count during treatment may not be a valuable or cost/effective approach to 
improving SVR rates.  
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The introduction to this thesis has summarised our current understanding of the 
epidemiology and natural history of HCV infection. In particular it outlines the 
patient, environmental and viral factors that influence spontaneous viral 
clearance, disease progression and the success of therapy.  
 
It has been proposed that those HCV infected patients with a persistently 
normal alanine aminotransferase (PNALT) represent a subgroup with mild, 
slowly progressive disease [403/404, 406]. Chapter 2 describes a study 
examining whether a PNALT predicts that the ALT will subsequently remain 
normal. It also explores the risk of disease progression as compared to patients 
with an elevated ALT. It illustrates that patients with PNALT are more likely 
to be female and to have a lower Body Mass Index (BMI) than those with an 
elevated ALT. Using a standard definition of PNALT[296], over 60% of 
patients subsequently had an elevated ALT within five years. The attrition rate 
in both PNALT groups continued beyond even more stringent definitions of 
PNALT [416], suggesting that very few patients maintain a PNALT throughout 
the course of their disease. This is consistent with evidence suggesting that the 
ALT fluctuates during the course of HCV infection[417].  
 
In line with previous studies, patients with PNALT were found to have lower 
Ishak fibrosis and necroinflammatory scores on their first liver biopsy than 
patients with an elevated ALT [401, 413].  Despite the lower Ishak score on the 
first biopsy and a similar estimated duration of infection, fibrosis progressed at 
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a similar rate between paired biopsies in those with PNALT as compared to 
patients with an elevated ALT. There was also no difference in the number of 
patients in whom the Ishak fibrosis score increased by ≥ 2 points. This is 
considered to be indicative of fibrosis progression rather than to any potential 
sampling error. Patients with a PNALT would appear, therefore, to have a 
similar risk of disease progression as those with an elevated ALT. In order to 
have been included in the analysis of fibrosis progression, however, patients 
needed to have remained treatment/naïve. Patients with an elevated ALT who 
remained treatment/naïve and underwent a repeat biopsy proved on further 
scrutiny to be a group with milder disease as compared to the whole elevated 
ALT cohort.  
 
The study of HCV infected patients with severe fibrosis on liver biopsy is 
described in chapter 3. It seeks to examine the natural history in a group of 
patients that typify those attending hepatitis clinics and avoids much of the 
selection bias associated with some natural history studies, by using a 
geographically determined population.  The study’s findings concern survival 
to death or transplantation and the cumulative probability of both HCC and 
decompensation. The patient population differs from those of previous studies 
in that almost half of patients acquired HCV through injecting drug use 
(previous studies were predominantly blood transfusion recipients [210/211, 
428/430]) and by the inclusion of patients who consumed excess alcohol. 
Neither alcohol consumption at the time of biopsy or past heavy alcohol intake 
were found to be prognostic factors, but mean alcohol consumption fell by 
approximately two thirds following the index biopsy, suggesting that if patients 
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diagnosed with severe fibrosis reduce their alcohol consumption, subsequent 
prognosis is not influenced by their prior alcohol intake. This underlines the 
importance of encouraging HCV infected patients to reduce alcohol 
consumption, particularly those with advanced disease.  
 
At the end of the study a quarter of patients had died or undergone liver 
transplantation, with the majority of deaths judged to be related to HCV. 
Following a diagnosis of severe hepatic fibrosis (Ishak stage >4), the 
probability of survival at 5 years was 80%, though this was only 19% if there 
was existing or prior evidence of hepatic decompensation. The cumulative risk 
of HCC was 15.4% at 5 years with a median estimated duration of infection 
prior to the diagnosis of HCC of 30 years.   The study also differs from 
previous studies in that a high proportion of patients received antiviral therapy. 
Treatment with either standard or pegylated Interferon in combination with 
Ribavirin was associated with survival in both univariate and multivariate 
analyses. Univariate analysis using Cox’s model also showed that age, together 
with indicators of poor liver function (Bilirubin, Albumin and the Child/Pugh 
grade) were prognostic factors for survival. An elevated serum IgM or IgA was 
also associated with a worse outcome in both univariate and multivariate 
analyses. This observation may arise from Ig/induced stimulation of hepatic 
stellate cells [438, 512] or raised Ig levels may simply be a surrogate marker 
for declining liver function (reduced antigen clearance by Kupffer cells [434/
436]).  
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The study of 46 HCV infected patients with Hepatocellular carcinoma (HCC) 
is described in chapter 4. Patients diagnosed with HCC had an estimated 
duration of infection of 24.5 years. Diabetes was present in 20%, while 65% 
were current or ex/smokers. Both are recognised risk factors for HCC. Seventy 
five percent of patients had been diagnosed with cirrhosis at least 6 months 
prior to the diagnosis of HCC and as such there was an opportunity for 
surveillance. Surveillance was variably applied with 80% of patients having 
some form of surveillance performed, but only a third had AFP testing and an 
ultrasound at 6 monthly intervals, as recommended in guidance produced by 
the British Society of Gastroenterology [447]. Twenty one percent of patients 
with HCC had a normal AFP at diagnosis. Tumours were more likely to fall 
within the Milan criteria (85% vs 17%) and patients more likely to receive a 
potentially curative therapy if HCC were detected as a result of surveillance. 
Nevertheless 30% of patients having appropriate surveillance did not have their 
tumours diagnosed as a result of surveillance practices. The 1, 3 and 5 year 
survival was 55, 31 and 19% and having had surveillance was not associated 
with a significant survival benefit. This suggests that new strategies to diagnose 
HCC at an earlier stage are needed in HCV infected patients.  

In comparison with a cohort of cirrhotic patients without HCC, increasing age 
and duration of infection, together with an elevated IgG were associated with 
an increased risk of HCC. Combination therapy with pegylated interferon and 
ribavirin, and separately an SVR were associated with a reduced risk. A 
multivariate model, however, did not identify any factors independently 
associated with development of HCC.  
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Several studies have shown that African Americans have an inferior treatment 
response as compared to other ethnic groups [325/330]. The picture for patients 
from the Indian subcontinent, which constitutes the main ethnic group in the 
UK, is less clear. The study described in chapter 5 examines the natural history 
and outcome of therapy for 2123 white and 120 Asian patients with HCV. The 
Asian patients were more likely to be female, to be older at time of diagnosis, 
to drink less alcohol and to be infected with genotype 3 than their white 
counterparts. Asian patients also had more severe disease on initial liver 
biopsy, but were older and are likely to have been infected with HCV for 
longer. An analysis of response to treatment was restricted to those patients 
with genotype 3 infection. Ethnicity was not associated with the outcome of 
treatment and in the multivariate analysis only cirrhosis on biopsy and an 
increasing GGT predicted treatment failure. Contrary to a previous report 
[485], patients from the Indian subcontinent do not have an inferior response to 
treatment. They are, however, diagnosed with HCV later in life and attention 
should focus on increasing awareness of HCV in the Asian population.  
 
Study 6 looked at factors associated with a sustained virological response in 
357 patients treated with pegylated interferon and ribavirin. In particular it 
focused on whether thrombocytopenia at beginning of or during treatment 
independently influenced the likelihood of success. Seventy eight percent of 
patients completed therapy without a reduction in drug dosage. The only factor 
independently associated with completion of therapy was cirrhosis on biopsy in 
genotype 2/3 infected patients. Thirty three percent of genotype 1 and 67% of 
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genotype 2/3 infected patients achieved an SVR. Increasing patient age in 
genotype 1 infection and increasing duration of infection and cirrhosis in 
genotype 2/3 were independently associated with treatment failure. The initial 
or minimum platelet count did not independently predict either completion of 
therapy or SVR. Focusing attention on increasing the platelet count during 
treatment may, therefore, not improve SVR rates. 

As a collection these studies add to our understanding of the epidemiology and 
natural history of HCV infection. They utilise the Trent HCV study database 
which thanks to the efforts of the enthused individuals who form the study’s 
steering committee and the hard work of its data entry clerks, is well 
maintained with low levels of missing data. That said any epidemiological 
study is only as good as the quality of the data collected. Data fields that at the 
study’s outset may not have seemed important to include are later seen to be 
relevant, as our knowledge of HCV infection increases. An example would be 
our awareness now of the increased risk of HCC seen in HCV infected patients 
with diabetes, but information on diabetic status was not available for the study 
in chapter 4.  Patients are enrolled with informed consent and some patient 
populations such as those with undiagnosed infection who present with HCC 
may be less likely to enter the study. Histological data obtained from liver 
biopsy features heavily in most of the data chapters comprising this thesis. A 
valid criticism of the statistical analysis of histological data is that the Ishak 
scores have in some instances been treated as a linear scale rather than distinct 
categories in order to generate annual fibrosis progression rates for comparison 
between patient groups. Though such analysis features prominently in several 
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peer reviewed published studies of the natural history of HCV [111/113, 116], 
the methodology can be justifiably criticised given that neither fibrosis 
progression in HCV nor progression through the Ishak stages is linear.  
 
There is still a great deal to understand about why there exists such variability 
in disease progression in HCV infection and why some patients clear the virus 
with treatment and others do not. We have had a glimpse of the future of 
natural history studies of HCV infection in the work described in chapter 1 
examining the role of genetic polymorphism at IL28 in determining the 
likelihood of spontaneous clearance or treatment response. Future research 
must link epidemiological data to a biobank of patient blood samples in order 
to further probe the role of both host and viral genetics on the outcome of HCV 
infection.   




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